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Synopsis 
 
This study is focused on the interaction of the metal ions technetium (Tc) and rhenium (Re) with 
amino acids and DNA bases, in particular with guanine. It is shown in this thesis that two guanine 
bases can coordinate to a ReI or a TcI centre yielding reasonably stable complexes with slow on and 
off rates, the on rates being comparable to an active form of cisplatin. For the first time x-ray 
structures of a Tc- and Re-complexes with two purine bases bound cis to the metal center are 
presented. Theoretical and 1H NMR studies indicate that the two guanines can freely rotate about 
the Re-N7(9) bond.  
Rhenium forms stable adducts with d(GpG) and d(CpGpG) via coordination of the N7 atom of 
guanine residues as corroborated by the pH-dependence studies of the H8 resonances at pH values 
near 2. The [Re(CO)3]+ moiety displays a principally similar reactivity pattern with plasmid DNA 
as e.g. cisplatin. It alters the tertiary structure of X174 DNA by altering the electrophoretic 
mobility of the open circular and the supercoiled form of plasmid DNA. The induced changes 
involve most likely covalent binding to two bases as found for cisplatin.  
The fac-[Re(CO)3]+ core can be derivatized with the amino acid serine and the appropriate 
nitrogenous base to yield nucleoside mimicking complexes. These compounds show an interesting 
solution behavior and are remarkably stable in Human Serum (HS). The amino acid complexes of 
Re can be bridged by CN- in B12 to yield robust complexes comprising the central structural feature 
[Co-CN-Re]. Certain Re complexes show high antiproliferative activity toward B16 F1 mouse 
melanoma cells. 
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Zusammenfassung 
 
Diese Arbeit befasst sich mit der Wechselwirkung von Technetium- und Rheniumionen mit 
Aminosäuren und Nukleobasen, insbesondere mit Guanin. Es wird gezeigt, dass zwei Guaninbasen 
an ein ReI- oder ein TcI-Metallzentrum koordinieren können und recht stabile Komplexe bilden mit 
langsamen Geschwindigkeitskonstanten für die Hinreaction, die ähnlich den Werten von Cisplatin 
in seiner aktivierten Form sind. Zum ersten Mal werden Kristallstrukturen von Tc- und Re-
Komplexen mit zwei cis-gebunden Purinbasen präsentiert. Theoretische Studien und NMR-
Messungen zeigen, dass die beiden Guanine frei um die Re-N7(9)-Bindung rotieren können. 
Rhenium bildet stabile Addukte mit d(GpG) and d(CpGpG) durch Koordination der N7-Atome 
der Guanineinheiten, was durch pH-abhängige Studien der H8-Resonanzen bestätigt wurde. Die 
[Re(CO)3]+-Einheit zeigt ein vornehmlich gleiches Reaktionsverhalten mit Plasmid-DNS wie z.B. 
Cisplatin. Sie verändert die Tertiärstruktur von ΦX174-DNS, was sich veränderter 
elektrophoretischer Mobilitäten von Plasmid-DNS in der entspannt zirkularen und in der 
Superhelixform zeigt. Diese Änderungen beinhalten höchstwahrscheinlich die kovalente Bindung 
zweier Basen, wie es bei Cisplatin gefunden wird. 
Die fac-[Re(CO)3]+-Einheit kann mit der Aminosäure Serin und mit den passenden 
Stickstoffbasen derivatisiert werden, um Nukleosid-imitierende Komplexe zu bilden. Diese 
Substanzen zeigen in Lösung ein interessantes Verhalten und sind in Humanserum erstaunlich 
stabil. Die Aminosäurekomplexe von Rhenium können über CN- mit B12 verbrückt werden, um 
stabile Komplexe mit der zentralen Einheit [Co-CN-Re] zu bilden. Einige Rheniumkomplexe 
zeigen hohe antiproliferative Aktivität gegen B16 F1-Mausmelanomzellen.  
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Introduction 
I.1 General Remarks 
This study is focused on the interaction of the metal ions technetium (Tc) and rhenium (Re) with 
amino acids and DNA bases, in particular with guanine. The thesis is structured in chapters with 
each chapter dealing with a specific issue of the study. Although every section is presented in a 
format resembling that of a scientific publication, with a results and discussion section following an 
introduction to the topic, the subject matters dealt within each chapter are intimately related to one 
another. These are presented in a consecutive logical manner that I hope will help the reader to 
better appreciate the scope and purpose of this study. All experimental details are given at the end 
of this work. 
 
I.2 The Elements Technetium and Rhenium 
I.2.1 Technetium 
Technetium (from Gr. technetos: artificial, element 43) was predicted on the basis of the periodic 
table, and was erroneously reported as having been discovered in 1925, at which time it was named 
masurium.1 The element was actually discovered by Perrier and Segre in Italy in 1937.2, 3 It was 
also found in a sample of molybdenum sent by E. Lawrence that was bombarded by deuterons in 
the Berkeley cyclotron. Technetium was the first element to be produced artificially. Since its 
discovery, searches for the element in terrestrial material have been made.  Finally in 1962, 
technetium-99 was isolated and identified in African pitchblende (a uranium rich ore) in extremely 
minute quantities as a spontaneous fission product of uranium-238 by B.T. Kenna and P.K. 
Kuroda.4, 5 Technetium has been found in the spectrum of red giant S-, M-, and N-type stars, and its 
presence in stellar matter is leading to new theories of the production of heavy elements in the 
stars.6, 7  
 
Technetium is a silvery-grey metal that tarnishes slowly in moist air.  The common oxidation 
states of technetium are +7, +5, and +4. Under oxidizing conditions technetium (VII) will exist as 
the pertechnetate ion, TcO4-.  The chemistry of technetium is similar to that of rhenium. Technetium 
dissolves in nitric acid, aqua regia, and concentrated sulphuric acid, but is not soluble in 
hydrochloric acid of any strength. The element is a remarkable corrosion inhibitor for steel. The 
metal is an excellent superconductor at 11K and below.  
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Twenty-two isotopes of technetium with masses ranging from 90 to 111 are reported. All the 
isotopes of technetium are radioactive. It is one of two elements with Z < 83 that have no stable 
isotopes; the other element is promethium (Z = 61). Technetium has three long-lived radioactive 
isotopes: 97Tc (t½ =2.6 x 106 yr), 98Tc (t½ = 4.2 x 106 yr) and 99Tc (t½ = 2.1 x 105 yr).   95mTc ("m" 
stands for meta state) (t½ = 61 d) is used in tracer work. However, the most useful isotope of 
technetium is 99mTc (t½ = 6.01 h). Technetium-99m in some chemical form is used in more than 
85% of the diagnostic scans done each year in hospitals. The nuclear properties of 99mTc are 
virtually ideal for diagnostic imaging.8 Technetium-99m emits a 140 keV γ-ray with 89% 
abundance which is close to optimum for imaging with gamma cameras found in most hospitals. Its 
6 h half-life is sufficiently long to synthesize the 99mTc-labeled radiopharmaceuticals, assay them 
for purity, inject them into the patient and perform the imaging studies yet short enough to 
minimize the radiation dose to the patient. Because 99Tc is produced as a fission product from the 
fission of uranium in nuclear reactors, large quantities have been produced over the years.  
 
I.2.2 Rhenium 
Rhenium, first detected by Noddack, Tacke, and Berg in 1925 in the X-ray spectra of certain 
mineral concentrates,1 was the last of the stable elements to be discovered. It is among the least 
abundant both in the crust of the earth and in the solar system. There are no sufficiently elevated 
concentrations anywhere in nature to permit economic extraction as the primary commodity, and 
the only commercial source is as a by-product of the molybdenum industry. When molybdenite is 
roasted in air to molybdenum trioxide, volatile dirhenium heptoxide passes into the effluent gases 
and flue dusts and may be recovered by wet scrubbing or leaching with water. Rhenium is then 
isolated from the aqueous extracts either by selective adsorption as ReO4- on an anion exchanger or 
by solvent extraction, and it is finally precipitated as NH4ReO4 or Re2S7. 
 
Rhenium, of atomic number 75 and atomic weight 186.2, belongs to group VII of the periodic 
table. It occurs naturally as a mixture of two isotopes, 185Re (37.40%) and 187Re (62.60%).9 The 
heavier isotope is a weak β-emitter, and the daughter 187Os is present in all rhenium-bearing rocks.10 
The end-point energy of the emitted β-particles (2.62 % ± 0.09 keV) is the lowest recorded for β-
decay and is even lower than the difference in the atomic binding energies of Re and Os (ca. 13.8 
keV).11, 12 The measured half-life for decay to continuum states, (6.6 % ± 1.3) x 1010 yr, is longer 
than the total half-life, (4.3 % ± 0.5) X 1010 yr, estimated from 187Re/187Os ratios in geologically 
dated molybdenltes.13
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On all counts, rhenium is an exceptionally rare element. A careful search in the Fraunhofer 
spectrum of the sun was negative, putting an upper limit of not more than 0.5 atom per 1012 H.14 
Concentrations in iron meteorites (0.0023-4.4 ppm based on the analysis of 70 specimens) are an 
order of magnitude less than those of osmium and iridium,15 and the mean osmium to rhenium ratio 
in chondritic meteorites is 11.4 % ± 1.3.16 A sample of 32 chondrites representing all classes was 
found to contain 0.0311-0.0804 ppm corresponding to 0.025-0.076 atom of Re per 106 silicon.16 
The atomic abundance in the Orgueil meteorite, a Type I carbonaceous chondrite generally 
considered most nearly representative of the composition of primitive solar dust, is 0.052 (Si = 106), 
almost equal to the mean in all chondrites (0.053).16 The abundance of rhenium in the solar system 
is usually taken as 0.055 and, together with that of Tb, Tm, Lu, and Ta, is the lowest among the 
stable elements.17
 
The earth's crust is essentially depleted in rhenium. On the basis of analyses on 14 igneous and 
metamorphic rocks, the crustal abundance has been estimated at 0.5 % ± 0.3 ppb.18 The element is 
highly dispersed within the crust, and elevated concentrations normally occur only in 
molybdenites.19 A strong geochemical association with molybdenum persists through all stages of 
magmatic crystallization, and rhenium is finally incorporated as an isomorphous solid solution of 
ReS2 in MoS2.19 A large number of molybdenites have been analyzed and the rhenium content has 
been found to vary over very wide limits from <0.1 ppm to >2000 ppm (0.2%).19 Of the many 
factors that influence the ratio of Re to Mo, one seems to be well established: molybdenites with the 
highest content of rhenium (ca. 0.1 %) tend to be associated with copper in multi-mineral 
accretions.19
 
I.3 Chemistry of the Elements20
Technetium and rhenium are known to exists in formal oxidation states ranging from –I (d8) to 
VII (d0). They form a large variety of complexes with coordination numbers ranging from 4 to 9 
encompassing virtually all known geometries. Oxo complexes of the elements can broadly be 
assigned to three major types: 5- or 6-coordinate species with a MO3+ core, 6-coordinate species 
with linear O=M=O+ core and species based on the linear O=M-O-M=O4+ core to which ligands are 
attached to form an octahedron around each metal. Both metals form strong triple bonds to nitrogen 
in oxidation states V and VI with M≡N2+ and M≡N3+ cores in octahedral geometry. 
 
M2O7 and MO4- oxides of both metals are well known as well as M2S7 sulfides which are 
obtained from H2S saturated solutions of MO4- in the presence of HCl. The pertechnetate and the 
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perrhenate ions (MO4-) dominate the aqueous chemistry of both elements. Both anions are 
tetrahedral and numerous salts are known. Interestingly TcO4- (but not ReO4-) shows catalytic 
activity and it is a remarkable corrosion inhibitor for iron and steel. Only three binary halides of Tc 
are known, TcF6, TcF5 and TcCl4 while a relatively large number of halides are known for Re. 
Among the most interesting are ReF7, the only known heptafluoride other than IF7 and Re2Cl10 
which shows in the crystal structure magnetic interaction but no actual Re-Re bond. Oxohalides, on 
the other hand, are fairly numerous and occur for oxidation states +5, +6 and +7.  
 
Both elements have a tendency to form M-M multiple metal bonds although several major 
differences in their chemistry exist. For example, trinuclear clusters of Re are very important but 
unknown for Tc. Re forms many Re26+ complexes with Re-Re quadruple bonds, whereas Tc prefers 
Tc25+ and Tc44+ complexes with lower bond order. Incidentally, the [Re2Cl8]2- ion was the first 
stable chemical entity shown to posses a quadruple bond. Finally Tc forms Tc6 and Tc8 prismatic 
clusters within which there are three or four Tc≡Tc units whereas Re forms rectangular Re4 clusters 
with two Re≡Re bonds. Other important complexes of Tc and Re are nitrene species, hydrido and 
dihydrogen complexes and organometallic compounds among which the carbonyl species are 
among the most significant and will be discussed in more details in the following section. 
 
I.4 Chemistry of the fac-[M(CO)3]+ Core (M = Tc, Re) 
The syntheses of carbonyl complexes [Re2(CO)10] and [Tc2(CO)10] are traditionally performed in 
autoclaves. [NEt4][ReBr3(CO)3] is prepared from [Re2(CO)10] by bromination to [ReBr(CO)5] and 
substitution of two COs with [NEt4]Br.21 Originally the complexes were prepared in organic 
solvents. Reduction of Tc(VII) and/or Re(VII) to Tc(I) or Re(I) under concomitant coordination of 
three COs could be achieved by bubbling of CO through a THF solution of the permetallates in the 
presence of BH3THF and Cl-. This resulted in the reduction of the metal center and coordination of 
at least three CO ligands.22, 23
 
Under these conditions different complexes in the +1 valency were found as products when 
varying the reaction conditions. When X- (X = Cl, Br) is present in the reaction mixture, [M2(µ-
X)3(CO)6] forms quantitatively (M = Tc, Re). Addition of excess [NEt4]X lead to cleavage and 
formation of the final product [TcX3(CO)3]2- or [ReX3(CO)3]2-. In the complete absence of X-, the 
mixed hydrido-carbonyl complexes [TcH(CO)4]3 and [Tc3H4(CO)9]- form together in almost 100% 
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yield. Addition of NaOH in methanol and subsequent acidification leads [TcX3(CO)3]2- (or 
[ReX3(CO)3]2-).22, 23
 
For many years the synthesis of carbonyl complexes in water was practically unknown, since 
there was no need to develop such an approach. Nowadays carbonylation of Tc can be archived via 
the so-called boranocarbonates, originally described by Malone and Parry in 1967.24, 25 Alberto 
found that K2H3BCO2, prepared continuously from commercially available H3BTHF solutions and 
reacted in situ with an alcoholic solution of potassium hydroxide, combines the possibility of in situ 
CO formation and reducing properties. [99mTc(OH2)3(CO)3]+ can now be prepared in water in a one-
pot synthesis without the necessity of an additional reducing agent or of gaseous CO. In fact, a 
small amount of K2H3BCO2 dissolved in a few ml of aqueous [99mTcO4]- gives [99mTc(OH2)3(CO)3]+ 
in yields of >98% after 10 min at 90 °C.26
 
When [TcX3(CO)3]2- or [ReX3(CO)3]2- are dissolved in water, the halides are readily substituted 
by H2O and very high halide concentration is required to get small amounts of mono-halide 
substituted species. Thus, [TcX3(CO)3]2- and [ReX3(CO)3]2- transform completely to the 
corresponding aqua-ions [M(OH2)3(CO)3]+ (M = Re, 1; M = 99Tc, 2). Three coordination sites are 
occupied by very tightly bound CO ligands, whereas the remaining sites are occupied by three 
labilized water ligands. Like most aqua-ions, 1 and 2 act as Bronstedt acids, and can also be 
expected to exhibit this characteristic. However, mono-cationic species are in general not very 
acidic and the pKa values are usually higher than 8. Deprotonation of coordinated water ligands 
leads temporarily to terminal hydroxo complexes which subsequently tend to oligo- or polymerize 
by formation of µ-OH or µ-O species. 
 
The fac-[M(CO)3]+ moiety is very stable in water and [M(S)3(CO)3]+ complexes (S = 
monodentate solvent molecule) exchange specifically the labile solvent ligands (i.e. H2O). This 
represents a major advantage over the vast majority of Tc(I) or Re(I) compounds, where the low 
valency is stabilized by pH independent ligands (i.e. phosphanes) which can hardly be substituted 
by other incoming chelators. The M(I) center possesses a d6 electronic configuration in an 
octahedral field. In general, such complexes are known to be kinetically inert.  
 
Complexes 1 and 2 bind a large variety of ligands. Aliphatic amines as isolated ligand groups 
coordinate only weakly to 1 or 2. Carboxylate groups and other anions showed similar features. 
Thioether groups coordinate very slowly, but their complexes are of extremely high (kinetic) 
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stability. On the other hand, aromatic amines show fast complexation and very high thermodynamic 
or kinetic stability. The combination of an aromatic and an aliphatic amine and even more with an 
additional carboxylic acid, are among the best ligands in aqueous solutions for 1 and 2. 
 
I.5 Chemo- and Radiotherapeutic Agents in Cancer Research 
The use of inorganic and organometallic complexes in cancer imaging and therapy is an ongoing 
active field of research. Virtually almost all transition metals from group 3 to 12 and elements of 
group 13 are investigated for such purposes.27 Complexes of Sc and Y are used in cancer imaging 
and therapy. Metallocenes of Ti, V, Nb and Mo are effective against different type of cancer cell 
lines including cisplatin resistant cell lines.27 Organometallic complexes of Tc and Re are amongst 
the most widely used radiopharmaceuticals.8, 28 Arene as well as amine and imine complexes of Ru 
and Os show remarkable antitumor activity.27, 29 µ-caboxylato dirhodium compounds also show 
antitumor properties by inhibiting DNA replication and protein synthesis.27 β-emitting 
radionuclides of Cu, Ag are used as therapeutic radiopharmaceuticals,28 In is commonly used in 
cancer imaging while Ga compound show activity against soft tissue tumors.27  
 
The anticancer drug cisplatin, however, remains the most effective inorganic compound for 
treatment of a variety of tumors. While the mechanism of action is not entirely understood, there is 
consensus in the community that binding of the drug to DNA is critical for its antitumor activity. A 
large body of evidence indicates a preference of the drug for DNA sequences containing two or 
more adjacent guanosine nucleosides. The bifunctional binding of cisplatin to purine bases occurs 
preferentially at GpG, ApG and GpNpG (where N = any nucleoside) sequences and these account 
all together for ≈ 90% of all cisplatin/DNA binding modes. Monofunctional adducts account for the 
remaining 10 %.
 
NMR and X-ray investigations have been carried out in the last twenty years to elucidate the 
structural feature of this interaction. Bifunctional binding to purines determines the loss of stacking 
in coordinated bases and leads to bending of the double helix associated to some extent with 
unwinding.30 These DNA modifications contribute to a cascade of events, including transcription 
inhibition and repair shielding of cisplatin-DNA cross-links which ultimately result in cell death.30  
 
One of the major disadvantages of cisplatin is its severe toxic side effects. The drug is unspecific 
in its interaction with DNA and virtually any base can be platinated. Furthermore many cancers 
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develop resistance to the drug.27 Also, the coordination sphere of the metal ion cannot be 
derivatized with targeting agents as the molecules thus obtained lose their activity. Therefore, much 
interest remains in synthesizing metal complexes capable to bind to DNA bases in a fashion similar 
to cisplatin but do not present the disadvantages listed above.  
 
I.6 Scope and Purpose of This Study 
It is well known that by combining radiotherapy and chemotherapy, important therapeutic 
advantages can be obtained to cure cancer.31 In cancer treatment it is therefore desirable to employ 
compounds that might function mechanistically as cisplatin derivatives, causing intrastrand linkages 
of DNA, in combination with an inherent radioactivity of the metal center. Such a class of 
compounds would act to inhibit DNA transcription while delivering a highly localized radiation 
dose in the target tumor tissues. At the same time the molecules may also be precisely localized in 
the body.  
 
In current clinical practice radionuclides that decay by β-particle emission are most extensively 
used for radiopharmaceutical applications (see section I.5). 186Re and 188Re are two such 
radionuclides that are used as FDA approved drugs as cytotoxic therapeutic agents in human 
medicine. Mono-nuclear octahedral 186ReI and/or 188ReI complex may combine the inherent 
radioactivity of the metal center with the mechanistic properties of cisplatin resulting in a novel 
class of compounds which may be defined as “chemo-radiotherapeutic agents”.  
 
This study therefore attempts to answer the following questions: 
1. Can a rhenium and/or technetium tricarbonyl core interact with DNA in a fashion similar 
to cisplatin? Whereby interaction with DNA in a fashion similar to cisplatin is meant the 
binding of two nucleobases in cis position around the metal core. 
2. If so, what are the differences?  
3. Can a rhenium-based DNA targeting radiopharmaceutical with chemotoxic properties be 
designed? 
 
The following chapters will describe the interaction of the fac-[M(CO)3]+ core (M = 99Tc, Re) 
with guanine bases (untethered, Chapter 1) or as part of an olygonucleotide sequence (Chapter 3). 
The reactivity pattern of the above mentioned core with plasmid DNA will be illustrated and 
compared to that of cisplatin (Chapter 2). It will also be shown how the tricarbonyl core can be 
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protected with amino acids (Chapter 2 and 5) and it will be shown the reactions of the compounds 
thus obtained with biologically relevant molecules like Vitamin B12 (Chapter 4) or derivatized 
DNA bases (Chapter 5). Finally the cytotoxicity of compounds presented (Chapter 6) will be 
described. The last chapter of this study (Chapter 7) is dedicated to the metal ion Ru in the +2 
oxidation state and there the first structurally characterized complex of Ru with two DNA bases 
covalently bound to the metal center will be presented. 
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Chapter 1. Interaction of [M(H2O)3(CO)3]+ Complex (M = Re, 99Tc) with Guanine. 
Comparison with Leading Anticancer Drug Cisplatin 
 
It is now generally accepted that the cytotoxicity of the leading anticancer drug cisplatin is due to 
the formation of 1,2-intrastrand adducts between the N7 atoms of two adjacent guanine residues in 
DNA.1 The products of this interaction are d(GpG) cross-links and less frequently d(ApG). Not only 
are these adducts been observed both in vitro and in vivo, but clinically inactive compounds fail to 
form such cross-links.1a  
 
Early structure-activity relationship studies indicated that for any cis-PtA2X2 analogue of cisplatin 
(A2 is two amines or a bidentate amine ligand and X is an anionic leaving group) the carrier amine 
ligand had to have at least one proton for the drug to retain its anticancer activity.2 This observation, 
along with the realization that d(GpG) can assume different conformations around the metal core,3 
led to the hypothesis that hydrogen bonding interactions between bound G ligands and the carrier 
amine of the drug were important for the stabilization of the DNA distortion induced by the 
intrastrand lesion.3a, 4 By using the so called “retro models”, Marzilli, Natile and coworkers have 
later demonstrated that the guanine O6 H-bonding to carrier amine ligand hydrogen is not important 
for the bases to assume a particular orientation around the metal center and they hypothesized that 
the small size of the NH group rather than its hydrogen-bonding ability is important for the 
anticancer activity of the drug.5  
 
In the area of new drug design, much interest remains in synthesizing metal complexes capable to 
bind to DNA bases in a fashion similar to cisplatin. It also remains of fundamental interests to 
understand the factors driving the formation of different head-to-head (HH) and head-to-tail (HT) 
conformers cis-bis-metal adducts of nucleobases. Understanding the factors driving the formation of 
different HH and HT conformers is of particular importance for cis-PtA2{d(GpG)} complexes. In 
fact, one principal hypothesis originally advanced by Lippard to explain the activity of the drug, 
suggests that the HH form in the intrastrand lesion is recognized by a damage recognition protein 
(Figure 1.1) whose binding prevents DNA repair, allowing the cisplatin adduct to persist long 
enough to activate apoptosis.6 Marzilli suggested that the HT form in the interstrand lesion causes 
weaker binding of the damage recognition protein making this lesion a better substrate for repair.7 
Therefore, according to this hypothesis, the formation of a HT conformer results in lower 
cytotoxicity of the drug.  
 
  
 
 
 
 
 
 
 
 
 
Figure 1.1. Crystal structure of high mobility group (HMG) domain proteins that bind to platinated 
DNA.1a  
 
Mononuclear and dinuclear tricarbonyl rhenium(I) complexes of the type 
[ReBr(CO)3(Ph2PCH2)2NR] and [Re2(µ-OR)3(CO)6] have recently been described to efficiently 
suppress the growth of solid and suspended tumor cell lines.2 Substitution of the alkoxide or 
hydroxide ligands and coordination to N7 in purine bases in a fashion similar to cisplatin was 
anticipated to be a possible mode of action for some of these complexes.2a 
 
Work on novel [M(OH2)3(CO)3]+ (M= 99mTc , 188Re) based radiopharmaceuticals, has shown that 
the d6 “fac-[M(CO)3]+“ moiety binds a wide variety of mono- and multidentate ligands to yield 
highly robust complexes. Aromatic amines in particular are potent ligands, and there exist a 
rhenium structure with a single N7 bound 9-ethylguanine.3 Hence, it is likely that [M(OH2)3(CO)3]+ 
would also bind to two bases, isolated or in DNA despite the octahedral geometry and therefore 
exhibit potential cytostatic properties based on a mechanism comparable to cisplatin. To assess this 
possibility the basic coordination chemistry of [Re(OH2)3(CO)3]+ (1) and [99Tc(OH2)3(CO)3]+ (2) 
with, guanosine (G) and 2-deoxyguanosine (2dG) was studied.  
 
New DNA-targeting chemotoxic agents based on a metal or metal fragment of octahedral 
geometry, which results exclusively in the formation of a HT conformer when bound to two purine 
bases, might be expected, for the reasons mentioned above, as being of low efficacy. It is, therefore, 
important to understand the factors determining the orientation of purine bases when coordinated to 
the [M(CO)3]+ core, and more generally to a metal of octahedral geometry. Reedijk and others, in 
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fact, have pointed out that the carbonyl oxygen of coordinated guanine becomes sterically 
demanding in octahedral complexes. Therefore, steric hindrance between O(6) in guanine ligands 
and the CO ligands might force the two bases in a HT orientation in rhenium tricarbonyl 
complexes.10
 
To this end, the interaction of 1 and 2 with 9-methylguanine (9-MeG) and 7-methylguanine (7-
MeG, Figure 1.2) was studied. The first of the two ligands was chosen as the simplest N(9) 
derivatized guanine, while 7-MeG was chosen because metal binding to N(9) does not impose steric 
hindrance.  
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Figure 1.2. Structure of 9-MeG and 7-MeG with numbering of relevant atoms.  
 
In this chapter the first x-ray structures of technetium and rhenium complexes bound to two 
guanines via the N7 atoms together with kinetic and thermodynamic data of the interaction of 1 and 
2 with G and 2dG is presented. The comparison of these data with those of [Pt(NH3)2(H2O)2]2+, 
implies that 1 or 2 are potential cytotoxic agents affecting DNA like cisplatin. Structural evidence 
points to the fact that, as in the Pt case, two guanine ligands can adopt several conformations in an 
octahedral [(CO)3Re(purine)2X] complex (X = H2O, Br). The results suggest that neither hydrogen 
bonding interactions nor steric factors are important in determining the orientation of the ligands. 
The apparent intramolecular hydrogen bonding interactions one observes in the solid state structures 
result from the intrinsic conformation assumed by the ligands when bound to [Re(CO)3]+ core. The 
presence of HH and HT conformers in complexes with either 9-MeG or 7-MeG points to the fact 
that the steric hindrance imposed by the carbonyl oxygen of coordinated guanine is not a driving 
force for the preference of one conformation over the other. 
 
Taken together, the results presented in this chapter suggest that complexes with 99mTc or 188Re 
could be used as novel radiodiagnostic or -therapeutic agents. 
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1.1 Results  
1.1.1 Interaction of 1 and 2 with G and 2dG 
The reaction of 1 with 2 eq. of G, or 2dG in CH3OH or in a CH3OH/H2O mixture (Scheme 1.1) 
can conveniently be monitored by 1H NMR spectroscopy or HPLC. The mono- and the bis-purine 
base substituted complexes [Re(S)2(G)(CO)3]+ (3a, S = solvent molecule), [Re(S)(G)2(CO)3]+ (3) 
and  [Re(S)2(2dG)(CO)3]+ (4a), [Re(S)(2dG)2(CO)3]+ (4) formed stepwise. This was also observed 
in the formation of [99Tc(S)(G)2(CO)3]+ (5). The Re and the 99Tc complexes could be obtained as 
analytically pure white microcrystalline solids although the formation of the bis-substituted 
complexes 3, 4 and 5 is not complete at a 1:2 stoichiometry. This is evident from 1H NMR 
experiments performed in D2O where by mixing 1 or 2 with 2 eq. of G or 2dG an equilibrium 
similar to the one depicted in Scheme 1.1 is reached and in the aromatic region of the spectrum the 
mono- and the bis-purine base substituted complexes are distinguished (Figure 1.3). No exchange-
NOE signal could be detected between the H8 protons of coordinated guanosines in complexes 3 to 
5. 
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Scheme 1.1. Formation of mono- and the bis-purine base substituted complexes of 1. 
 
Although in H2O and CH3OH one single stereoisomer is found, this is not the case in aprotic 
solvents. The existence of distinct stereoisomers in other solvents such as DMSO parallels the 
chemistry of 1 and cisplatin. Dissolving (4)Br (prepared from aqueous methanol) in DMSO-d6 
shows initially one single species as indicated by a single set of two sharp H8 signals for the 
independent guanosines. Within days however three different isomers are in stable equilibrium and 
they do not exhibit any cross-peaks between the H8 protons of coordinated purines (2D exchange-
NOESY, Figure 1.4). This indicates that in the single species the two H8’s are separated by more 
than 3 Å.  
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Figure 1.3. NMR spectrum (12h, 310K, D2O, 7.5-9.1 ppm) of A: 1 plus 2eq. of G; B: 1 plus 2eq. of  
2dG; C: 2 plus 2eq. of G. 
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Figure 1.4. 2D exchange-NOESY 1H NMR spectrum (DMSO-d6, 25 oC, 7.8-8.4 ppm) of aged 
solution of (4)Br. 
 
The rates of substitution and the stability constants K1 and K2 of the purine bases G and 2dG are 
important for comparing the behaviour of 1 with cisplatin. The species distribution at equilibrium, 
measured by 1H-NMR,  allowed an estimation of the stability constants according to Scheme 1.1. 
The values are 1.04 x 103 ± 0.46 M-1 (K1) and 4.31 x 102 ± 0.45 M-1 (K2) for G and 1.92 x 103 ± 
0.98 M-1 (K1) and 4.48 x 102 ± 0.31 M-1 (K2) for 2dG. The rate of formation k1 of 
[M(OH2)2(G)(CO)3]+ was determined under pseudo first order conditions by monitoring the growth 
of the monoligated species with 1H NMR in D2O. The rates of decomposition k-2 for 3 and 4 were 
received from the decrease of the corresponding 1H signals in water considering the back and 
forward reaction according to literature.12 From K1, K2, k1, and k-2 the remaining k-1 and k2 could be 
calculated (Table 1.1).  
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Although the conditions for the determination of the rate constants for ReI-G differ slightly from 
those of PtII it is obvious that they are in the same order of magnitude. k1 is larger for Re than for Pt, 
but the reverse is true for k2. This might reflect the sterically more demanding octahedral Re 
complex. Binding of G to the Tc complex is about 5 times faster in k1, a behaviour that is expected 
going one group higher in the periodic table. Comparison of stability constants K1 and K2 is 
difficult since platination of a base can be considered irreversible. 
 
Rate constants exclusively refer to the interaction of Re and 99Tc with N7 in G or 2dG. Although 
the nucleosides offer multiple binding sites, the metals coordinate selectively to N7 and no evidence 
for coordination to i.e. carbonyl oxygen, or to the ribose was seen. Steric hindrance from the sugar 
excludes binding to N3 and direct binding of a metal to the exocyclic C2NH2 group has never been 
observed under physiological conditions.14
 
 
 
Table 1.1. Rate constants for the formation of the 1:1 (k1/10-2 M-1s-1) and 1:2 (k2/10-2 M-1s-1) 
complexes between cis-[Pt(NH3)2(H2O)2]2+ or [M(H2O)3(CO)3]+ (M = Re, 99Tc) with G and 2dG. 
 
Complex Base k1 k2 T (K) 
[Pt(NH3)2(OH2)2]2+ a G 23.7 ± 0.3 15.8 ± 0.2 298.2 
[Re(OH2)3(CO)3]+ b G 28.5 ± 1.6 4.40 ± 0.27 310.2 
[Re(OH2)3(CO)3]+ b 2dG 14.5 ± 2.2 6.01 ± 0.15 298.2 
[99Tc(OH2)3(CO)3]+ b G 104.1 ± 9.3  298.2 
a = Unbuffered aqueous solution: pH = 3.85-4.15.13 b = Unbuffered aqueous solution. 
 
1.1.2 [ReBr(BzIm)2(CO)3] Complex 
In order to gain further insights on the possible orientation of G and 2dG in complexes 3 and 4, 
[ReBr(BzIm)2(CO)3] (6) was initially synthesized. In this compound, obtained from the reaction of 
1 with 2 eq. of BzIm, the aromatic ligand is intended as a simple model purine. As in the case of the 
µ-oxo bridged Re2O3Cl4(Me3BzIm)4 and the RuX2(dmso-S)2-n(CO)n(L)2 (X = Cl, Br ; L = BzIm, 
Me3BzIm) complexes, the two cis BzIm ligands in 6 are in a HH arrangement. All Re-L distances 
(where L = coordinated atom of ligand) fall within ranges of expected values found in ReI 
compounds. No pronounced asymmetry between Re-N7-C5 and Re-N7-C8 bond angles (see Figure 
1.5) was found. Unsymmetrical angles are common in all CoIII, RuII and ReI complexes with 
Me3BzIm, where Metal-N-C8 bond angles are consistently more acute than Metal-N-C5 angles: 
Metal-N-C8 angles range 119.2(2)–124.8(4)o, Metal-N-C5 angles range 129.5(3)–135.9(2)o. 
 
As mentioned in the previous section, in D2O and DMSO-d6 no exchange-NOE signal could be 
detected between the H8 protons of coordinated guanosines in complexes 3 to 5. This indicates that 
the two protons are separated by a distance greater than 3 Å. In 6 the corresponding hydrogens are 
separated by 3.75 Å. The H8-H8 distance in 6 was measured as a function of the BzIm ligand 
rotation with respect to other BzIm-N/Re/Br/cis-CO's plane and the results are shown in Figure 1.5. 
It is predicted that an exchange-NOE signal between H8 protons would be detected if the two N-
donor heterocyclic ligands in 6 were in a HT conformation. These results tentatively point toward a 
HH arrangement of the coordinated bases in complexes 3, 4 and 5. If this assignment is correct then 
the difference in H8 chemical shifts in the species formed following equilibration of 4 in DMSO-d6 
is due to a slight different average mutual tilt between the two HH ligands. 
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Figure 1.5. X-ray structure of 6 (left) and H8-H8 displacement from crystal equilibrium position as 
a function of ligand rotation around the Re-N bond (right). 
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1.1.3 Interaction of 1 and 2 with 9-MeG and 7-MeG 
 
Synthetic Aspects. Reaction of 1 and 2 with 2 eq. of 9-MeG or 7-MeG in CH3OH or in a 
CH3OH/H2O mixture can be conveniently monitored by 1H NMR and HPLC analysis. Both the 
mono- and bis-ligated species are observed, and in fact, reaction of the [Re(CO)3]+ fragment with 
guanine bases lead to the equilibrium depicted in Scheme 1.1. As is the case with G and 2dG, 
complexes [Re(CH3OH)(9-MeG)2(CO)3]+ (7), [99Tc(CH3OH)(9-MeG)2(CO)3]+ (8) and 
[Re(CH3OH)(7-MeG)2(CO)3]+ (9) formed stepwise. The reaction in the presence of water gave the 
corresponding complexes i.e. [Re(OH2)(9-MeG)2(CO)3]+ (10), [99Tc(H2O)(9-MeG)2(CO)3]+ (11) 
and [Re(H2O)(7-MeG)2(CO)3]+ (12). Although the reaction did not go to completion at a 1: 2 
stoichiometry, compounds 7, 8, 10 and 12 could be obtained as analytically pure, white 
microcrystalline solids when a slight excess of the corresponding base was utilized. No appreciable 
difference in the HPLC chromatograms was found if the reaction was carried out in water or a 
methanol/water mixture. Oriskovich had originally shown that the above mentioned fragment can 
bind a single 9-ethylguanine (9-EtG) via the N7 atom after displacement of a labile CH3CN to yield 
a stable complex, where the remaining two coordination sites were occupied by bipyridine.21 In this 
case, coordination of purine ligands occurred via displacement of the weakly bound water and/or 
methanol molecules.  
 
X-ray Crystallography. Crystal data and experiment details are listed in the crystallography 
section while selected geometrical parameters are listed in Table 1.2. Crystals suitable for X-ray 
analysis were obtained in one of two ways. Slow solvent evaporation of a methanol/water solution 
gave crystals of the HH conformer of complex 10 (10HH) and the HT conformer of complex 12 
(12HT), while vapor diffusion of pentane into a methanolic solution gave crystals of the HH 
conformer of complex 12 (12HH) and of the HT conformer of complexes 7 (7HT), 8 (8HT) and 10 
(10HT). In all but one case, a solvent molecule is found occupying the sixth coordination site with 
exception of 12HH, where a bromide is found. All relevant bonds and angles (Table 2) are in good 
agreement with the structure reported by Oriskovich et al.21
 
 
 
 
 
 
 24
 
Table 1.2. Selected Bond Distances (Å) and Angles (deg.) of Complexes 7HT-12HH.a
 7HT 8HTb 10HT 10HH 12HTc 12HHc Re(9-EtG)d
Distances        
Re-N(7) 2.185(4) 2.190(3) 2.203(4) 2.212(13) 2.213(3) 2.215(10) 2.220(10) 
Re-N(17) 2.193(5) 2.204(3) 2.193(4) 2.186(13) 2.184(4) 2.198(10)  
Re-C(21) 1.914(5) 1.897(4) 1.922(7) 1.880(17) 1.931(4) 1.916(18) 1.875(17) 
Re-C(22) 1.922(6) 1.918(4) 1.918(5) 1.916(15) 1.911(4) 1.891(15) 1.896(15) 
Re-C(23) 1.925(5) 1.919(4) 1.959(6) 1.881(16) 1.893(4) 1.901(19) 1.919(14) 
Re-O(1) 2.163(4) 2.177(3) 2.168(4) 2.167(11) 2.184(3)   
Re-Br(1)      2.599(2)  
Angles        
N(7)-Re-N(17) 85.12(16) 86.05(11) 83.05(16) 82.0(4) 86.46(13) 84.8(4)  
N(7)-Re-C(21) 95.5(2) 95.21(15) 96.7(2) 173.8(5) 178.08(15) 177.2(5) 176.1(6) 
N(7)-Re-C(22) 93.9(2) 176.17(14) 92.4(2) 95.4(5) 92.78(16) 93.3(5) 93.8(5) 
N(7)-Re-C(23) 175.2(2) 93.30(15) 172.3(2) 96.9(5) 92.76(16) 92.1(5) 97.8(5) 
N(17)-Re-C(21) 96.2(2) 95.72(14) 91.6(2) 93.8(5) 92.37(17) 93.1(6)  
N(17)-Re-C(22) 175.4(2) 91.25(14) 175.0(2) 177.0(5) 176.91(16) 92.8(5)  
N(17)-Re-C(23) 91.5(2) 176.35(15) 97.5(2) 94.4(5) 92.15(17) 175.6(5)  
O(1)-Re-N(7) 81.71(17) 82.62(12) 83.30(17) 81.9(4) 85.95(12)   
O(1)-Re-N(17) 80.27(18) 81.02(12) 81.64(16) 88.0(4) 84.04(13)   
Br(1)-Re-N(7)      83.3(3)  
Br(1)-Re-N(17)      84.5(3)  
C(21)-Re-C(22) 88.3(2) 87.91(17) 86.8(3) 88.7(6) 88.3(2) 88.6(6) 87.0(7) 
C(21)-Re-C(23) 88.3(3) 87.75(17) 91.0(3) 87.9(6) 88.8(2) 89.9(6) 87.3(7) 
C(22)-Re-C(23) 89.2(3) 89.22(17) 87.3(2) 87.5(6) 90.9(2) 90.5(6) 89.4(6) 
a C(21), C(22), C(23) refer to carbonyl groups. b 8HT values refer to 99Tc. c For complexes 12HH 
and 12HT N(7) and N(17) refer to N(9) and N(19) respectively, that is to the N atoms bound to Re. 
d See reference 21. 
 
 
The crystal structure of the cations 7HT and 8HT are given in Figure 1.6. In these complexes the 
two 9-MeG bases are in HT orientation which is the most common solid-state conformation of cis-
bis(ligand) complexes of purines with PtII, CoIII, CuII and ZnII.8 In both complexes one of the 9-MeG 
ligands is stabilized by a hydrogen bond between the carbonyl oxygen (O16 in Figure 1.6) and a 
proton of the coordinated CH3OH molecule. In both complexes the guanines coordinate through N7 
only while the carbonyl oxygens (O6 and O16) are not involved in coordination as encountered 
with other metals.7 In both species the O6 carbonyl group of one guanine bisects the plane between 
two CO ligands with average O6-CO oxygen distances of 3.2 Å.  
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Figure 1.6. X-ray structures of cations 7HT (top) and 8HT (bottom).  
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Replacing CH3OH by H2O affords a better model of the complexes in aqueous solution. X-ray 
quality crystals of 10HT were obtained from 7 in water. The crystal structure of the cation 10HT is 
given in Figure 1.7. Although water offers a second proton, no reorientation of the bases took place 
and the structural features resemble closely those of 7HT and 8HT with no additional hydrogen 
bond being formed. In this complex also the two 9-MeG bases are in HT orientation with one base 
stabilized by a hydrogen bond between the carbonyl oxygen (O16 in Figure 1.7) and a proton of the 
coordinated H2O molecule.  
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Figure 1.7. X-ray structure of cation 10HT.  
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Figure 1.8. X-ray structure of cation 10HH.  
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In complex 10HH (see Figure 1.8), the same bases are found in a HH orientation. Both carbonyl 
oxygens can now participate in hydrogen bonding with the coordinated water molecule; however, 
only O6 shows a significant interaction (coordinated water-H-O6 bond = 1.878(1) Å; coordinated 
water-H-O16 bond = 3.065(9) Å, see Figure 1.8). It is also interesting to note that in crystal 
structures of cis-[(NH3)2Pt(9-EtG)2](X)2 (X = Cl-, ½ SO42- or ½ Pt(CN)42-) where the two bases are 
found in a HH conformation, only a single intramolecular hydrogen bond is formed between O6 and 
a NH3 group.22 
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Figure 1.9. X-ray structure of cation 12HT.  
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Figure 1.10. X-ray structure of 12HH.  
 
Complexes with 7-MeG also exhibit both HH and HT orientation of the bases. The crystal 
structure of the cation 12HT given in Figure 1.9. The structural features of this complex resemble 
those of 10HT. In this case the two purines are in a HT orientation with one base stabilized by a 
hydrogen bond between N3 and the a proton of the coordinated H2O molecule (coordinated water-
 27
H-N3 bond = 1.914(2) Å, see Figure 1.9). Complex 12HH is the only complex bearing a bromide at 
the sixth coordination site. The crystal structure of this molecule is given in Figure 1.10. 
Interestingly the two bases were found in a HH orientation.  
 
 
NMR Studies. 1H NMR spectra of 10 and 12 are easily interpreted since in D2O only two 
resonances are found, one in the aromatic region, while the other in the 3-4 ppm region, with a 
relative intensity of 1:3. These signals correspond to the aromatic H8 proton and to the methyl 
group covalently bound to the N9 or N7 atom. Figure 1.11 shows the aromatic region of 1H NMR 
spectra obtained when crystals of (10HT)ClO4 and of (10HH)Br are dissolved in D2O. The single 
major peak resonating at 8.09 ppm corresponds to the bis-ligated species, while the two smaller 
signals flanking it, at 8.33 and 7.81 ppm, correspond to the mono-ligated species and to free 9-
MeG, respectively. With time, the intensity of the small signals increases while the signal of 10HT 
(and/or 10HH) decreases, correspondingly, until the equilibrium depicted in Scheme 1.1 is reached. 
When crystals of (12HT)ClO4 and 12HH are dissolved in D2O, a similar spectrum and a similar 
behavior is observed.  
 
 
○
●
10HH
○ ●
10HT
 
 
 
 
 
 
 
 
 
Figure 1.11. 1H NMR spectrum (7.7-8.5 ppm) of 10HT (left) and 10HH in D2O (298 K). The open 
circle (○) indicates the mono-bound species, the filled circle (●) free 9-MeG. 
 
Raman Spectroscopy. Raman spectra of crystals of (10HT)ClO4, (10HH)Br and of 9-MeG are 
shown in Figure 1.12. The spectra were recorded and compared in order to see if the intermolecular 
base stacking observed in the solid state structure of (10HH)Br (Figure 1.13B) would give rise to a 
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Raman hypochromic effect.23 All spectra show highly characteristic guanine vibrational modes 
around 1580, 1500 and 1370 cm-1. In addition, spectra of (10HT)ClO4 and (10HH)Br show 
characteristic carbonyl ligand bands around 2030-1890 cm-1. No appreciable decrease in signal 
intensity of the guanine bands was found in the spectrum of (10HH)Br. In this latter spectrum, the 
bands at around 1580 and 1370 cm-1 are actually found to have a higher relative intensity to the 
carbonyl ligand bands when compared to the spectrum of (10HT)ClO4. The spectra reported bear a 
resemblance to those of HH conformers of 9-EtG adducts of cisplatin.22 As in this later case, it is 
likely that since the intermolecular base stacking does not exceed the dimer level in (10HH)Br, it 
cannot cause a large enough hypochromic effect to reduce the intensity of the guanine bands.  
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Figure 1.12. Solid state Raman spectra (2100-1300 cm-1) of 9-MeG (a), (10HT)ClO4 (b) and 
(10HH)Br (c). 
 
1.2 Discussion 
 
Crystal Packing. Packing diagrams of the four structures are given in Figure 1.13. Complex 
10HT (Figure 1.13A) shows alternating metal complexes separated along the x-axis by the 
perchlorate counter ions (on average Re-Cl > 6 Å). The packing is stabilized by extensive hydrogen 
bonding interactions involving the complex, the counter ion and the water molecules (see Hydrogen 
Bonding subsection). No evidence of base-base π-stacking interactions was found in this case. 
Complex 10HH (Figure 1.13B) shows π-stacking of one coordinated purine involving the six 
member ring of the bases which are separated on average by 3.8 Å. The bases participating in π-
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stacking are oriented in an antiparallel fashion. In complex 12HT (Figure 1.13C) both bases 
participate in π-stacking interactions however one couple of bases shows only partial overlap. The 
other two bases are fully eclipsed and are oriented in an antiparallel fashion so as to maximize 
dipole-dipole interactions. In this latter case the mean average base-base separation is 3.8 Å. The 
packing diagram of complex 12HH (Figure 1.13D) shows two cavities along the (001) projection. 
The larger of the two cavities is occupied by disordered pentane molecules while the smaller one by 
water molecules. Solvent molecules are however not shown in Figure 1.13D for clarity.  
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Figure 1.13. Perspective views of the crystal packing of structures comprising cations 10HT-12HH 
generated by PLUTON.44 Solvent molecules and counter ion are not shown in C and D for clarity. 
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No evidence of base-base π-stacking interactions was found and the overlap involving the six 
member ring visible in the figure is only apparent as the rings are separated by a distance greater 
than 7.5 Å. 
 
Base Geometry and Conformation. Extensive studies on cis-PtA2{d(GpG)} and simpler cis-
PtA2G2 adducts have now established that the two bases can assume a HH and a HT conformation 
around the metal core.24-35 Solid state structural data indicate that base tilt (or cant) can have two 
different directions, right-handed (R) and left-handed (L).24, 31-35  Furthermore, HT isomers can be 
divided into two groups differing in the degree of canting. ∆HTR and ΛTHL isomers show less 
tilted bases while ΛHTR and ∆THL isomers show more tilted bases.5b-c, 36-38 In discussing the Re 
structures presented in this study it is used the same nomenclature employed to describe the HT and 
HH isomers of Pt compounds.  
In all Re structures the two bases show right-hand canting. The two HT isomers of 7- and 9-MeG 
are of ΛHTR subgroup. This form is, to our knowledge, never been observed in the solid state 
structure of a metal fragment bound to two nucleotides. For cis-PtA2G2 models where G = 
nucleoside and nucleotide, for example, the ∆HTR form is observed exclusively in the solid state.25-
28, 39 A high degree of canting allowing the ΛHTR form is found only when G is not a 5’-nucleotide 
or when the base is part of an oligonucleotide.22, 29, 31-34, 40-41 Therefore, structures 10HT and 12HT 
represent the first examples of ΛHTR forms of a metal fragment bound to two nucleotides. The 
ΛHTR form is unfavoured by electronic (dipole-dipole) interactions. It is now established that 
G(dipole)-G(dipole) interactions favour the less tilted HT atropisomer as this orientation of the 
bases places the H8 end of the dipole closer to the negative six-member ring of the cis-G base than 
in the more tilted form.3, 5, 36-38 This feature stabilizes the ∆HTR form and it is one of the reasons for 
the exclusive crystallization of this form when the two bases are nucleotides. In structures 10HT 
and 12HT this is not the case and the ΛHTR form is observed. 
 
Dihedral Angles. The base-base (B/B') and the base-coordination plane (B/CP) dihedral angles 
are useful parameters for comparing structural features of metal complexes of purines. B/B' is the 
angle formed by the intersection of the planes that pass through the two bases in a cis arrangement 
while B/CP is the angle formed by the intersection of the plane that passes through one of the bases 
and the plane defined by Re, the two N atoms of the bases coordinated to it and two C atoms trans 
to them. The B/B' angle is calculated according to the method outlined by Orbell, Marzilli and 
Kistenmacher by confining one of the two bases to the plane of the paper so that the N→Re vector 
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points leftward and the second base projects outward toward the viewer.42 Relevant conformational 
parameters and dihedral angles are given in Table 1.3. 
 
Table 1.3. Conformational Parameters of Complexes 10HT-12HH. 
 Dihedral angles (deg.)a L NB-Re-NB'  
X-Ray Structure B/B' B/CP B'/CP (deg.) Base canting 
10HT 66 48 50 83.06(17) ΛHTR 
10HH 57 51 46 81.9(4) HHR 
12HT 75 38 78 86.45(13) ΛHTR 
12HH 62 48 47 84.8(4) HHR 
Optimized 
Geometry 
     
A 84 51 61 86.4  
B 86 64 53 89.1  
C 84 30 79 86.3  
D 81 71 86 87.4  
a See text for definitions. 
 
The average B/B' angle of the Re complexes is 65° smaller than the average B/B' angle reported 
for cis-bis nucleotide complexes of Pt where the angle is generally greater than 70°.22, 25, 30, 39 B/CP 
angles are small (near 50°) for all complexes except 12HT where one of the bases shows a rather 
large B/CP angle of 78° while the other base a very small angle of 38°. Orbell et al. found that it 
was possible in some case to rationalize a large (near 90°) or a small B/CP dihedral angle in terms 
of intramolecular effects. They found, for example, that interligand hydrogen bonding tends to 
favour a small B/CP angle, while repulsive interligand steric factors tend to favour a large B/CP 
angle.40 All Re complexes with the exception of 12HH, show a strong (on average 1.91 ± 0.03 Å) 
intramolecular hydrogen bond between one base and the coordinated water molecule and show no 
intramolecular hydrogen bonding between coordinated purines. Complex 12HT, however, is the 
only complex in which both bases participate in π-stacking interactions and neither of them shows 
base-base intermolecular hydrogen bonding. In this case, therefore, intermolecular rather than 
intramolecular effects can rationalize the B/CP angles. Intermolecular base-base hydrogen bonding 
tends to favour a small B/CP angle, while π-stacking interactions tend to favour a large B/CP angle. 
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Hydrogen Bonding. All structures have extensive hydrogen-bonding interactions between the 
guanines and the counter ions and the water molecules present in the crystals. Complete tables of 
these interactions are given in Supporting Information. Solvent molecule-guanine hydrogen-
bonding involves mainly the N(2)H2 and O6 groups of the bases. Although the Re complexes are 
generally well separated (on average in the four structures Re-Re > 8 Å), some intercomplex 
interactions occur. All structures with exception of 12HT, shows base-base intermolecular 
hydrogen bonding. These interactions are shown in Figure 1.14. Complex 10HT (Figure 1.14A) 
shows the unusual base-pairing scheme involving N2 and N3 (N2H-N3 bond 2.184(4) Å) which has 
been observed previously in the HT structure of the Pt-acyclovir complex.31 The intermolecular 
base-base hydrogen bonding scheme of complex 10HH (Figure 1.14B) involves, on the other hand, 
the carbonyl O6 atom and N2H2 and N1H with distances of 2.353(7) and 1.972(1) Å respectively. 
To our knowledge this type of intermolecular interaction has never been reported in cis-bis purine 
metal complexes. Complex 12HH shows the most unusual intermolecular base-base hydrogen 
bonding pair of the three structures. The hydrogen bonding scheme of complex 12HH (Figure 
1.14C) involves the carbonyl O6 atom and the H8 proton (2.445(2) Å). This type of interaction can 
be explained in electronic terms. As it is the case with other metals, the binding by N7 to ReI leads 
to donation of electron density from the base imidazole ring to the metal. This interaction makes the 
H8 proton, already electron deficient and bearing a partial positive charge,43 even more positive and 
therefore likely to participate in hydrogen bonding.     
 
Theoretical Calculations. In order to obtain further information about the relative orientation of 
the coordinated purine ligands, the minima of the total energy surface corresponding to both HH 
and HT conformations of complexes [Re(9-MeG)2(H2O)(CO3)]+ and [Re(7-MeG)2(H2O)(CO3)]+ 
have been first fully optimized by aid of DFT calculations.16 The most stable conformations found 
for both complexes exhibit a HH orientation while the HT conformers lie +5.8 and +6.9 kcal/mol 
higher in energy for complexes with 9-MeG and 7-MeG, respectively (Figure 1.15). The calculated 
values for the base-base (B/B’) and the base-coordination plane (B/CP) dihedral angles defining the 
orientations of the purine ligands in the optimized conformers are in a reasonable agreement with 
those observed in the corresponding crystal structures (Table 1.3). However, it is well established 
that in the gas phase (DFT calculations level), the lowest energy structure maximizes the hydrogen 
bonding between ligands whereas in condensed phase systems, the hydrogen bonding will most 
likely be with surrounding solvent molecules. Thus, one can assume that the calculated energetic 
preference for the HH conformers is due to the fact that the two ligands in a HH orientation are well 
suited to make two intramolecular hydrogen bonds with the coordinated water, whereas the bases in  
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Figure 1.14. Intermolecular base-base hydrogen bonding in complexes 10HT (A), 10HH (B) and 
12HH (C). 
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a HT orientation can support only one such interaction. Consequently, further calculations were 
performed in which a free water molecule was added in the vicinity of the coordinated water 
molecule, in order to allow only one guanine ligand to interact with the coordinated water in both 
conformers. The most stable conformations found for both complexes now exhibit HT orientations: 
the HH conformers are higher in energy by +5.3 and +4.2 kcal/mol for complexes with 9-MeG and 
7-MeG, respectively (See Figure 1.16). Furthermore, linear transit calculations simulating the 
rotation of one ligand around the Re-N bond in both cases of the cis-bis-guanine complex with 9-
MeG and 7-MeG show that the energetic barriers ∆E rise approximately to 8.7 and 6.5 kcal/mol, 
respectively (the non-coordinated water molecule being still involved in the calculation). Finally, 
from our DFT calculations, one can conclude that in solution free rotation of the guanine ligands 
occurs, leading to relative orientations of the ligands in the solid state mainly governed by intra- or 
inter-molecular interactions. 
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Figure 1.15. Optimized geometries and relative energies (∆E) of HH and HT conformers of 
complexes 10HT-12HH (A-D). 
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Figure 1.16. Optimized geometries and relative energies (∆E) of complexes 10HT•H2O (A') and 
10HH•H2O (B'). 
 
1.3 Conclusions 
 
It was shown in this chapter that two guanine bases can coordinate to a ReI or a TcI centre 
yielding reasonably stable complexes with slow on and off rates, the on rates being comparable to 
an active form of cisplatin. The first x-ray structure of a Tc-complex with purine bases was 
presented. They are in a HT orientation in the solid-state. Guanine ligands can assume both a HH 
and a HT conformation in an octahedral complex around the ReI tricarbonyl core. The structural 
evidence presented clearly shows the two conformations. Although it is clear that intermolecular 
packing forces are responsible for the exclusive crystallization of one form, the 1H NMR evidence 
indicates that these two forms are present in solution in equilibrium. Because conformer 
intercoversion is fast on the NMR time scale, it is impossible to use NMR methods to distinguish 
among the forms present in solution. This is the same “dynamic motion problem” present in most 
cisplatin adducts of untethered guanines.3, 5  
 
The presence of a single H8 resonance in the 1H NMR spectrum of 10HT and 10HH indicates 
that the two guanines can freely rotate about the Re-N7(9) bond. This implies that no steric 
hindrance is imposed by the O6 carbonyl oxygen. The presence of HH and HT conformers in 
complexes with either 9-MeG or 7-MeG in the solid state and in solution delineates the fact that 
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intramolecular hydrogen bonding and steric hindrance imposed by the carbonyl oxygen of 
coordinated guanines are not driving forces for the preference of one or the other conformation. 
DFT calculations confirmed the expected free rotation of the guanine ligands in solution leading to 
relative orientations of the ligands, because of small energy differences between conformers and 
relatively low energetic barriers leading from one conformer to the other. 
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Chapter 2. Guanine and Plasmid DNA Binding of Mono- and Trinuclear [Re(CO)3]+ 
Complexes with Amino Acid Ligands 
 
In the last decades metal-based antitumor drugs have been playing an important role as 
therapeutic agents in antiblastic chemotherapy. Cisplatin remains the most effective metal-based 
drug used in clinics but other nonphysiological and physiological transition metal ions have 
received much attention. Among the metal ions studied for their therapeutic potential the octahedral 
geometry is often encountered. Ruthenium (II) and (III) compounds, for example, have raised great 
interest and complexes of the type [trans-RuCl4(X)(X')]+ (X = imidazole, indazole; X' = Me2SO, 
indazole) have already entered phase I clinical trials.1 Although the mode of actions of these 
complexes is not yet well understood, there is evidence for DNA as a likely target, similar to the 
well established platinum drugs.2-19 Dinuclear rhodium acetate [Rh2(µ-(O2CCH3)4)(H2O)2], and 
related complexes have shown good antitumor activity as well20 and structural studies suggest that 
their activity may be analogous to that of cisplatin by binding adjacent purines on DNA.21-24 
 
As mentioned in the previous chapter, recent studies have reported that a number of different 
compounds all based on the fac-[Re(CO)3]+ core show cytotoxic properties. Studies on L1210 
lymphoid leukemia and other cell lines indicated that ReI alkoxo/hydroxo carbonyl complexes were 
effective in inhibiting DNA synthesis via the inhibition of dihydrofolate reductase and other 
enzymes for purine and pyrimidine pathways. Interaction with DNA, however, was not ruled out 
and it was anticipated that the compounds may bind to the nitrogenous bases after displacement of 
the alkoxide or hydroxide ligands.25 Similarly the cytotoxicity of ReI carbonyl 2-
(dimethylamino)ethoxide complexes may involve binding to DNA bases or side-chains or amino 
acid residues in peptides26 while phosphine-derivatized amine complexes seem unlikely alkylating 
agents.27  
 
In chapter 1 it has been shown that the [M(CO)3]+ moiety (M = Re, 99Tc) can bind two guanine 
bases in a cis fashion,28 and X-ray crystallography confirmed that the two bases can assume both a 
head-to-head (HH) and a head-to-tail (HT) conformation around the Re core.29 It was also 
demonstrated that the two bases can freely rotate about the Re-N7 bond and that neither 
intramolecular hydrogen bonding nor steric hindrance imposed by the carbonyl oxygen of 
coordinated guanines are driving forces for the preference of one or the other conformation in the 
octahedral complex.29 
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In order to understand if the cytotoxicity exhibited by some fac-[Re(CO)3]+ core based complexes 
is due to an alkylating event which may result in the formation of inter- or intrastrand links between 
DNA bases in a mode of action analogous to cisplatin, the interaction of a series of rhenium 
tricarbonyl complexes (Figure 2.1) with ΦX174 plasmid DNA has been studied. For these studies 
four new complexes were prepared and fully characterized. Three of these are based on the amino 
acids L-proline (Pro) and N,N-dimethylglycine (DMGly, 13, 14, and 15 in Figure 2.1) and are rare 
examples of structurally characterized molecules in which an amino acid is bound to the above 
mentioned core.  
 
The amino acids were chosen as a kind of protecting group for the rhenium [Re(CO)3]+ core as in 
human serum (HS) [Re(H2O)3(CO)3]+ (1, see Figure 2.1) interacts unspecifically with potential 
coordination sites in serum proteins and is therefore not available at high concentration. Amino 
acids seem good candidates for protecting groups for the rhenium [Re(CO)3]+ core for two main 
reasons. First, depending on the choice of the amino acid, they afford robust bi- or tridentate 
protecting groups for the metal core. Second, since amino acids are not foreign to biological 
systems, once displaced from the metal core, which can then be thought as activated, they will not 
give rise to toxic side effects but they will simply be recycled in the biochemical pathways.  
 
It will be shown in this chapter that reaction of 1 with the amino acids Pro and DMGly gives 
complexes with the unusual trimeric structures 13 and 14 (see Figure 2.1) and that specific 
complexes influence the tertiary structure of ΦX174 DNA by altering the electrophoretic mobility 
of the open circular and the supercoiled form of plasmid DNA. The induced changes involve 
covalent binding to two bases rather than simple electrostatic interaction.  
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Figure 2.1. Rhenium complexes investigated in this chapter. 
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2.1 Results and Discussion 
 
Synthetic Aspects. In this section the preparation of complexes 13-16 is discussed in more details 
and the reasons behind the choice of specific ligands are elucidated. As mentioned earlier, 
[Re(H2O)3(CO)3]+ (1) is readily trapped in human serum (HS) by the serum proteins and it is not 
easily released. The [Re(CO)3]+ moiety must, therefore, be protected by ligands that, on one hand, 
prevent its interaction with serum proteins and are on the other hand labile enough to be displaced 
and to allow the Re core to bind to bases in DNA.  
 
The two NH3 groups in [ReBr(NH3)2(CO)3] (16) were intended to serve the function of the cis-
labile exchangeable chloride ligands encountered in cisplatin and other transition-metal complexes 
tested for anti-tumor activity. Contrary to the latter, where the function is usually fulfilled by 
halides, the NH3 ligand was chosen to confer an overall neutral charge to the complex. Behrens and 
Pässler first prepared and studied the [ReCl(NH3)2(CO)3] complex by reacting [ReCl(CO)5] in a 
benzene/liquid ammonia mixture under controlled pressure.37 It was found that the bromide analog 
can be obtained by a much simpler route by reacting [ReBr(CO)5] in a NH3 saturated benzene 
solution heated to 60 0C. Complex 16 thus obtained is soluble in polar organic solvents. In a 
water/methanol mixture (1:1), however, 16 hydrolyzes to give 1 with rate constants of about 3.8 ± 
0.9 x 10-3 s-1 (k1) and 2.0 ± 0.5 x 10-4 s-1 (k2) as determined by HPLC methods. 
 
The NH3 ligand is too labile to serve a as protecting group for the [Re(CO)3]+ core. We therefore 
focused our attention on amino acids. Amino acids without coordinating side chain afford bidentate 
protecting groups for the Re core. The interaction of organometallic complexes with amino acids 
and peptides, actually pioneered bioorganometallic chemistry,38-40 and has again received much 
attention in recent years.41 Reaction of 1 with the amino acids L-proline (Pro) and N,N-
dimethylglycine (DMGly) yields trinuclear complexes of the type [Re(L)(CO)3]3  (L = Pro, 13; L = 
DMGly, 14).  The reaction goes to completion within a few hours in a methanol/water mixture (9:1) 
and in the presence of a slight excess of amino acids required to neutralize the proton released upon 
coordination of the carboxylate group. Proline was first chosen because secondary amines are 
weaker coordinating and easier to replace. 
 
In order to investigate whether [Re(Pro)(CO)3]3 (13) binds to DNA bases its interaction with 9-
methylguanine (9-MeG) was studied. Complex 13 reacts with 9-MeG in a methanol/water mixture 
to give [Re(Pro)(9-MeG)(CO)3] (15) in good yield as the only product even if excess nucleobase is 
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used. Obviously proline, forming a stable five-membered ring upon coordination, is still a good 
bidentate ligand/protecting group for the [Re(CO)3]+ core and cannot easily be displaced by free 
guanine or incorporated though bidentate binding into DNA. Thus, since 13 has a single available 
coordination site for DNA binding, the complex is unlikely to be able to form cis-bis intra- or 
interstrand adducts with the nitrogen in purine or pyrimidine bases. Under the same condition other 
DNA bases show little or no reaction with 13. 
 
Since Pro seemed to be too inert to be displaced from the metal core by DNA bases, the reaction 
of 1 with N,N-dimethylglycine (DMGly) was investigated. DMGly, containing a tertiary amine, 
should be even less strongly coordinating than the secondary amine in Pro. The extra CH3 group on 
the amine should give a more labile ligand due to steric hindrance. Reaction of 1 with the DMGly 
also yields a trinuclear complex, [Re(DMGly)(CO)3]3 (14). It is noteworthy to mention that 13 and 
14 are obtained as trimeric species in the solid state. In aqueous solution however, 1H NMR and 
ESI-MS evidence suggests that the corresponding monomeric species [Re(L)(H2O)(CO)3] (L = 
amino acid) are also present. These related equilibria have not been investigated in detail as it is 
beyond the scope of this study. In the schemes therefore presented the trinuclear rather than the 
mononuclear species is always shown.  
 
In a water/methanol mixture, (50 oC) 14 reacts with an excess of 9-MeG stepwise. In our HPLC 
gradient complex 14 has a retention time (rt) of 15.5 min (see Figure 2.2). After 1h a second peak is 
observed with rt of 18.5 min. HPLC-MS chromatography indicates that this species is 
[Re(DMGly)(9-MeG)(CO)3] (17). After a further 1h a third peak appears at 17.5 min which was 
identified as [Re(9-MeG)2(H2O)(CO)3]+ (10). The reaction proceeds further until a fourth peak is 
seen at 16.5 min and an equilibrium is reached. This final species was identified by HPLC-MS as 
[Re(9-MeG)(H2O)2(CO)3]+ (10a, see Figure 2.2).  
 
As anticipated, the conversion of 14 to complex 10 implies that DMGly can be displaced due to 
increased steric hindrance from the Re coordination sphere in favour of 9-MeG. In fact, as 
described in more details later, the Re-N(1) and Re-O(1) bond lengths in 14 are 0.06 and 0.04 Å 
respectively longer than in 13 and the N(1)-Re-O(1) bite angle is about 0.7o more acute in 14 (see x-
ray crystallography subsection 2.2.2). These differences lead to a weakening of the Re-N/O bonds 
and consequently to an increased reactivity of 14 inducing excess 9-MeG  to displace DMGly.  
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Figure 2.2. HPLC chromatogram of the reaction of 14 with excess 9-MeG and equilibrium scheme. 
 
The results suggest that 14 might be a good candidate for a model Re pro-drug. While a ligand 
like DMGly protects the [Re(CO)3]+ core from reacting with coordinating sites in blood proteins the 
steric hindrance imposed on one (or both) of the coordinated atoms renders the ligand weak enough 
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to be displaced by stronger (even monodentate) ligands such as guanine. Indeed, in human serum 
little or no reaction of 14 with serum proteins was seen during a 12h incubation period at 37 °C. 
 
X-ray Crystallography. Crystal data and experiment details are listed in the crystallography 
section. The crystal structure of compound 16 is shown in Figure 2.3. The structure consists of 
discrete molecules separated by van der Waals distances with short contacts occurring exclusively 
between Br, carbonyl oxygens and protons of NH3 (on average NH-Br = 2.940(5) Å, NH-OC = 
2.605(7) Å). The molecule crystallizes in the orthorhombic space group Pnma with Br, Re and C2O 
laying on a mirror plane at x, ¾, z. The geometry around rhenium is octahedral with Re-N1 distance 
of 2.240(6) Å which is comparable to the average Re-NH2R distances (2.238 Å) in the bidentate en 
of the related [Re(en-N,N')(en-N)(CO)3]+ (en = ethylenediamine) complex and significantly longer 
than the average distance in the monodentate en.42  
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Br
N1
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Figure 2.3. Crystal structure of [ReBr(NH3)2(CO)3] (16). Selected bond distances (Å) and angles 
(deg) are the following: Re-N1 2.240(6), Re-Br 2.6604(14); N1-Re-Br 84.65(17), N1-Re-N2 
81.4(3). 
 
Figure 2.4 and Figure 2.5 depict the molecular structure in the crystal of complexes 13 and 14. 
Both molecules are macrocyclic trimers in which the rhenium atoms are bridged by the carbonyl 
oxygen of the amino acid ligand with the metal atoms being 5.43 Å apart from each other. In 13 the 
three Re atoms are related to each other by a three-fold rotation axis while in 14 there is no 
symmetry element that relates the three metal atoms. In both structures the rhenium is bonded in a 
distorted octahedral geometry with N-Re-O bite angles of 75-79o. All bond lengths are in good  
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Figure 2.4. Crystal structure of [Re(Pro)(CO)3]3 (13). Selected bond distances (Å) and angles (deg) 
are the following: Re-N1 2.205(5), Re-O1 2.138(4), Re-O2 2.195(4); N1-Re-O1 75.69(17), N1-Re-
O2 76.93(17), O1-Re-O2 83.29(17). 
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Figure 2.5. Crystal structure of [Re(DMGly)(CO)3]3 (14). Selected bond distances (Å) and angles 
(deg) are the following: Re-O1 2.172(8), Re-N1 2.260(10), Re-O2 2.189(8); O1-Re-N1 75.0(4). 
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agreement with the structure of [Re(His)(CO)3] (18, see Figure 2.1). Complexes 13 and 14 are rare 
examples of structurally characterized molecules in which an amino acid is bound to the [Re(CO)3]+ 
core and to our knowledge they represent the first example a macrocyclic trimer of the [Re(CO)3]+ 
core not involving a µ-type bridge. 
 
These unusual Re trinuclear complexes are closely related to a family of chiral-at-metal trimers of 
general formula [{(ηn-ring)M(L)}3](BF4)3 (where M = Ru, Os, Rh, Ir; L = amino acid) which result 
from the reaction of  [(ηn-ring)MCl(L)] with AgBF4.41 In these cationic complexes the 
aminocarboxylate ligand also acts as a tridentate bridging group where, as in 13 and 14, the nitrogen 
atom and one the carboxylic oxygen atoms are bonded to a metal center forming a five-membered 
metallacycle and the remaining oxygen coordinates to a second neighboured metal center. The 
structures of 13 and 14 also resemble the self-assembled ruthenium macrocyclic ionophores with 
high affinity and selectivity for Li+ and Na+ recently described by Severin.43-44 The twelve atoms 
forming the central macrocyclic cavity in 13 and 14 are shown in Figure 2.6 along with mean 
average distances.  
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Compound 13  Compound 14 
 
Avg. CO-OC       4.36 Å        4.48 Å 
Avg. Re-Re       5.43 Å        5.43 Å 
Avg. O-O       4.10 Å        4.11 Å 
 
 
 
 
Figure 2.6. The twelve atoms forming the central macrocyclic cavity in 13 and 14. Mean average 
distances are shown to the right. 
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The average O-O distance (where O =  bridging carboxyl oxygen of  the amino acid) is about 1 Å 
longer than the average O-O distance of Severin’s inophores. Compounds 13 and 14 might 
therefore be selective for larger cations like K+ and/or Rb+ although a high thermodynamic stability 
is not expected. 
 
The molecular structure of 15 is shown in Figure 2.7. The complex crystallizes in the monoclinic 
space group P21 with three independent molecules in the unit cell. In the crystal the molecules show 
an extensive network of intermolecular hydrogen-bonding interactions between the guanines and 
the amino acids. Two types of such interactions are shown in Figure 2.8. The proton bound to N1 
and one of the protons of the extracyclic N2H2 group always form a hydrogen bond with the 
oxygens O1 and O2, respectively, of the carboxylate group of the coordinated proline. The average 
mean distances for these interactions are N1H-O1 = 2.068(6) Å and N2H-O2 = 1.992(3) Å.  
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Figure 2.7. Crystal structure of [Re(Pro)(9-MeG)(CO)3] (15). Selected bond distances (Å) and 
angles (deg) are the following: Re-O1 2.163(4), Re-N7 2.208(4), Re-N4 2.216(4); O1-Re-N7 
81.58(15), O1-Re-N4 75.95(15), N7-Re-N4 83.29(15). 
 
The second proton of the N2H2 group forms one of three unique hydrogen bonds: either with the 
carboxylic oxygen O2 of an adjacent complex (Figure 2.8A, on average N2H'-O2 = 2.064(4) Å), or 
with N3 (Figure 2.8B, on average N2H'-N3 = 2.116(3) Å) or finally with the oxygen of a solvent 
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methanol molecule (on average N2H'-OHCH3 = 2.170(7) Å). The geometry is octahedral with all 
bond distances and angles falling within expected values. Finally, the position of the guanine in the 
crystal state is stabilized by an intramolecular hydrogen bond (on average 2.041(6) Å) between the 
proline N4H proton and the carbonyl oxygen O6 of the base. 
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Figure 2.8. Two types of intermolecular hydrogen-bonding interactions in the crystal of 15. Labels 
are as in Figure 2.7. Solvent methanol molecules are not shown for clarity. 
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Conformational Change of ΦX174 DNA Induced by ReI Complex Binding. Gel mobility shift 
assays demonstrate the conformational changes in macromolecules. The study of metal-DNA 
binding and of the changes induced by metal complexes on the tertiary structure of DNA by this 
technique is now well established. Different Pt and Ru complexes, for example, cause unwinding of 
supercoiled (sc) or winding of open circular (oc) plasmid DNA.45-58 These structural changes can be 
observed on the gel matrix. Unwinding of sc plasmid DNA for example causes relaxation of the 
DNA molecule and, consequently, the frictional force between DNA and the gel matrix during 
electrophoresis increases. Thus, the band corresponding to the DNA-metal adduct moves relatively 
slower than the one of native sc DNA. The opposite is true if a metal complex causes winding of oc 
plasmid DNA. In this case winding of oc DNA renders the molecule more compact, the frictional 
force is reduced and the band of the corresponding DNA-metal adduct moves relatively faster. 
 
The analysis of the binding and of the influence of compounds shown in Figure 2.1 on the tertiary 
structure of DNA was determined by their ability to alter the electrophoretic mobility of the open 
circular and supercoiled form ΦX174 DNA. Figure 2.9A shows the mobility of native ΦX174 
plasmid DNA and plasmid DNA (abbreviated as pDNA) incubated with compound 1. Clearly, 
increasing the rb value (rb = metal/base pair ratio) for the incubation of DNA with 1 induces a 
gradual increase in mobility of the oc form. Increase in mobility starts at rb = 0.18 (lane 5) and 
progresses until at rb = 18 (lane 7) when a high degree of DNA mobility is reached. At a rb = 180 
(lane 8) the band disappears from the gel.  
 
The same effect is observed when ΦX174 pDNA is incubated with cisplatin. Figure 2.9B shows 
the mobility of native ΦX174 pDNA and pDNA incubated with compound 1 and cisplatin under the 
same conditions. The influence on the tertiary structure and mobility of DNA produced by the two 
compounds is similar although the analogous effect as induced by 1 can be obtained already with a 
10 times lower concentration of cisplatin. At rb = 0.018 (lane 2), in fact, 1 causes no change in the 
mobility of DNA as indicated by the presence of both the oc and the sc forms of the plasmid as in 
reference lanes 1 and 8. At rb = 0.018 (lane 5), however, cisplatin induces a shift similar to the one 
caused by 1 at rb = 0.18 (lane 3). The same is true if comparing lanes 4 and 6 where rb values are 1.8 
and 0.18 for 1 and cisplatin respectively. At higher cisplatin concentration (rb = 1.8, lane 7) the band 
disappears from the gel as previously noted.47, 56 
 
It is well established that Pt binding to pDNA causes winding of the oc form and unwinding of 
the sc form.45-55 The same effect is known to occur with other metal ions like Ru when covalent 
binding to N7 in G and noncovalent, hydrophobic interactions take place.53, 56-58 It is therefore likely 
that the shift in mobility of ΦX174 pDNA caused by Re is due to similar molecular events taking 
place as with Pt and Ru. Since in almost all our experiments both oc and sc forms are present at the 
same time, binding of Re to DNA results in a concerted unwinding of the sc form together with 
winding of the oc form. These events result in an equilibrium tertiary DNA structure which is 
revealed by a single band on the gel. 
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Figure 2.9. (A) Electrophoresis in 0.75% agarose gel of ΦX174 DNA (5 nM, batch 1) incubated 
with various concentrations of 1. Lane 1 reference ΦX174 DNA. Lanes 2 to 7 ΦX174 DNA plus 1. 
rb levels for lanes 2-8: (2) 0.00018; (3) 0.0018; (4) 0.018; (5) 0.18; (6) 1.8; (7) 18; (8) 180. (B) 
Electrophoresis in 0.75% agarose gel of ΦX174 DNA (5 nM, batch 2) incubated with various 
concentrations of 1 (lanes 2-4) and cisplatin (lanes 5-7). Lanes 1 and 8 reference ΦX174 DNA. rb 
levels for lanes 2-7: (2, 5) 0.018; (3, 6) 0.18; (4, 7) 1.8. (C) Electrophoresis in 0.75% agarose gel of 
ΦX174 DNA (5 nM, batch 2) incubated with various concentrations of 1 (lanes 2-4) and 19 (lanes 
5-7). Lanes 1 and 8 reference ΦX174 DNA. rb levels for lanes 2-7: (2, 5) 0.018; (3, 6) 0.18; (4, 7) 
1.8. 
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In order to evaluate whether these changes are due to electrostatic rather than to a covalent 
interaction, ΦX174 pDNA was  incubated with 1 and 19 ([Re(Im)3(CO)3]+, Figure 2.1) under the 
same conditions (Figure 2.9C). The high kinetic stability of complex 1932 rules out possible ligand 
exchange and inner sphere coordination to DNA. Any eventually observed change of the tertiary 
structure of the plasmid can therefore not be attributed to coordination to one of the nucleobases. 
However, while 1 induced the shift in mobility (lanes 2-4), complex 19 has no effect at all (lanes 5-
7, see Figure 2.9C) indicating that metal binding to DNA is responsible for the observed changes 
rather than simple electrostatic interactions. 
 
The question now arises whether the structural changes induced by compound 1 are due to the 
binding of [Re(CO)3]+ to one or two DNA bases. To answer this question 1, 10, 13, and 18 (Figure 
2.1) were subjected to the same study and incubated with pDNA. Compounds 1 and 10 have two 
coordination sites allowing the formation of cis-bis adducts of guanine, whereas 13 has only one 
such site as demonstrated with compound 15 and is therefore not able to form cis-bis intra- or 
interstrand adducts with the purine bases. Compound 18, finally, is inert towards ligand 
substitution31 and it has no available coordination sites. Figure 2.10 shows the mobility of ΦX174 
pDNA with and without incubation with compound 1, 10, 13, and 18 under the same conditions. As 
expected complex 1 (lanes 2-4) and complex 10 (lanes 5-7) induce the increase in mobility of 
plasmid DNA while complexes 13 (lanes 8-10) and 18 (lanes 1-13) do not. These results imply that 
two available coordination sites are necessary to induce the DNA shift in mobility. Consequently 
the shift in mobility is most likely due to binding of the [Re(CO)3]+ core to two DNA bases. 
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Figure 2.10. Electrophoresis in 0.75% agarose gel of ΦX174 DNA (5 nM, batch 2) incubated with 
various concentrations of 1 (lanes 2-4), 10 (lanes 5-7), 13 (lanes 8-10), 18 (lanes 11-13). Lanes 1 
and 14 reference ΦX174 DNA. rb levels for lanes 2-13: (2, 5, 8, 11) 0.018; (3, 6, 9, 12) 0.18; (4, 7, 
10, 13) 1.8.  
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Furthermore, when analyzing the binding and the influence of compounds 14 on the tertiary 
structure of ΦX174 DNA effects analogous to those induced by 1 and 10 were observed (Figure 
2.11). As discussed before (Figure 2.2) the reaction of 14 with excess 9-MeG establishes an 
equilibrium with species 10 and 10a, indicating that DMGly is displaced from the rhenium 
coordination sphere in favor of the base (see Figure 2.2). The shift in mobility induced by 14 is 
visible at rb values of 0.13 (lane 7), 0.36 (lane 9), 3.6 (lane 10), 0.54 (lane 12) and 5.4 (lane 13). 
These results further suggest that the shift in mobility of ΦX174 pDNA is due to binding of 
rhenium to two DNA bases following, in this case, displacement of DMGly. 
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Figure 2.11. Electrophoresis in 0.75% agarose gel of ΦX174 DNA (5 nM, batch 2) incubated with 
various concentrations of 1 (lanes 2-4) and 14 (lanes 5-13). Lanes 1 and 14 reference ΦX174 DNA. 
rb levels for lanes 2-13: (2, 5) 0.013; (3, 6) 0.13; (4, 7) 1.3; (8) 0.036; (9) 0.36; (10) 3.6; (11) 0.054; 
(12) 0.54; (13) 5.4. 
 
The interaction of Re with DNA may also involve binding to the phosphate backbone. However, 
Re binding to the bases is most likely the molecular event. Interaction between Re and phosphate 
oxygen of phosphate containing model ligands has never been observed in our studies. Since two 
available coordination sites on the metal are the prerequisite to induce changes in the tertiary 
structure of plasmid DNA, bidentate binding to the phosphate backbone would give rise to a rather 
strained four-member ring not obviously affecting the tertiary structure, while interaction with the 
bases can be easily rationalized on the base of our previous results. 
 
The stability of the Re-DNA adduct is an important factor for using such Re-complexes as DNA 
binding agents in cancer therapy. One principal hypothesis, originally advanced by Lippard to 
explain the activity of cisplatin, suggests that the HH form in the intrastrand lesion is recognized by 
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a damage recognition protein whose binding prevents DNA repair. The cisplatin adduct persists 
then long enough to activate apoptosis.59 If this hypothesis is correct, a relatively stable Re-DNA 
adduct is required to activate the same cellular response.  
 
Figure 2.12A shows the mobility of native ΦX174 pDNA incubated with compound 1 and 
compound 16 while Figure 2.12B shows the same samples after a further 22h incubation period in 
the presence of 6 eq. of histidine. As expected, compound 16 induces the same mobility shift of 
DNA as 1 (Figure 2.12A). When the adducts thus formed are challenged with histidine (Figure 
2.12B) no appreciable changes in lanes 2, 3 (rb = 0.018 and 0.18, compound 1), 5 and 6 (rb = 0.018 
and 0.18, compound 16) was found. Lanes 4 and 7 (rb = 1.8, compound 1 and 16 respectively) 
however, show a remarkable decrease in mobility when compared to the same lanes in Figure 
2.12A. This effect is most likely due to trapping of unspecifically bound Re (e.g. weakly bound to 
adenine). The Re-DNA adduct formed, however, is clearly stable. 
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Figure 2.12. (A) Electrophoresis in 0.75% agarose gel of ΦX174 DNA (5 nM, batch 1) incubated 
with various concentrations of 1 (lanes 2-4) and 16 (lanes 5-7). (B) Electrophoresis in 0.75% 
agarose gel of same solutions of (A) challenged with histidine for 22 h. Lane 1 reference ΦX174 
DNA. rb levels for lanes 2-7: (2, 5) 0.018; (3, 6) 0.18; (4, 7) 1.8.  
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2.2 Conclusion 
 
It was shown in this chapter that the [Re(CO)3]+ moiety displays a principally similar reactivity 
pattern with pDNA as e.g. cisplatin. It binds selectively to two free guanines, implying a possible 
interaction with adjacent guanines in DNA as well. To protect the Re center in plasma from 
unwanted coordination (trapping) to serum proteins coligands such as proline or N,N-
dimethylglycine were used yielding Re complexes in the form of pro-drugs. DMGly in particular 
can be replaced by coordination to N7 of guanine. The complexes with proline are too stable in this 
respect but both complexes do not cross react with human serum.  
 
If the coligands are labile enough the corresponding complexes such as [Re(DMGly)(CO)3]3 
influence the tertiary structure of ΦX174 DNA by altering the electrophoretic mobility of the open 
circular and the supercoiled form of plasmid DNA. The induced changes involve most likely 
covalent binding to two bases as found for cisplatin. Although less potent, the presented model 
complexes depict the in vitro reactivity characteristics as required for therapeutic agents. They 
might therefore serve as future inorganic medicinal drugs provided that they are able to accumulate 
to a sufficient extent in the cell and in the nucleus in particular. Cell uptake and cytotoxicity studies 
will be presented in chapter 5. 
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Chapter 3. Interaction of [Re(H2O)3(CO)3]+ Complex (1) with d(GpG) and d(CpGpG) 
 
NMR and X-ray investigations have been carried out in the last twenty years to elucidate the 
structural feature of the interaction of the anticancer drug cisplatin with DNA bases. Bifunctional 
binding to purines determines the loss of stacking in coordinated bases and leads to bending of the 
double helix associated to some extent with unwinding. These DNA modifications contribute to a 
cascade of events, including transcription inhibition and repair shielding of cisplatin-DNA cross-
links which ultimately result in cell death.1-3  
 
Insights into the nature of the GpG platinum adducts emerged from the X-ray structure 
determination of (NH3)2Pt{d(pGpG)} (see Figure 3.1) followed by those of longer 
oligonucleotides.4-9 To our knowledge this structure remains to date the only structure of a metal 
fragment bound to GG. For other transition metals of interest in cancer therapy, among which Ru 
and Rh play a predominant role, the structure of the d(GpG) adducts has been determined only in 
solution via NMR studies.  
 
Cauci and coworkers have demonstrated that the antitumor octahedral trans-RuCl2(DMSO)4 
complex forms with d(GpG) a stable compound characterized by covalent bifunctional binding to 
N7.10 Via NMR and molecular modeling studies they showed that the guanine bases in the Ru-
d(GpG) adduct are in a head-to-head (HH) orientation. Their model shows structural features 
similar to the those exhibited by the corresponding platinum adduct demonstrating that such a way 
of interacting with DNA is not exclusive to Pt or to metals with square planar geometry, as 
originally suggested by Lippard, but might be a common feature of transition metals with two 
available cis position for covalent binding.10
 
More recently, Chifotides, Dunbar and coworkers have presented a binding study of the d(pGpG) 
fragment with antitumor tetrakis(µ-carboxylato)dirhodium(II,II) compounds.11-13 They have shown 
that the interaction of the dirhodium units with d(pGpG) yields an adduct in which both metal-metal 
bonded rhodium centers are capable of engaging in cis binding to GG intrastrand sites by 
establishing N7/O6 bridges that span the Rh-Rh bond. In their model the guanine residues are also 
found in a left-handed HH arrangement.  
 
In solution cis-[Pt(NH3)2{d(GpG)}], the simplest cross-link model, has only one set of 1H NMR 
signals. This observation has been taken to imply that this cross-link model favours the HH 
conformer, which undergoes slow Pt-N7 bond rotation. The phosphate backbone of the dinucleotide 
is thought to stabilize an HH arrangement, thereby rendering an HT form less favourable. By using 
the so called “retro models”, Marzilli, Natile and their coworkers have later demonstrated that at 
least four different conformers of comparable stability exist of cis-[Pt(N2)2{d(GpG)}] (where N = 
derivatized amine), three HH conformers and one HT adduct.14-24
 
In the previous chapters it was demonstrated that the fac-[Re(CO)3]+ core binds two guanine 
bases yielding reasonably stable complexes. It was shown that the guanine ligands can assume both 
a HH and a HT conformation around the metal center and that the two bases can freely rotate about 
the Re-N7 bond. It was also shown that the [Re(CO)3]+ moiety displays a principally similar 
reactivity pattern with plasmid DNA as e.g. cisplatin implying a possible interaction with adjacent 
guanines in DNA as well.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Molecular structure of cis-[Pt(NH3)2{d(pGpG)}].5
 
In this chapter the interaction of 1 with d(GpG) and d(CpGpG) is described. The reactions of 1 
with these DNA fragments, studied in solution via NMR and other spectroscopic methods, yield 
stable adducts in which the metal center binds to the guanine residues via N7. In the case where the 
DNA fragment is d(GpG), two major products form in the reaction with 1. These are assigned to a 
HH and a HT species based on NMR evidence and ring current shift calculations. On the other 
hand, a single major product is found in the reaction of 1 with d(CpGpG). 
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3.1 Results and Discussion 
Interaction of 1 with d(GpG). The reaction of 1 with 1 eq. of d(GpG) in D2O was monitored by 
1H NMR spectroscopy. At 37 oC the addition of 1 to a solution of d(GpG) causes the immediate 
appearance in the spectrum of six peaks in the 8.5-8.7 ppm region. With time the resonances due to 
the H8 signals of free d(GpG) decrease in intensity, two new sets of sharp well separated peaks of 
the non equivalent H8 protons appear between 7.7 and 8.2 ppm while the original peaks in the 8.5-
8.7 ppm region remain relatively constant with respect to the total H8 signal intensity. Figure 3.1 
shows the aromatic region (7.7-8.7 ppm) at the end of the reaction of 1 with d(GpG) (≈ 18h 
incubation). 
 
 20a
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Figure 3.1. 1H NMR spectrum (D2O, 37 oC, 7.7-8.7 ppm) obtained after ≈ 18h incubation of 1 with 
1eq d(GpG). The star indicates an unreactive impurity present in the sample. 
 
The peaks in the 8.5-8.7 ppm are assigned to mono bound Re-d(GpG) species. In Chapter 1 it was 
shown that in mono bound species of the type [Re(B)(H2O)2(CO)3]+ (where B = 9/7-MeG, G or 
2dG) the H8 signal is shifted downfield by about 0.55 ppm with respect to the free base. This occurs 
because binding by N7 to ReI leads to donation of electron density from the base imidazole ring to 
the metal. This interaction makes the H8 proton, already electron deficient and bearing a partial 
positive charge, even more positive (i.e. electron deficient) causing a downfield shift of the 
resonance associated with the proton. Coordination of a second nucleoside to [Re(B)(H2O)2(CO)3]+, 
however, results in a relative upfield shift of the same resonance. This is most likely due to ring 
current effects of the nucleobases which shield to some extent the proton from the external 
magnetic field of the probe. 
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The two sets of peaks between 7.7 and 8.2 ppm are consequently assigned to bis bound Re-
d(GpG) species (20a and 20b). The two guanine bases bind to Re through N7, a fact corroborated 
by the pH independence of the H8 resonances at pH values near 2 (Figure 3.2). In fact all chemical 
shifts of the H8 are unaffected by lowering the pH below 4, contrary to what is expected for a free 
guanine N7. On the other hand resonances assigned to mono bound Re-d(GpG) species suffer a 
progressive downfield shift as the pH is lowered below 4. 
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Figure 3.2. pH dependence of the H8 1H NMR resonances of bis bound Re-d(GpG) adducts. 
 
At alkaline pH (pH > 8) a single set of peaks is observed. CD spectroscopy and MS analysis 
indicate that at pH > 8, 1 dissociates from d(GpG). The CD profile of a solution of d(GpG) shows 
minima at 235 and 283 nm and a maximum at 258 nm (Figure 3.3, spectrum a). After the addition 
of 1 eq. of 1, in the same profile maxima are detected at 254 and 292 nm with a minimum present at 
274 nm (Figure 3.3, spectrum b).  The CD spectrum of the alkaline NMR solution described above 
shows features closely resembling those of free d(GpG).  
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Figure 3.3. CD profile (H2O, 37 oC) of a 0.1 mM solution of d(GpG) (a) and of the same solution 
after the addition of 1 eq. of 1 (b, 24h incubation). 
 
Furthermore, at pH 7, MS analysis of the products formed in situ in the NMR tube shows a single 
peak with a clear Re1 pattern at 866.6 m/z corresponding to [Re(d(GpG))(CO)3]+ (see Figure 3.4). 
However, when the pH is raised above 8 the peak can no longer be detected. Metal dissociation 
from d(GpG) at alkaline pH appears to be a unique behaviour of the [Re(CO)3]+ core as to our 
knowledge the same has never been described for d(GpG) complexes of Pt, Ru or Rh. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. MS spectrum (845-888 m/z) of a d(GpG) solution incubated (H2O, 37 oC, 12h) with 1. 
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Binding of 1 to the guanine residues causes a downfield shift of about 0.3 ppm of the 31P 
resonances of free d(GpG) (Figure 3.5). Such a downfield shift of the 31P signal with respect to free 
d(GpG) is common for Pt and Rh metal macrochelates of this DNA fragment.11-13, 25-27 A down 
field shift of the main 31P signal in DNA usually indicates an increase in the unwinding angle 
characterized by changes in the R-O-P-O-R torsion angles. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. 31P NMR spectrum of d(GpG) (top) and of a 1:1 mixture of 1 : d(GpG) incubated in 
D2O, 37 oC, ≈ 18h (bottom). 
 
A strong NOE cross-peak was detected between H8 and H1 of 3'G of 20a, suggesting a syn 
orientation of 3'G (Figure 3.5). On the other hand, no exchange-NOE signal could be detected 
between the H8 protons of coordinated guanosines in the 20a and 20b. This indicates that the two 
protons are separated by a distance greater than 3 Å. 
 
Based on these observations a model structure of 20a was calculated. The structure presented in 
Figure 3.6 does not represent the exact solution structure of 20a. Calculation were performed in 
order to determine the relative orientation of the two bases (i.e. HT vs. HH orientation). The H8-H1 
distance of 3'G of 20a was fixed to 2.8 Å and two different conformations of the molecule were 
calculated, one in which the two guanine residues were in a HT orientation and the other in which 
the bases were in a HH orientation. The HH model placed the two H8 protons in close proximity to 
each other (H8-H8 distance < 3 Å). In this orientation a NOE cross-peak is expected between the 
two hydrogen atoms in disagreement with the experimental results. In the HT model, on the other 
hand, the two H8 protons are separated by a distance of 3.9 Å. In this case no exchange-NOE signal 
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is expected and the relative orientation of the guanine residues in 20a is assigned to a HT 
orientation. 
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Figure 3.5. Expanded NOESY spectrum (8.3-5.9 ppm) of 1-d(GpG) adducts. Arrows indicate the 
protons showing the strong NOE cross-peak. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. MM+ optimized structure of 20a based on NMR data. The guanine residues are 
calculated in a HT conformation. 
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The relative orientation of the ligands in 20a was further corroborated by ring current shift 
calculations based on model structure 10HT and 10HH (see Chapter 1). In 1977 Abraham and 
coworkers developed a theoretical model in order to quantify ring current shifts in porphyrin (Ph) 
and phthalocyanine (Pc) complexes.28-36 Abraham’s model breaks down the porphyrin ring into 
eight current loops (12 for Pc), each loop with an equivalent dipole placed at its center (Figure 3.7). 
The magnetic field of each loop is approximated by the equivalent magnetic dipole. The ring 
current shift at any nucleus H at polar coordinates (r, θ) is obtained by summing the contribution of 
each equivalent dipole and it is calculated according to Equation 3.1.  
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Figure 3.7. The dipole network for Pc (left) and the coordinate axes (right) of Abraham’s model.  
 
 
 
 
Equation 3.1. ∆δH = ppm shift. µH and µP represent magnetic dipole of pyrrole and benzene rings 
respectively. cosθiH = ZH / rH where r is the distance of H from the dipole µ and θ is the angle that r 
makes with the z axis. 
 
The µH and µP were placed at the center of each heterocycle of the guanine ligands in structure 
10HT and 10HH 0.64 Å above and below the plane of the base as the average position of the π 
electron cloud as described in the original references. The known pyrrole and benzene dipole values 
were then assigned to µH and µP and based on Abraham’s equation the average ring current shift 
that each guanine residue exerts on the H8 proton of the adjacent ligand was calculated. Figure 3.8 
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shows structures 10HT and 10HH and the position of µH and µP within the ligand system. Table 3.1 
summarizes the results of these calculations. 
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Figure 3.8. Structures 10HT  and 10HH and the position of µH and µP within the ligand system. 
 
Table 3.1 Observed and Calculated ∆δ (ppm) of 3' and 5'G for 20a and 20b with respect to d(GpG). 
H8 of base Observed Observed Calculated a Calculated a
 20a 20b 10HT 10HH 
3'G -0.03 -0.14 -0.49 -0.83 
5'G -0.18 +0.01 -1.42 +0.32 
a = Values corrected by +0.55 ppm due to downfield shift caused by Re binding. 
 
Although the calculated values do not exactly agree with the observed values the trend outlined 
by the calculations is similar to the observed one. One must bear in mind that the calculations are 
based on rigid crystal structures and that the pyrrole and benzene µH and µP values certainly do not 
represent µ values for a guanine base. However, in a HT conformation an upfield shift is predicted 
for both H8 protons of 3'G and 5'G with H8 5'G shift > H8 3'G shift as observed in the case of 20a. 
In a HH orientation an upfield shift is predicted for H8 of 3'G while a downfield shift is expected 
for H8 of 5'G as observed in the case of 20b. Based on these considerations 20a may be assigned as 
a HT adduct of Re-d(GpG) while 20b as a HH adduct. These assignments are undoubtedly 
speculative as a number of different conformations may be suggested. Adducts 20a and 20b, for 
example, might both be HT conformers with the tip of the imidazole ring of 3'G pointing in one 
case towards a carbonyl ligand and in the other case towards the water molecule trans to it. 
Different HH and HT conformers of d(GpG) bound to a Pt atom are known and they show 
remarkably different NMR spectra.  
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 The initial approach of 1 to d(GpG) must obviously be monofunctional binding, with metalation 
occurring either at the 3'G or at the 5'G followed by closure of the macrochelate. The time course of 
the macrochelate closure (i.e. formation of complexes 20a and 20b) in the reaction of 1 with 
d(GpG) was followed by 1H NMR spectroscopy. Kinetic data reveal that 20a and 20b form at the 
same rate (Figure 3.9). The t½’s for the formation of 20a and 20b are virtually identical within 
experimental error and they are about twice the t½ value for d(GpG) disappearance. This implies 
that d(GpG) is consumed twice as fast as 20a or 20b are formed, indicating that macrochelate 
closure is not the rate determining step but a rather fast reaction.  
 
d(GpG) disappearance 
t1/2 = 1.27 ± 0.03 h
20a Formation
t1/2 = 2.45 ± 0.40 h
20b Formation
t1/2 = 2.69 ± 0.41 h
 
 
 
 
 
 
 
 
 
Figure 3.9. The time course of d(GpG) disappearance and formation of complexes 20a and 20b in 
the reaction of 1 with d(GpG) was followed by 1H NMR spectroscopy. 
 
Interaction of 1 with d(CpGpG). The reaction of 1 with 1 eq. of d(CpGpG) in D2O was also 
monitored by 1H NMR spectroscopy. As described above for d(GpG), at 37 oC the addition of 1 to a 
solution of d(CpGpG) causes the immediate appearance in the spectrum of four peaks in the 8.4-8.7 
ppm region. With time the resonances due to the H8 signals of free d(CpGpG) decrease in intensity, 
a new set of sharp well separated peaks of the non equivalent H8 protons appear between 7.7 and 
8.0 ppm while the original peaks in the 8.5-8.7 ppm region remain relatively constant with respect 
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to the total H8 signal intensity. Figure 3.10 shows the aromatic region (7.0-9.0 ppm) at the end of 
the reaction of 1 with d(CpGpG) (1h incubation). 
 
 
mono bound species
d(CpGpG)
21
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. 1H NMR spectrum (D2O, 37 oC, 7.0-8.0 ppm) of d(CpGpG) (top) and the same sample 
after 1h incubation with 1eq of 1 (bottom). 
 
In accordance with what has been described in the previous section, the peaks in the 8.4-8.7 ppm 
are assigned to mono bound Re-d(CpGpG) species. The two peaks of the single major product 
between 7.7 and 8.0 ppm are consequently assigned to H8 resonances of a bis bound Re-d(CpGpG) 
species (21). While the H8 signals of 21 resonate upfield with respect to free d(CpGpG), the 
cytosine resonances (the two peaks at 7.6 and 7.7 ppm, top spectrum in Figure 3.10) suffer a 
downfield shift.  
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The two guanine bases bind to Re through N7, a fact corroborated by the pH independence of the 
H8 resonances at pH values near 2 (Figure 3.11). In fact all chemical shifts of the H8 are unaffected 
by lowering the pH below 4, contrary to what is expected for a free guanine N7. On the other hand 
resonances assigned to mono bound Re-d(CpGpG) species suffer a progressive downfield shift as 
the pH is lowered below 4. The cytosine signals also suffer a remarkable downfield shift as the pH 
is lowered below 6. This suggests that the three most common metal binding sites of N1 blocked 
cytosine (namely N3, O2 and N4) are not protected by metal coordination and are consequently 
affected by pH changes. This implies that only the guanine residues are bound to the Re center. 
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Figure 3.11. pH dependence of the 1H NMR resonances of adduct 21 between 7.6 and 8.3 ppm. 
 
Binding of 1 to d(CpGpG) also causes a downfield shift of the 31P resonances with respect to the 
free ligand (Figure 3.12). As mentioned above, such a downfield shift of the 31P signal is common 
for metal macrochelates of similar DNA fragments and it might be indicative of an increase in the 
unwinding angle characterized by changes in the R-O-P-O-R torsion angles. Since this DNA 
fragment binds to Re via the guanine residues one might expect that the greater change in the R-O-
P-O-R torsion angles concerns the -GpG phosphate while the CpG- phosphate would be relatively 
less affected. The most downfield signal of the bottom spectrum in Figure 3.12 is therefore assigned 
to the -GpG phosphate. The other signal, closer to free d(CpGpG) resonances, is assigned to the 
CpG- phosphate.  
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Figure 3.12. 31P NMR spectrum of d(CpGpG) (top) and of a 1:1 mixture of 1 : d(CpGpG) 
incubated in D2O, 37 oC, 1h (bottom). 
 
Addition of 1 to d(CpGpG) alters the CD spectrum of this DNA fragment to a lesser extent than 
in the case of d(GpG). The CD profile of a solution of d(CpGpG) shows a minimum at 238 and 
maxima at 259 and 286 nm (Figure 3.13, spectrum a). After the addition of 1 eq. of 1, in the same 
profile the minimum shifts to 224 nm while enhanced maxima are detected at 258 and 292 nm 
(Figure 3.13, spectrum b).   
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Figure 3.13. CD profile (H2O, 37 oC) of a 71 µM solution of d(CpGpG) (a) and of the same 
solution after the addition of 1 eq. of 1 (b, 24h incubation). 
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In water, at RT, species 20a, 20b and 21 are only slightly soluble. Following the NMR 
experiments (37 oC) the complexes precipitate out of solution as white microcrystalline solids as the 
temperature equilibrates to ambient (~25 oC). After the reaction of 1 with d(GpG)  20a and 20b are 
obtained as a mixture of products while complex 21 is obtained as a single product with the 
monobound species and free d(CpGpG) remaining in solution (see Figure 3.10). The IR spectrum of 
20a, 20b and 21 is shown in Figure 3.14. Both spectra show typical fac-[ReI(CO)3] carbonyl 
vibrations at around 2025 and 1900 cm-1 together with vibrations assigned to the olygonucleotide 
ligands. All attempts to grow single x-ray quality crystals from the isolated solids proved 
unsuccessful. 
 
 
 
3420
2925
2925
2950
2950
2028
1903 1636
1172
1072
3422
2024
1898
1689
1638
1225
1061
 
 
 
 
 
 
 
 
 
 
Figure 3.14. IR spectrum (KBr pellet, cm-1) of 21 (top) and of a mixture of 20a and 20 b (bottom). 
 
3.2 Conclusion 
 
In this chapter it was shown that ReI forms stable adducts with d(GpG) and d(CpGpG) via 
coordination of the N7 atom of guanine residues as corroborated by the pH-dependence studies of 
the H8 resonances at pH values near 2. Reaction of 1 with d(GpG) yields two major adducts. NMR 
data and ring current shift calculations based Abraham’s model, tentatively suggest that these may 
be HH and HT conformers. Kinetic investigations have revealed that macrochelate closure is not the 
rate determining step but rather a fast step in the reaction. Interaction of 1 with d(CpGpG) yields a 
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single major product. NMR investigation has proven that the olygonucleotide binds to the fac-
[ReI(CO)3] core via the N7 atom of guanine bases.  
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Chapter 4. Vitamin B12 as a Shuttle for Rhenium Complexes 
 
In the previous chapters it was demonstrated that the fac-[Re(CO)3]+ core can bind two guanine 
bases in a cis fashion and that complexes based on this moiety alter the tertiary structure of plasmid 
DNA by covalently binding to two bases. In Chapter 2 amino acid were introduced as a kind of 
protecting group for the above mentioned core as in human serum (HS) [Re(H2O)3(CO)3]+ (1, see 
Chapter 2) interacts unspecifically with potential coordination sites in serum proteins and is 
therefore not available at high concentration. An important aspect, which has not yet been 
considered in this study, is the problem of targeting our compounds to the biological site of interest 
(i.e. cancer cells) for using these molecules in chemo- or radiotherapy. 
  
In radiotherapy the common strategy followed by many is to protect the fac-[Re(CO)3]+ core with 
robust tridentate ligands and to attach the molecule thus obtained to receptor seeking biomolecules 
(usually peptides) via a chemical spacer. The peptide then “shuttles” the radionucleide to the target 
tumor site. In this Chapter, a different approach is introduced in as much as a vitamin (namely 
Vitamin B12) is used as the shuttle for rhenium complexes. 
 
 Vitamin B12 is an essential biomolecule, produced by a few bacteria only but fundamental for 
most living organisms. It plays a key role in enzymatic processes in mitochondria, the cell nucleus, 
and in the cytoplasm. Its uptake in humans is very complex, comprising at least the three different 
transport proteins intrinsic factor (IF), transcobalamin, and haptocorrin. The human organism treats 
vitamin B12 very economically. The daily requirement is only about 10µg. The chemistry, 
biochemistry, and biology has comprehensively been reviewed.1-4
 
The demand for vitamin B12 (abbreviated as B12) is distinct at places of enhanced proliferation, 
in particular in cancer cells or at sites of bacterial infections. Its inevitable need makes B12 very 
attractive as a targeting agent in chemo- or radiotherapy. Corresponding applications of B12 are 
persistently studied in the delivery of radioisotopes or various cytotoxic agents to cancer cells.5, 6 
Studies from the Mayo Clinic with radiolabelled B12 are in preclinical trials7, 8 and Grissom and 
others showed that B12 can be used as a Trojan horse.9-11 For both strategies, derivatization of B12 
is required and the introduction of ligands or receptor binding molecules has been reported.5, 7, 8, 11 
Chelators for radiometals have been conjugated to peripheral acid groups, received by controlled 
amide hydrolysis, and to the 5‘-OH group in the ribose ring of the backloop. Alternatively, Co(III) 
was reduced to Co(I) and a molecule introduced by oxidative alkylation.10, 12 Both approaches 
require rather tedious synthetic procedures.  
 
The only functionality in B12 that has not received much attention is the Co(III) coordinated 
cyanide. It is well established that M-CN moieties distinctly tend to bridge two metal centers to 
form a M-C≡N-M‘ unit. Numerous examples have been described and reviewed in literature12 but 
examples with porphyrin like systems are rare13-15 and, to our knowledge, unknown for B12. The 
reverse situation in which [Fe(CN)6]3- or nitroprusside [Fe(NO)(CN)5]- are coordinated to Co(III) or 
Co(II) of aqua-cobalamin has been studied in detail.16-22  
 
In this brief Chapter the synthesis and characterization of [Re(DMGly)(CO)3]-B12 adducts 
(DMGly = N,N-dimethylglycine) is described and it is show that B12 acts as the monodentate 
ligand for rhenium complexes via the Co(III) coordinated cyanide. [Re(DMGly)(CO)3]3 (14, see 
Chapter 2) was chosen for the reaction because, as demonstrated in Chapter 2, while DMGly 
protects the metal tricarbonyl core, 14 is able to influence the tertiary structure of ΦX174 plasmid 
DNA indicating that DMGly is displaced from the rhenium coordination sphere in favor of DNA 
bases (see Figure 2.2).  
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Scheme 4.1. Structure of vitamin B12 and coordination of 14 to the vitamin. 
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4.1 Results and Discussion 
 
The reaction of 14 with B12 in methanol afforded the formation of [(14-B12)] (22), in good yield. 
HPLC analysis of the reaction with Re gave only two well separated peaks in a ratio of about 1:1 
(see Figure 4.1). The peaks can be understood by the two possible orientations adopted by the 
bidentate N,O ligand DMGly relative to the corrin ring (complexes [M(L2)(OH2)(CO)3] where L2 = 
bidentate N,O ligand are racemic) and, thus, the presence of two diastereomers. Both peaks, 
separated by preparative HPLC, showed the same and correct mass [M2+=869.1; M+=1736.9] in 
ESI-MS and 1H and 31P NMR confirmed the proposed composition.  
 
 
  
22a
22bB12
 
 
 
 
 
 
 
 
 
Figure 4.1. HPLC trace (UV/vis at λ= 350 nm) of the reaction between B12 and 14 showing the 
two diastereomers.  
 
We attempted to determine the orientation of B12 relative to the bidentate ligand by ROESY 
experiments as recently performed for a B12 derivative in which the CN- has been replaced by a 
(methoxycarbonyl)-methyl group.23 However, no cross peaks could be observed even at low 
temperature, indicating fast rotation of the complex. Since the equatorial planes of the complexes 
are relatively far away from the corrin framework, they are not locked in a fixed position. The two 
isomers of 22 can be separated well by preparative HPLC. X-ray quality crystals for one of isomer 
22a (see Figure 4.1) could be grown and the structure elucidated (see Figure 4.2).  
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Figure 4.2. X-ray analysis of 22a. Important bond lengths and angles are: Co-CN: 1.90(1) Å, Co-
N(benzimidazole): 2.032(7) Å, C-N(cyanide): 1.180(12) Å, CN-Re: 2.14(1) Å, Co-C-N: 167.7(9)°, 
C-N-Re: 169.2(9)°. 
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Figure 4.3. Hydrogen bonding in 22a (left) and orientation of the DMGly ligand relative to the 
corrin ring (right). C2 represents the carbon to which the a-sidechain is attached. 
 80
The relative orientation of the N,O ligands L2 in 22a is shown in Figure 4.3. Complex 22a depicts 
a hydrogen bridge between the coordinated carbonyl oxygen O72 and the amide nitrogen of the a-
side chain in B12 (Figure 4.3). The bridge probably determines the orientation of the Re complex in  
the crystal. The b-side chain is also bent upwards but does not display any interaction to the 
complex. We assume that the diastereomers of complex might be represented by different 
orientations of the DMGly ligand relative to the corrin ring. 
 
We observed that diastereomerically pure complexes [M(L2)(L‘1)(CO)3] with one labile ligand 
(e.g. L-serine (L2) and guanine L’1) always return to equilibrium in water within hours, probably 
through a five-coordinate intermediate by dissociation of the monodentate ligand. The pure 
diastereomers of 22 do not interconvert into each other even after days in water at r.t. confirming 
the high kinetic stability of monodentately bound B12. Acetonitrile is a strong ligand for complexes 
[Re(L2)(OH2)(CO)3]. Dissolving 22a or 22b in an H2O/CH3CN mixture and analyzing the solution 
for days showed only about 10% cleavage for both species confirming again the stability of the Co-
CN-[Re] bond. 
 
 
 
Vitamin B12
22a
22b
475 nm
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Electronic spectra (H2O/Acetone, 2:1) of the two diastereomers of 22 and of Vitamin 
B12. Abs (nm) in 360, 410, 560 and 550 region. 
 81
 82
Interestingly, the electronic spectra of the two diastereomers of 22 are different (Figure 4.4). 
Although both have essentially the B12 shape, the weak shoulder at about 482 nm in B12 becomes 
a distinct peak at 475 nm.  
 
Biological applications of these compounds require stability in serum and affinity for the various 
B12 binding proteins. It is known that haptocorrin tolerates derivatives of B12 whereas the 
transcobalamins are more sensitive towards structural changes.24-26 Derivatizations at the Co(III) 
center are generally more tolerated by both proteins and a direct labeling of B12 with 
[99mTc(L2)(OH2)(CO)3] is feasible. Complexes [99mTc(L2)(OH2)(CO)3] reacted quantitatively with 
B12 between 10-2 and 10-3 M within 60 min at 50°C. The CN- in B12 is a slow ligand (hence the 
relatively high concentrations). Once formed and separated by HPLC, the isomers are stable over at 
least 24 h at 37° C. This opens a convenient way for studying the biological behaviour of labelled 
native B12 by varying the nature of L2. The intracellular B12 dependent enzymes might not 
recognize these derivatives anymore but then the radionuclide has already reached its target. It 
should be emphasized that the Re center is likely to mediate biologically active molecules and B12 
if the ligand L2 is coupled to a peptide or a cytotoxic agent (e.g. the free COOH in dipic).  
 
4.2 Conclusion 
In conclusion, we have shown that CN- in B12 bridges to Re(I) to yield robust complexes 
comprising the central structural feature [Co-CN-Re]. This concept allows direct labeling of B12 
with complexes [99mTc(OH2)(N∩O)(CO)3] for radiodiagnosis or with Re as a mediator between 
B12 and additional biologically active molecules. The observed kinetic stability let us expect 
coordination of other fragments with d6 or d8 configuration as well. B12 as an enantiomerically pure 
and stereochemically demanding ligand provides water solubility and is potentially useful in 
enantioselective synthesis in combination with an appropriate catalyst.  
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Chapter 5. Novel Nucleoside-Mimicking Complexes Based on the fac-[Re(CO)3]+ Moiety: 
Structure, Reactivity and Solution Behaviour of [Re(CO)3(Ser)(7-MeG)], [Re(CO)3(Ser)(3-
pic)] and [Re(CO)3(Ser)(Ade)] 
 
In radiopharmaceutical design the quadridentate N2S2 and N3S type ligands have been most often 
employed in the synthesis of 99mTc and Re complexes (almost always encompassing a MV=O 
core).1-9 The compounds thus obtained are generally appended to a peptide as the biological vehicle 
for delivering the radiopharmaceuticals to the target tumor site.10-14 This strategy results in the 
design of compounds exclusively suited for radiotherapeutic purposes where the metal core is 
prevented from further interacting at the target site. 
 
The fac-[M(CO)3]+ core, on the other hand, permits the synthesis of 99(m)Tc and Re based 
complexes that could be used not only as radio- but also as chemotherapeutic agents. In Chapter 1 it 
was demonstrated that [M(H2O)3(CO)3]+ (1, M = Re, 2, M = 99Tc) forms cis-bis(purine) complexes 
with guanine, and it was shown that the rate constants for the binding of guanosine to the complex 
are in the same order of magnitude of one the active forms of cisplatin, namely [Pt(NH3)2(OH2)2]2+. 
 
One can therefore envision that if surrounded by a proper set of ligands, the above mentioned 
moiety may, upon delivery, actively participate in the biochemistry at the desired target tumor site. 
In Chapter 2 amino acids were chosen as a kind of protecting group for the rhenium [Re(CO)3]+ 
core as in human serum (HS) [Re(H2O)3(CO)3]+ (1, see Figure 2.1) interacts unspecifically with 
potential coordination sites in serum proteins and is therefore not available at high concentration. It 
is also mentioned in the same chapter that amino acids seem good candidates for protecting groups 
for the rhenium [Re(CO)3]+ core for two main reasons. First, depending on the choice of the amino 
acid, they afford robust bi- or tridentate protecting groups for the metal core. Second, since amino 
acids are not foreign to biological systems, once displaced from the metal core, which can then be 
thought as activated, they will not give rise to toxic side effects but they will simply be recycled in 
the biochemical pathways.  
 
Given the structural features of 15 ([Re(Pro)(9-MeG)(CO)3] see Chapter 2) a guanosine 
mimicking complexes could be designed by substituting the amino acid proline with serine and the 
monodentate base 9-MeG with 7-MeG (Scheme 5.1). Similarly, by varying the monodentate base 
different nucleoside mimicking complexes may be obtained.  
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Scheme 5.1. Synthetic scheme for the formation of guanosine mimicking complexes 24 and 25. 
 
In this chapter the synthesis and characterization of [Re(CO)3]+-based nucleoside mimicking 
complexes is described. It will also be shown that these new compounds are remarkably stable in 
Human Serum (HS) when compared to 10 and 12 (see Chapter 1). Finally the interaction of some of 
the reported compounds, namely  [Re(CO)3(L-Ser)(7-MeG)] (24), [Re(CO)3(D-Ser)(7-MeG)] (25) 
and [Re(CO)3(L-Ser)(3-pic)] (26), with ΦX174 plasmid DNA and the phosphotransferase 
Thymidine Kinase Herpes Simplex Virus Type I (HSV1 TK) is described. 
 
5.1 Results and Discussion 
 
Synthetic Aspects. Reaction of 1 with the amino acid L-serine (L-Ser) yields a complex of the 
type [Re(L-Ser)2(CO)3]3 (23) with one amino acid bound in a bidentate and the other in a 
monodentate fashion (see crystallography and NMR subsections).  The reaction goes to completion 
within a few hours in a methanol/water mixture (9:1) and in the presence of a slight excess of amino 
acids required to neutralize the proton released upon coordination of the carboxylate group. When 
dissolved in H2O, complex 23 is stable for days over a wide pH range (3 ≤ pH ≥ 8). Reaction of 1 
with the amino acid D-serine (D-Ser) yields a complex (23a) with similar spectroscopic feature as 
of 23. Although the compound that formed in this reaction was not isolated we speculate that it is 
structurally similar to 23. 
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Although no evidence of ligand exchange was found in water over 3 weeks, upon addition of a 
nitrogenous base one of the coordinated amino acids in 23 is displaced in favour of the stronger 
mono dentate ligand. Addition of 7-methylguanine (7-MeG) to a solution of 23 yields complex 
[Re(CO)3(L-Ser)(7-MeG)] (24) in a few hours. Similarly, after addition of 7-MeG to 23a complex 
[Re(CO)3(D-Ser)(7-MeG)] (25) could be obtained. Complexes 24 and 25 were isolated as 
analytically pure white microcrystalline solid although their formation is not complete at a 1:1 
stoichiometry (i.e. 1:1 23(a):7-MeG).  
 
Reaction of 23 with 3-picoline (3-pic) yields complex [Re(CO)3(L-Ser)(3-pic)] (26) according to 
Scheme 5.2. It must be mentioned at this point that although 23 is isolated as “bis”-L-Ser complex, 
in all the schemes 23 is shown as a mono-aquo complex where the H2O molecule indicates the site 
of the nitrogenous base coordination. It was found that 3-pic is a weaker ligand for 23 than 7-MeG. 
To ensure complexation at least 4 eq. of 3-pic were added to a solution of 23 and the pH had to be 
adjusted to ≈ 6. As mentioned earlier, during formation of 23 coordination of the carboxylate group 
of the amino acid releases a proton and the pH drops to ≈ 3. While coordination of 7-MeG does not 
suffer greatly under these conditions and yields (by HPLC analysis) are generally >90%, a close to 
neutral pH is required for 3-pic coordination. Finally no evidence of coordination of 2,4-
dihydroxypyrimidine-5-carboxylic acid (which would afford a much closer thymidine mimicking 
complex) to 23 was found.  
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Scheme 5.2. Synthetic scheme for the formation of the thymidine mimicking complex 26. 
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Reaction of 23 with adenine (Ade) does not yield a single complex but a mixture of five distinct 
species (27a-27e, see Figure 5.1). As a ligand Ade is a weaker than 3-pic and to ensure 
complexation an excess of Ade (>12 eq.) must be added to a solution of 23. Upon addition of Ade 
to a solution of 23 three species first appear (27a-27c) with HPLC Rt of 15.6, 16.6 an 17.2 min 
respectively. These three species are then followed by two other species with HPLC Rt of 19.6 and 
20.9 min (27d and 27e). HPLC-MS analysis revealed that species 27a-27c have a molecular weight 
of 509.9 m/z (Re1 pattern) corresponding to [Re(CO)3(L-Ser)(Ade)], while species 27d and 27e 
have a molecular weight of 882.5 m/z (Re2 pattern) corresponding to [Re(CO)3(L-Ser)]2(Ade) (see 
Figure 5.1). Attempts to isolate species 27a failed, however the bridging nature of Ade in species 
27d was confirmed by x-ray analysis (see Figure 5.2).  
 
 
27a
b
c
d
e
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. HPLC chromatogram of the reaction of 23 with an excess of Ade and MS of species 
27a-27e. 
 
Due to the poor crystal quality no details of structure 27d can be discussed. It is however 
interesting to note that the [Re(L-Ser)(CO)3] moieties are bridged via the imidazole ring of Ade 
with one Re bound to N7 and the other Re bound to N9. Possible structures of species 27a-27c are 
shown in Scheme 5.3. 
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Figure 5.2. Molecular structure of species 27d obtained from low X-ray quality crystals. 
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Scheme 5.3. Synthetic scheme for the formation of the adenosine mimicking complexes 27a-27c. 
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X-ray Crystallography. Crystal data and experiment details are listed in the crystallography 
section. The crystals structure of compound 23 is shown in Figure 5.3. The molecule crystallizes in 
the orthorhombic space group P212121 with no atoms in special position. The geometry around 
rhenium is octahedral with one face occupied by three carbonyl ligands and the other three 
coordination sites occupied by two L-Ser. One of the two amino acids is bound in a bidentate 
fashion with Re-N1 and Re-O1 distances of 2.193(11) and 2.138(8) Å. If compared with structures  
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Figure 5.3. Crystal structure of [Re(L-Ser)2(CO)3] (23). Selected bond distances (Å) and angles 
(deg) are the following: Re-N1 2.193(11), Re-O1 2.138(8), Re-O4 2.137(8); N1-Re-O1 77.1(3), 
N1-Re-O4 76.2(4), O1-Re-O4 81.5(3). 
 
13, 14 and 15 (see Chapter 2) one finds that on average the Re-N1 bond distance is 0.03 Å shorter 
in 23, while  the Re-O1 bond distance is virtually identical to 13 and again 0.03 Å shorter on 
average than 14 and 15. The other amino acid is bound as a zwitter ion in a monodentate fashion via 
the carbonyl oxygen labelled O4 in Figure 5.3. The Re-O4 bond distance is virtually identical to the 
Re-O1 distance in the bidentate coordinated L-Ser. Finally, while the OC-Re-CO angles are on 
average close to 89°, smaller angles are measured between the other atoms bound to the metal 
center. The O1-Re-O4 angle is 81.5°, the O1-Re-N1 and O4-Re-N1 angles are 77.1° and 76.2° 
respectively. 
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Diffraction-quality crystals of 24 were grown from methanol and pentane. Two different 
conformations of the complex are present in the asymmetric unit and the crystal structures of these 
are given in Figure 5.4. The difference in the two structures is represented by the orientation of the 
CH2OH Ser arm. In structure A the arm projects toward 7-MeG, below the plane defined by the 
coordinated amino acid and two CO groups, while in structure B the arm is in the plane. The 
orientation the CH2OH arms is locked in the solid state by H-bonding interactions involving the 
hydroxyl proton of O3A (i.e. O3 of structure A) and O6B and the hydroxyl proton of O3B and O2A 
(please refer to hydrogen bonding subsection). In both structures the 7-MeG ligand bisects the plane 
defined by the coordinated amino acid and two CO groups with the tip of the imidazole ring 
pointing in between O1 and the CO group cis to it. 
 
Coordination of 7-MeG to 23 causes an elongation of the Re-O1 bond by about 0.02 Å while the 
Re-N4 bond (Re-N1 bond in 23, see Figures 5.3 and 5.4) remains virtually unchanged (on average 
the bond suffers an elongation of < 0.005 Å). The bite angle of the amino acid also decreases by 
0.8°. If compared with structures 13 and 15 (see Chapter 2) one finds that the transition from the 
trimeric structure 13 to the mono-bound 9-MeG derivative 15 causes an elongation of both Re-O1 
(+0.03 Å) and Re-N1(4) (+0.01 Å) bonds. 
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Figure 5.4. Crystal structure of [Re(L-Ser)(7-MeG)(CO)3] (24). Selected bond distances (Å) and 
angles (deg) are the following: A: Re-N9 2.184(9), Re-N4 2.188(9), Re-O1 2.153(7); N9-Re-O1 
79.2(3), N9-Re-N4 83.0(3), N4-Re-O1 76.9(3). B: Re-N9 2.197(9), Re-N4 2.206(8), Re-O1 
2.152(7); N9-Re-O1 81.1(3), N9-Re-N4 85.6(3), N4-Re-O1 75.9(3). 
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 As a consequence one finds that the bite angle of the amino acid does not decrease but rather 
increases by 0.3°. 
 
The crystal structure of molecule 25 is shown in Figure 5.5. The structural features of 25 
resemble closely those of 24 indeed these two molecules are enantiomers. As with 24 two different 
conformations of 25 are present in the asymmetric unit. Again the difference in the two structures is 
represented by the orientation of the CH2OH Ser arm. Extensive hydrogen bonding interactions lock 
in position A' and B' (see Figure 5.5) and these will be discussed in more details later on in this 
chapter. 
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Figure 5.5. Crystal structure of [Re(D-Ser)(7-MeG)(CO)3] (25). Selected bond distances (Å) and 
angles (deg) are the following: A′: Re-N9 2.188(7), Re-N4 2.224(7), Re-O1 2.157(6); N9-Re-O1 
80.5(3), N9-Re-N4 83.6(3), N4-Re-O1 76.8(2). B′: Re-N9 2.186(7), Re-N4 2.240(7), Re-O1 
2.157(5); N9-Re-O1 80.9(2), N9-Re-N4 84.1(3), N4-Re-O1 75.5(2). 
 
The crystal structure of molecule 26 is shown in Figure 5.6. The molecule crystallizes in the 
monoclinic space group P21 with two independent molecules occupying the unit cell. These 
molecules differ in the coordination geometry of amino acid. In 26A L-Ser is bound so that the 
CH2OH arm projects away from the pyridine base while in 26B L-Ser is rotated by 180° with 
respect to its position in 26A and the CH2OH arm projects toward the pyridine base. By comparing 
the two structure one finds that Re-N1 and Re-O1 bond distances are longer in 26B (by 0.005 and 
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0.03 Å respectively). This might reflect the need of 26B to minimize steric repulsion between the 
CH2OH arm and the CH3 group of the pyridine base. Rotation around the Re-N2 bond in 26B brings 
the CH3 group at C9 (see Figure 5.6) in close proximity of O3. Although the molecule might  
compensate by simply rotating the CH2OH arm so that O3 projects away from 3-pic, elongated Re-
N1 and Re-O1 bonds certainly help 26B to ease the steric demand imposed by the geometry. 
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Figure 5.6. Crystal structure of [Re(L-Ser)(3-pic)(CO)3] (26). Selected bond distances (Å) and 
angles (deg) are the following: A: Re-N1 2.21(2), Re-N2 2.12(2), Re-O1 2.101(18); N1-Re-O1 
77.4(7), N1-Re-N2 86.6(10), N2-Re-O1 83.2(9). B: Re-N1 2.21(3), Re-N2 2.24(3), Re-O1 
2.134(15); N1-Re-O1 76.7(7), N1-Re-N2 76.7(7), N2-Re-O1 83.2(8). 
 
Complexes 23-26 belong to a class of compounds showing typical coordination modes for α-
amino acids where the anion is coordinated as a N,O-chelate. The complexes were prepared by 
classical substitution reactions, a methodology successfully applied especially for compounds in 
which the organometallic coligands (Cp*, CO, η6-arene, etc.) function solely as spectator ligands. 
Numerous octahedral α-aminocarboxylate carbonyl metal complexes have been reported. Among 
them, complexes of Cr, Mo, W, Mn, Re, Fe, Ru, Os, Rh and Pt are common.15-21 However, α-
aminocarboxylate complexes based on a fac-[M(CO)3] core are relatively rare.  
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Tetracarbonyl [M(CO)4] (M = W, Re) compounds of amino acids N,O-chelates are known,22, 23 
however more common are N,O-chelate complexes of the type [M(CO)L(PR3)2] (M = Ru, Os) 
where L can be either a second CO ligand, or H.24, 25 Also known are bis carbonyl η5-
cyclopentadienyl (Cp) complexes of the type [(Cp)M(CO)2] (M = Mo, W) and a number of square 
planar carbonyl compounds of Rh and Pt in which the amino acid is also found as a N,O-chelate.16-
21, 26, 27 Tricarbonyl complexes of the type fac-[M(CO)3] (M = Cr, Mo, W, Mn, Tc, Re) are generally 
reported with tridentate ligands such as L-histidine and L-cysteine14 although examples of 
tricarbonyl ruthenium chloride complexes of the type fac-[RuCl(CO)3] where the other two 
coordination sites are occupied by either glycine or proline are known. Compared with the closely 
related [Re(His)(CO)3] structure (where His = histidine, 18, see Chapter 2) one finds that in 23-26 
while Re-O bonds (O = oxygen of N,O-chelate) are on average virtually identical to the same bond 
in 18, Re-N bonds are longer (on average 0.02 Å, but in some cases up to 0.05 Å). This however 
does not come as a surprise as tridentate ligands are stronger chelators for the above mentioned 
moiety.  
 
NMR Studies. The 1H NMR spectra of free L-Ser and 23 are given in Figure 5.7. The two spectra 
show similar features with one set of signals between 3.98 and 3.87 ppm assigned to resonance of 
the serine CH2OH arm (the OH group is silent as it exchanges with D2O) and one signal shifted 
more up field assigned to resonance of the proton on the α-carbon. Overall the L-Ser resonances 
shift down field upon coordination to the [Re(CO)3]+ core. Interestingly, a single set of signal is 
observed for the crystallografically non-equivalent amino acids in the 1H NMR spectra of 23. This 
indicates that the two ligands are in rapid equilibrium and that the resonances observed represent an 
average of the two conformations. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. 1H NMR spectrum (3.7-4.2 ppm, D2O:MeOH-d4, 2:1, 25 oC) of L-Ser (top) and 23. 
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Scheme 5.4. Proposed rearrangement of 23. 
 
The proposed rearrangement taking place in solution is shown in Scheme 5.4. A fast H+ transfer 
between amino groups favors dissociation of the nitrogen atom in the chelate and allows the other 
NH2 group to enter the Re-coordination sphere. If at time = 0 one considers structure 23 (see Figure 
5.3) where the CH2OH arm of the chelate serine points toward the other L-Ser ligand, H+ transfer 
between amino groups, followed by bond dissociation/formation, gives a complex in which the 
CH2OH arm points away from the other L-Ser ligand. In essence one might think as if the net result 
of the rearrangement is to promote an exchange in position in the Re-coordination sphere between 
the carboxylate oxygen and the amino group. 
 
Temperature dependent NMR studies (see Figure 5.8) revealed that only at -80 °C do the signals 
begin to coalescence, indicating that H+ transfer and intramolecular rearrangement are still fast on 
the NMR time scale at this low temperature. 
 
The aromatic region of the 1H NMR spectrum of 24 is shown on the right of Figure 5.9. When 
crystals of 24 are dissolved in a D2O/MeOH-d4 mixture (1:1) a single resonance (8.14 ppm) 
corresponding to the H8 signal of coordinated 7-MeG is initially present. Within a few minutes 
however a second and third signals appear at 8.09 and 7.93 ppm. The signal at 7.93 ppm 
corresponds to the H8 proton of free 7-MeG while the resonance at 8.09 ppm corresponds to the H8 
signal of a new species resulting from an intramolecular rearrangement of 24. The rate constant of 
this intramolecular rearrangement was measured by NMR and it is 1.36 x 10-2 ± 0.24 s-1. A likely 
rearrangement is shown to the left of Figure 5.9.  
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Figure 5.8. Temperature dependent 1H NMR spectrum of 23 (3.5-4.1 ppm, MeOH-d4). 
 
Although the new species formed could not be isolated, indirect evidence supporting the proposed 
product is provided by: 1, the intramolecular rearrangement of 23; 2, the crystal structure of 26; 3, 
the 1H NMR spectrum of 26. Further considerations on these intramolecular rearrangements are 
given later in this section. Finally, when crystals of 25 were dissolved in a D2O/MeOH-d4 mixture 
(1:1) a similar spectrum and a similar behavior were observed.  
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Figure 5.9. 1H NMR spectrum (right, 7.8-8.4 ppm, D2O:MeOH-d4, 1:1) and proposed 
intramolecular rearrangement (left) of 24. 
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The aromatic region of the 1H NMR spectrum of 26 is shown in Figure 5.10. As mentioned in 
subsection 5.2.2, crystals of 26 show two independent molecules in the unit cell. When these 
crystals are dissolved in MeOH-d4 two sets of resonance are observed for the 3-pic ligand of each 
conformer of 26. With time however, a new set of signals corresponding to free 3-pic appears and 
one of the original sets of signal increases in intensity with respect to the other. It is clear that, as is 
the case for 24 and 25, ligand dissociation takes place in 26. However, since 3-pic is a weaker 
ligand for 23 than 7-MeG, more free 3-pic is observed. Also, since one of the original sets of 
resonances increases with respect to the other one of two possibilities must be considered. Either an 
intramolecular rearrangement is taking place in favor of the more thermodynamically stable 
conformer of 26, or 3-pic dissociation refers more predominantly to one of the two conformers.  
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Figure 5.10. 1H NMR spectrum (7.0-9.0 ppm, 1 day, MeOH-d4) of 26. 
 
The 1H NMR spectra of 23-26 presented in this section clearly points to an intramolecular 
rearrangement in the complexes. In the case of 24 and 25 the rearrangement may proceed as shown 
in Scheme 5.5. Possible protonation of the amino group with 7-MeG dissociation gives Re-N bonds 
breaking. Deprotonation of the NH2 group followed by Re-N bonds formation gives the proposed 
rearrangement product. 1H NMR evidence confirms the presence of free 7-MeG and NH2-D2O 
exchange. Figure 5.11A shows the 1H NMR spectrum (5.3-8.4 ppm) of crystals of 24 taken a few 
minutes after crystals were dissolved while Figure 5.11B shows the same spectrum taken 24 hours 
later. 
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Scheme 5.5. Proposed rearrangement of 24. 
 
In Figure 5.11A the signals corresponding to the amino group of the coordinated amino acid are 
visible although rearrangement is already in progress as revealed by the presence of two H8 signals 
in the aromatic region. After 24h, however, the NH2 signals disappear indicating that NH2-D2O 
exchange had taken place. Furthermore, the presence of a small H8 signal corresponding to free 7-
MeG (of constant relative intensity with respect to the other H8 signals) confirms dissociation of the 
nitrogenous base. However, if protonation of the NH2 group does occur this is slower on the NMR 
time scale than the intramolecular rearrangement as shown in Figure 5.12.  
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Figure 5.11. A: 1H NMR spectrum (5.3-8.4 ppm, D2O:MeOH-d4, 1:1) of crystals of 24 taken a few 
minutes after crystals were dissolved. B: Same 1H NMR spectrum of A taken 24 hours later. 
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Figure 5.12. 1H NMR spectrum (5.3-8.4 ppm, D2O:MeOH-d4, 1:1, 30s intervals) of crystals of 24. 
 
HS Stability of Complexes. The stability of complexes 23-26 in Human Serum (HS) is important 
to assess the possibility of using the compounds for in vivo biological studies. When crystals of 23 
are dissolved in HS (final [1mM]) under physiological conditions (37 oC, O2) the complex is readily 
trapped by serum proteins within minutes. The binding of 23 to HS proteins is irreversible as 
indicated by challenging studies. Once the complex is trapped it is not released when challenged 
with an excess of imidazole or other rescue agents like sodium diethyldithiocarbamate, over a 
period of 3 days.  
 
Under the same conditions however, compounds 24 and 25 are stable for hours in HS showing 
only about 50% decomposition (i.e. reaction with serum proteins) after a 12h incubation period 
(Figure 5.13B). While in H2O dissociation of 7-MeG from 24 or 25 establishes the equilibrium 
depicted in Scheme 5.1 and all species are visible by HPLC (Figure 5.13A), in HS the peak 
corresponding to the mono bound Re serine species (Rt = 8 min, indicated as 23 in Figure 5.13A) is 
absent. The absence of the peak corresponding to 23 (see Figure 5.13B and Figure 5.13C) indicates 
that the Re serine species is trapped by the serum proteins following dissociation of the nitrogenus 
base.  
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Figure 5.13. A: HPLC chromatogram of a 1mM solution of 24 (or 25) incubated in H2O for 24h at 
37 oC. B:  HPLC chromatogram of a 1mM solution of 24 (or 25) incubated in HS for 12h at 37 oC. 
C: HPLC chromatogram of a 1mM solution of 24 (or 25) incubated in HS for 24h at 37 oC. 
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Complexes 24 and 25 are however remarkably stable in HS and they are still visible in the HPLC 
chromatogram after a 24h incubation period (see Figure 5.13C). Compound 26 on the other hand, is 
completely trapped by the proteins within 12h. Trapping of 26 by HS proteins also follows 
dissociation of the nitrogenous base as is the case for 24 and 25. 
 
In order to better appreciate the remarkable HS stability of 24 and 25, compound 12 ([Re(H2O)(7-
MeG)2(CO)3](ClO4), see Chapter 1) was subjected to the same study for comparison. Figure 5.14A 
shows the HPLC chromatogram of a 1mM solution of crystals 12 incubated in H2O for 1h at 37 oC 
while Figure 5.14B shows the HPLC chromatogram of a 1mM solution of crystals 12 incubated in 
HS for 1h at 37 oC. While in H2O both the mono bond species [Re(H2O)2(7-MeG)(CO)3]+ (Rt = 
17.3 min) and the bis bound species 12 (Rt = 18 min) are visible, in HS 12 is completely trapped 
within 1h (Figure 5.14B). 
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Figure 5.14. A: HPLC chromatogram of a 1mM solution of 12 incubated in H2O for 1h at 37 oC. B:  
HPLC chromatogram of a 1mM solution of 12 incubated in HS for 1h at 37 oC. 
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Interaction of 24 and 25 with Thymidine Kinase Herpes Simplex Virus Type I (HSV1 TK). 
Thymidine Kinase Herpes Simplex Virus Type I (HSV1 TK) belongs to a family of viral kinases 
which phosphorylate thymidine (dT) to thymidine monophosphate (TMP). The protein however 
also recognizes aciclovir and penciclovir (see Figure 5.15) as substrates for its enzymatic 
phosphorylation reaction. These molecules are therapeutic compounds that interfere with acute 
herpes-virus infections by acting as fraudulent substrates of DNA-polymerases blocking viral DNA 
replication after being activated by HSV1 TK.29
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Figure 5.15. Structures of Aciclovir (left) and Penciclovir (right). 
 
Since 24 and 25 were designed as guanosine mimicking complexes, we explored the possibility 
that HSV1 TK might also recognize these complexes as substrates and catalyze the phosphorylation 
of the pendent hydroxyl group of the coordinated serine as depicted in Figure 5.16.  
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Figure 5.16. Structures of Aciclovir (left) and Penciclovir (right). 
 
Although docking experiments (see Figure 5.17) showed a good fitting of molecules 24 and 25 
into the active site of the enzyme, when the compounds were subjected to in vitro phosphorylation 
tests and affinity measurements with HSV1 TK the results showed neither evidence of 
phosphorylation of 24 or 25 nor inhibition of HSV1 TK activity. Figure 5.18 shows the HPLC 
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chromatogram of the reaction mixture of the phosphorylation assay. At the end of the reaction the 
peak corresponding to 24 or 25 (Rt = 2.6 min) remains unchanged indicating that no 
phosphorylation of the pendent hydroxyl group of the coordinated serine had taken place. 
Furthermore, the appearance of peaks at 4.6 and 7.2 min points to ADP and TMP production 
respectively, indicating no inhibition of  HSV1 TK activity. 
 
Phosphate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17. Crystal structure of active site of HSV1 TK containing a penciclovir molecule30 
(violet) with the crystal structure of 24 (green) fitted upon it.  
 
While the lack phosphorylation of the pendent hydroxyl group of the coordinated serine might be 
explained by the fact that in the active site of the enzyme the serine arm is to far away from the 
phosphate group (about 7.4 Å while the distance of the penciclovir OH group is about 5.3 Å, see 
Figure 5.19) the lack of inhibition of  HSV1 TK activity suggests that 24 and 25 are not substrates 
for HSV1 TK. 
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Figure 5.18. HPLC chromatogram of 24 and 25 of in vitro phosphorylation assay and affinity 
measurements with HSV1 TK. * is EDTA. 
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Figure 5.19. Distance of the pendent hydroxyl group of the coordinated serine of 24 from 
phosphate group in the active site of HSV1 TK. Obtained from docking experiments on the X-ray 
structure of HSV1 TK. 
 
Interaction of 23, 24 and 25 with ΦX174 Plasmid DNA. The analysis of the binding and of the 
influence of different Re compounds on the tertiary structure of DNA, determined by their ability to 
alter the electrophoretic mobility of the open circular and supercoiled form ΦX174 DNA, was 
described in Chapter 2 (section 2.2.3). Here the results of analogous experiments performed with 
complexes 23-25 are given. Figure 5.19 shows the mobility of native ΦX174 plasmid DNA and 
plasmid DNA (abbreviated as pDNA) incubated with compound 23, 24, and 25. None of the 
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compounds tested induces the increase in mobility of pDNA. In agreement with what described in 
Chapter 2, these results confirm that two available coordination sites are necessary to induce the 
DNA shift in mobility. 
 
 
1 2 3 4 5 6 7 8 9 10 11
 
 
 
 
 
 
Figure 5.19. Electrophoresis in 0.75% agarose gel of ΦX174 DNA (5 nM) incubated with various 
concentrations of 23 (lanes 2-4), 24 (lanes 5-7), 25 (lanes 8-10). Lanes 1 and 11 reference ΦX174 
DNA. rb levels for lanes 2-11: (2, 5, 8) 0.018; (3, 6, 9) 0.18; (4, 7, 10) 1.8.  
 
Hydrogen Bonding. Structures 23-26 show extensive hydrogen-bonding interactions in the solid 
state. In complex 23 the NH3+ group of the mono coordinated L-Ser is mainly involved hydrogen-
bonding, making four types of unique interactions with four distinct oxygen atoms. The NH3+ group 
forms one hydrogen bond with O1 (oxygen atom of the N,O-chelate) of an adjacent molecule, two 
bonds with the carboxylate oxygens O2 and O5 of the N,O-chelate and of the mono bound zwitter 
ion respectively, and one final bond with the pendent hydroxyl group of the bidentate coordinated 
serine. These interactions are shown in Figure 5.20. Other hydrogen bonds are formed between the 
oxygen and nitrogen atoms of the N,O-chelate and the OH groups of both coordinated serines but 
these are not shown for clarity. 
 
Similar atoms are involved in the hydrogen-bonding interactions of complex 26. Since the 
pyridine base does not offer any sites to form bonds described in this section, in the crystal structure 
one finds only intermolecular hydrogen bonds between the amino protons of 26A and neighbouring 
carboxylate groups or the pendent CH2OH arm of 26B, and a strong interaction between the OH 
group of the CH2OH arm of 26A and the neighbouring carboxylate group of 26B. These 
interactions are shown in Figure 5.21. These types of interactions are common for metal carbonyl 
complexes of amino acids and have been described before. 
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Figure 5.20. Intermolecular hydrogen bonding in complexes 23. Labels are as in Figure 5.3. 
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Figure 5.21. Intermolecular hydrogen bonding in complexes 26. Labels are as in Figure 5.6. 
 
Molecules 24 and 25 also show an extensive network of intermolecular hydrogen-bonding 
interactions between amino acids residues but also between the guanines and the amino acids. 
Different types of such interactions for 24 are shown in Figure 5.22. Hydrogen bonds between 
amino acids residues are comparable to those described for 23 and 26 involving again the amino 
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protons and neighbouring carboxylate groups or the pendent CH2OH arm. The proton bound to N1 
in 24A forms a bond with an adjacent 24A carboxylate O2 while the protons of the extracyclic 
N2H2 group in 24A are found bridging the hydroxyl groups of the serine arm of 24A and 24B. The 
average mean distances for these interactions are N1H-O1 = 2.068(6) Å and N2H-O2 = 1.992(3) Å. 
The same protons in 24B (i.e. N1 and the protons of the extracyclic NH2 group) only participate in 
hydrogen-bonding interactions with solvent molecules which are not shown in Figure 5.22 for 
clarity. 
 
In the closely related [Re(Pro)(9-MeG)(CO)3] complex (15, see Chapter 2) the proton bound to 
N1 and one of the protons of the extracyclic N2H2 group were always found forming a hydrogen 
bond with the oxygens O1 and O2, respectively, of the carboxylate group of the coordinated 
proline. In 24 however, this is not the case. The presence of the CH2OH arm of the chelate amino 
acid, which offers further sites to promote these interactions, and the different coordination 
geometry of 7-MeG compared to 9-MeG create a completely different hydrogen-bonding network. 
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Figure 5.22. Intermolecular hydrogen bonding in complexes 24. Labels are as in Figure 5.4. 
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5.2 Conclusion 
 
It was shown in this chapter that [Re(CO)3]+-based nucleoside mimicking complexes can be 
obtained from the reaction of the appropriate nitrogenous base with  the serine complex of the 
above mentioned tricarbonyl core. The compounds show an interesting solution behavior displaying 
an intramolecular rearrangement which, to our knowledge, has never been described for octahedral 
organometallic complexes in which the α-aminocarboxylate ligand is bound as a N,O-chelate. 
 
Compounds where the nitrogenous base is 7-MeG are remarkably stable in Human Serum (HS) 
showing only about 50% decomposition (i.e. reaction with serum proteins) after 12h and being still 
visible in the HPLC chromatogram after a 24h incubation period. When the same compounds were 
subjected to in vitro phosphorylation tests and affinity measurements with HSV1 TK neither 
evidence of phosphorylation of pendent serine arm nor inhibition of  HSV1 TK  activity was seen. 
In agreement with the results presented in Chapter 2, none of the nucleoside mimicking complexes 
influence the tertiary structure of ΦX174 DNA as determined by their inability to alter the 
electrophoretic mobility of the open circular and supercoiled form of plasmid DNA. 
 
However, the remarkable HS stability of the guanosine mimicking makes the compounds 
potentially useful inorganic medicinal drugs. In our vision, they may actively participate in the 
biochemistry at the desired target tumor site provided that they are able to accumulate to a sufficient 
extent in the cell and in the nucleus in particular and provided that they are substrates for enzymes 
involved in DNA synthesis.  
 
5.3 References 
(1) Liu, S.; Edwards, D. S. Chem. Rev. 1999, 99, 2235-2268. 
(2) Baidoo, K. E.; Scheffel, U.; Stathis, M.; Finley, P.; Lever, S. Z.; Zhan, Y. G.; Wagner, H. N. 
Bioconjugate Chem. 1998, 9, 208-217. 
(3) Hnatowich, D. J.; Qu, T.; Chang, F.; Ley, A. C.; Ladner, R. C.; Rusckowski, M. J. Nucl. Med. 
1998, 39, 56-64. 
(4) Breitz, H. B.; Weiden, P. L.; Vanderheyden, J. L.; Appelbaum, J. W.; Bjorn, M. J.; Fer, M. F.; 
Wolf, S. B.; Ratliff, B. A.; Seiler, C. A.; Foisie, D. C.; Fisher, D. R.; Schroff, R. W.; Fritzberg, 
A. R.; Abrams, P. G. J. Nucl. Med. 1992, 33, 1099-1112. 
(5) Visser, G. W. M.; Gerretsen, M.; Herscheid, J. D. M.; Snow, G. B.; Vandongen, G. J. Nucl. 
Med. 1993, 34, 1953-1963. 
 109
(6) Edwards, D. S.; Liu, S.; Harris, A. R.; Poirier, M. J.; Ewels, B. A. Bioconjugate Chem. 1999, 
10, 803-807. 
(7) Srivastava, S. C.; Mease, R. C. Nucl. Med. Biol. 1991, 18, 589-603. 
(8) Meares, C. F. Nucl. Med. Biol. 1986, 13, 311-318. 
(9) Liu, Y. F.; Wu, C. C. Pure Appl. Chem. 1991, 63, 427-463. 
(10) Dilworth, J. R.; Parrott, S. J. Chem. Soc. Rev. 1998, 27, 43-55. 
(11) Giblin, M. F.; Wang, N.; Hoffman, T. J.; Jurisson, S. S.; Quinn, T. P. Proc. Natl. Acad. Sci. 
USA 1998, 95, 12814-12818. 
(12) Egli, A.; Alberto, R.; Tannahill, L.; Schibli, R.; Abram, U.; Schaffland, A.; Waibel, R.; 
Tourwe, D.; Jeannin, L.; Iterbeke, K.; Schubiger, P. A. J. Nucl. Med. 1999, 40, 1913-1917. 
(13) Alberto, R.; Schibli, R.; Egli, A.; Schubiger, A. P.; Abram, U.; Kaden, T. A. J. Am. Chem. 
Soc. 1998, 120, 7987-7988. 
(14) Alberto, R.; Schibli, R.; Waibel, R.; Abram, U.; Schubiger, A. P. Coord. Chem. Rev. 1999, 
192, 901-919. 
(15) Ioganson, A. A. Russ. Chem. Rev. 1985, 54, 277-292. 
(16) Zhou, Y. L.; Wagner, B.; Polborn, K.; Sunkel, K.; Beck, W. Z. Naturforsch. B 1994, 49, 
1193-1202. 
(17) Cavoli, P.; Graziani, R.; Casellato, U.; Uguagliati, P. Inorg. Chim. Acta 1986, 111, L35-L37. 
(18) Erickson, L. E.; Brower, D. C. Inorg. Chem. 1982, 21, 838-840. 
(19) Nance, L. E.; Frye, H. G. J. Inorg. Nucl. Chem. 1976, 38, 637-639. 
(20) Carturan, G.; Uguaglia.P; Belluco, U. Inorg. Chem. 1974, 13, 542-546. 
(21) Konya, K.; Fujita, J.; Nakamoto, K. Inorg. Chem. 1971, 10, 1699-1702. 
(22) Darensbourg, D. J.; Draper, J. D.; Reibenspies, J. H. Inorg. Chem. 1997, 36, 3648-3656. 
(23) Darensbourg, D. J.; Atnip, E. V.; Klausmeyer, K. K.; Reibenspies, J. N. Inorg. Chem. 1994, 
33, 5230-5237. 
(24) Severin, K.; Sunkel, K.; Beck, W. Chemische Berichte 1994, 127, 615-620. 
(25) Werner, H.; Daniel, T.; Knaup, W.; Nurnberg, O. J. Organomet. Chem. 1993, 462, 309-318. 
(26) Zhou, Y. L.; Beck, W. J. Organomet. Chem. 1994, 479, 217-220. 
(27) Meder, H. J.; Beck, W. Z. Naturforsch. B 1986, 41, 1247-1254. 
(28) Ru(CO)3 gly pro ref 
(29) Pospisil, P.; Pilger, B. D.; Marveggio, S.; Schelling, P.; Wurth, C.; Scapozza, L.; Folkers, 
G.; Pongracic, M.; Mintas, M.; Malic, S. R. Helv. Chim. Acta 2002, 85, 3237-3250. 
(30) Bennett, M. S.; Wien, F.; Champness, J. N.; Batuwangala, T.; Rutherford, T.; Summers, W. 
C.; Sun, H. M.; Wright, G.; Sanderson, M. R. Febs Letters 1999, 443, 121-125. 
 110
Chapter 6. Cytotoxicity of ReI Complexes 
 
One of the main structure-activity relationship for antitumor active platinum compounds is the 
presence of two cis-coordinated leaving groups e.g. chloride ions.1, 2 In the previous chapters it was 
demonstrated that the fac-[Re(CO)3]+ moiety displays a principally similar reactivity pattern with 
plasmid DNA as e.g. cisplatin implying a possible interaction with adjacent guanines in DNA as 
well. It was also shown that 1 forms stable adducts with d(GpG) and d(CpGpG) via coordination of 
the N7 atom of guanine residues. If the coordination of rhenium complexes to biologically relevant 
ligands such as DNA bases is important for its biologically activity, one expects that complexes 
with two exchangeable cis-coordinated leaving groups would show higher cytotoxicity than 
complexes lacking this feature.  
 
In this brief chapter, the cytotoxicity of different rhenium complexes toward B16 F1 mouse 
melanoma cells is presented. A new compound, namely [Re(L-Tryp)2(CO)3] (27), obtained from the 
reaction of 1 with the amino acid L-Tryptophan (L-Tryp) is also introduced. The series of rhenium 
compounds investigated in this study may be divided in two major categories: molecules with at 
least two exchangeable cis-coordinated ligands and molecules with one or no exchangeable ligands. 
Complexes belonging to the first category are 1, 10, 14, 22a and 22b; all others belong to the 
second category. Compounds 1, 10, and 14 were shown in Chapter 2 to be ale to alter the tertiary 
structure of plasmid DNA by covalently binding to two DNA bases while the remaining molecules 
did not. 
 
6.1 Results and Discussion 
 
Complex 27 was synthesized as a lipophilic analog of [Re(L-Ser)2(CO)3]3 (23), described in 
section 5.2.1. Crystal data and experiment details are listed in the crystallography section. The 
crystals structure of compound 27 is shown in Figure 6.1. The molecule crystallizes in the triclinic 
space group P1. The geometry around rhenium is octahedral with one face occupied by three 
carbonyl ligands and the other three coordination sites occupied by two L-Tryp. One of the two 
amino acids is bound in a bidentate fashion with Re-N1 and Re-O1 distances of 2.221(13) and 
2.085(9) Å. The other amino acid is bound as a zwitter ion in a monodentate fashion via the 
carbonyl oxygen labelled O3 in Figure 6.1. The Re-O3 bond distance is 2.150 (13) Å longer than 
the Re-O1 distance in the bidentate coordinated L-Tryp.  
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Figure 6.1. Crystal structure of [Re(L-Tryp)2(CO)3] (27). Selected bond distances (Å) and angles 
(deg) are the following: Re-N1 2.220(21), Re-O1 2.088(27); Re-O3 2.151 (19), N1-Re-O1 77.54 
(76), N1-Re-O3 76.40 (66), O1-Re-O3 83.48 (71). 
 
Cell proliferation was analyzed by the non-radioactive, colorimetric assay system using XTT, 
which was first described by Scudiero et al.3, 4 and improved in subsequent years by other 
investigators.5, 6 The assay is designed, among other applications, for measurement of cytotoxicity 
or the assessment of cytotoxic or growth inhibiting agents. The analysis is based on the cleavage of 
the yellow tetrazolium salt XTT to form an orange formazan dye by metabolic active cells. 
Therefore, this conversion only occurs in viable cells. The formazan dye is soluble in aqueous 
solutions and it was directly quantified by a spectrophotometer.  
 
In a typical experiment (Figure 6.2) an average of 2000 cells were grown in microtiter plates (tissue 
culture grade, 96 wells, flat bottom) in a final volume of 100 µL culture medium per well in a 
humidified atmosphere (37 oC, >6.5% CO2). After 24 h the rhenium complex was added to the 
wells (final concentrations 200 µM) and the cells were grown for further 24 h under a humidified 
atmosphere. After the incubation period 50 µL of the XTT labeling mixture were added to each 
well. The plates were incubated again for 4 h. After the this final incubation period the 
spectrophotometrical absorbance (optical density OD) of each well was measured at 450 nm. 
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Control experiments were performed as described above without the addition of the rhenium 
compounds. Blanks were obtained by adding 50 µL of H2O instead of the XTT labeling mixture. 
Experiments were done in double and the results represent the average. The % of cell survival was 
calculated base on the relative OD of the samples. Maximum control OD was set to 100% cell 
survival. 
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Figure 6.2. Scheme of a typical XTT cell proliferation assay. 
 
Cytotoxicity data of the Re complexes investigated in this study are listed in table 6.1 while 
Figure 6.3 shows a graphic representation of the same data. With the exception of 1 and 19, all 
complexes show low cytotoxicity (i.e. % of cell survival > 50). No structure-activity relationships 
 
Table 6.1. Cytotoxicity of Rhenium complexes, expressed as % of cell survival.a
aσ = ±5%. b in H2O, 200 µM. c in H2O:MeOH (9:1), 200 µM. d in H2O, 100 µM. e in H2O:MeOH (9:1), 150 µM. 
Compound 1b 10b 13c 14c 18c 19b 22ad 22bd 23b 24e 25e 27e
% Cell Survival 25 80 91 71 100 20 83 83 78 91 88 86 
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can be extrapolated from the results as both compounds belonging to the first category (i.e. 
molecules with two exchangeable cis-coordinated ligands) and compounds belonging to the second 
category (i.e. molecules with one or no exchangeable ligands) show comparable low cytotoxicity. 
Increased lipophilicity also does not seem to improve the cytotoxic index as both 23 and 27 seem to 
have very little effect on cell proliferation. The more hydrophilic compound 23 shows a slightly 
better inhibition of cell growth than 27 although the concentration of the former is higher. For all 
practical purposes, however, the molecules do not seem to inhibit cancer proliferation. 
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Figure 6.3. Cytotoxicity of Rhenium complexes, expressed as % of cell survival (σ = ±5%). 
 
Cell proliferation is best inhibited by compounds 1 and 19 which show high cytotoxicity (i.e. % 
of cell survival < 30) at 200 µM concentration. While it is not possible at the present stage to 
indicate a mode of action of these molecules, the high kinetic stability of complex 19 rules out 
possible ligand exchange and inner sphere coordination to biologically relevant ligands such as 
DNA. While complex 19 might act as an inhibitor in a biochemical pathway, complex 1 might 
target DNA or peptide residues of proteins. 
 
The cytotoxic effects of 19 came to us as a striking result. Following cisplatin, some of the most 
promising metal based anticancer agents are [ImH][trans-RuCl4(Im)2], ICR,7-9 and [ImH][trans-
RuCl4(DMSO)(Im)], NAMI-A (where Im = Imidazole)10-12 which both contain imidazole as a 
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ligand. While structure-function studies have demonstrated, at least for NAMI-A, that the biological 
activity of the molecule is strictly related to the progressive release of one or more of its chloride 
ligands, it has also been shown that by replacing Im for thiazole the compounds become virtually 
noncytotoxic, demonstrating that Im is crucial for the activity of the drug.13
 
These considerations prompted us to study in more details the interaction of Im complexes of 
rhenium with DNA bases. To this end complex [Et4N][ReBr2(Im)(CO)3] (28), synthesized 
according to reported procedures,14 was reacted with 9-MeG after precipitation of the halides with  
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Figure 6.4. Scheme and HPLC chromatogram of reaction of 28 with 2.2 eq. of 9-MeG (24h, 37 °C). 
 
AgNO3. In a water, (37 oC) 28 reacts with 9-MeG stepwise. In our HPLC gradient complex 28 has a 
retention time (rt) of 13.9 min (see Figure 6.4). After 1h a second peak is observed with rt of 17.4 
min. HPLC-MS chromatography indicates that this species is [Re(Im)(9-MeG)(H2O)(CO)3] (29). 
After a further 12h a third and a fourth peak appear at 17.0 and 16.2 min which were identified by 
HPLC-MS chromatography as [Re(9-MeG)2(H2O)(CO)3]+ (10) and [Re(9-MeG)(H2O)2(CO)3]+ 
(10a) respectively. The relative height of the peaks, with species 10 and 10a increasing in 
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concentration, gave the only other change observed after a further 12h period of incubation. Also 
observed in the HPLC chromatogram is a shoulder at ~18 min which may be assigned to the 
intermediate [Re(Im)(9-MeG)2(CO)3] species, however, our data are not conclusive. The results 
suggest that imidazole also might be a ligand for a model Re pro-drug protecting the [Re(CO)3]+ 
core from reacting with coordinating sites in blood proteins.  
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Table 6.2. Cytotoxicity of Rhenium complexes, expressed as % of cell survival.a
 Compound cisplatinb 1b 19b 28b 30b 31b
% Cell Survival 11 28 25 43 21 20 
 
 
aσ = ±10%. b in H2O, 200 µM based on Re. 
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Figure 6.5. Cytotoxicity of Im and HPz Re complexes, expressed as % of cell survival (σ = ±10%). 
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Complex 28, together with complexes [ReBr(HPz)2(CO)3] (30) and [Re2(µ-OH)2(Im)2(CO)6] 
(31), synthesized according to published procedures,14, 15 was the subjected to cell proliferation 
studies. Cytotoxicity data of this second set of Re complexes are listed in table 6.2 while Figure 6.5 
shows a graphic representation of the same data. Cell proliferation is inhibited (i.e. % of cell 
survival < 30) by compounds all compounds bearing at least one Im or HPz ligand but 28. While it 
is not possible at the present stage to make any definitive conclusions, the results seem to suggest 
that, as in the case of Ru-based anticancer agents, five-membered imidazole/pyrazole type rings 
might also be significant for the antiproliferative activity of Re compounds.  
 
6.2 Conclusion 
In this brief chapter the cytotoxicity of a series of Re complexes toward B16 F1 mouse melanoma 
cells was presented. No structure-activity relationship can be extrapolated from the results as both 
compounds with two exchangeable cis-coordinated ligands and compounds with one or no 
exchangeable ligands show comparable activity. However, compounds bearing at least one Im or 
HPz ligand generally best inhibit cell proliferation. The results suggest that Im or HPz might be 
ligands for a model Re pro-drug protecting the [Re(CO)3]+ core from reacting with coordinating 
sites in blood proteins. 
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Chapter 7. Binding of 9-Methylguanine to [cis-Ru(2,2'-bipyridine)2]2+
 
Different ruthenium-based metal complexes are currently being investigated for their antitumor 
properties. Although the mode of actions of these complexes is not yet well understood, there is 
evidence that suggests that, similar to the well established platinum drugs, DNA is a likely target for 
these compounds.1-11  
 
Barton and Lolis,1 and subsequently Thorp and co-workers,2 have reported the enatiomeric 
selectivity for the Λ isomer of cis-[Ru(phen)2Cl2] and cis-[Ru(bpy)2(H2O)2]2+ (phen = 1,10-
phenanthroline; bpy = 2,2'-bipyridine) type complexes in covalent binding to B-DNA. A direct 
correlation between cytotoxicity and DNA binding was observed by Clarke and co-workers for the 
representative cis-[Cl2(NH3)4RuIII]Cl2 and trans-[(Im)2Cl4RuIII]- (Im = imidazole) type compounds 
in cell cultures3 and it was shown that DNA binding of [(H2O)(NH3)5Ru]2+ occurs preferentially at 
G.4,5 Brabec and co-workers showed similar results.6 Furthermore, compounds like mer-
[Ru(terpy)Cl3] (terpy = 2,2':6', 2''-terpyridine), mer-[Cl3(Me2SO)3Ru] and trans-[Cl4(Me2SO)2Ru]- 
have all been shown to from interstrand cross-links in DNA and to bind guanine derivatives in a 
trans configuration while trans-[Cl2(Me2SO)4Ru] forms a stable d(GpG) adduct.7-10
 
To our knowledge, there is no ruthenium complex with two DNA bases covalently bound to the 
metal center which has been structurally characterized. Reedijk and co-workers have shown that 
cis-[Ru(bpy)2Cl2] only forms a mono adduct with 9-ethylguanine (9-EtG) and 9-
methylhypoxanthine and they were able to obtain the crystal structure of the mono 9-EtG adduct.12 
In this brief chapter we present the first example of a structurally characterized cis-bis purine 
complex of ruthenium.  
 
7.1 Results and Discussion 
 
Complex 33 was obtained by refluxing 32 with 2.4 eq. of 9-MeG in aqueous ethanol (Scheme 
7.1).13 Diffraction-quality crystals were grown from ethanol and CH2Cl2 and the x-ray structure of 
Λ-33 is given in Figure 7.1.14 The complex crystallizes in the monoclinic P21/n space group so the 
Λ and ∆ isomers are both present in the unit cell. The guanines coordinate through N7 with the two 
bases in a head-to-tail (HT) orientation with a base-base dihedral angle of 60.4°. The purine 
moieties are situated with the keto groups between the pyridyl rings of the bpy ligands. In both 
bases the carbonyl groups are slightly bent out of plane with O(6)-C(6)-N(3) and O(16)-C(16)-
N(13) angles of 171.2° (4) and 170.8° (5) respectively.  
 
All bond distances and angles are in good agreement with the closely related cis-[Ru(bpy)2(9-
EtG)Cl]+ structure9 although we find that Ru-N(bpy) distances are on average 0.017(2) Å longer in 
33. Furthermore, the bpy ligands are not planar. In the bpy ligand with labels N23 and N24 in 
Figure 7.1 the two pyridine rings are twisted with respect to each other by an angle of 16.4° while in 
the other bpy ligand (with labels N21 and N22) the two pyridine rings are twisted by 11.6°. Bond 
distances and twist angles might be taken together as an indication of the steric hindrance imposed 
by the need of accommodating two guanines around the metal center. 
 
 
 
 
 
 
 
 
 
Scheme 7.1. 
 
As previously shown, the guanine ligands can not rotate freely about the Ru-N7/(17) bond.12 Due 
to this hindered rotation one might expect the two H8 protons to differ significantly in chemical 
shift. Indeed, when crystals of 33(SO3CF3)2 are dissolved in water two distinct sharp singlet 
separated by about 1.2 ppm are observed. The aromatic region of the 1H NMR spectrum of 33 is 
shown in Figure 7.2. We find no appreciable change in the spectrum during a 4h period at 298K, 
however, after 3 days the peak of free 9-MeG grows by about 40% indicating that base dissociation 
takes place. Compared to the cis-bis guanine complex of the fac-[Re(CO)3]+ core, which remains 
the focus of our current research, complex 33 seems more stable as also indicated by the shorter M-
N7 distance (on average Re-N7 bond distance = 2.199(9) Å).15 Although the H8 protons are 
separated by 2.619(5) Å in the crystal we could not detect a NOESY cross-exchange signal in our 
2D NMR experiments. 
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Figure 7.1. Crystal structure of Λ-[Ru(bpy)2(9-MeG)2]2+ (33). Selected bond distances (Å) and 
angles (deg) are the following: Ru-N7 2.122(5), Ru-N17 2.131(4), Ru-N21 2.044(5), Ru-N22 
2.053(5), Ru-N23 2.047(4), Ru-N24 2.050(4); N7-Ru-N17 89.12(16), N7-Ru-N21 175.26(16), N7-
Ru-N22 97.20(19), N7-Ru-N23 83.77(17), N7-Ru-N24 95.74(17), N17-Ru-N21 93.30(16), N17-
Ru-N22 86.50(17), N17-Ru-N23 97.36(17), N17-Ru-N24 173.49(17), N21-Ru-N22 78.90(19), 
N21-Ru-N23 99.95(17), N21-Ru-N24 82.17(18), N22-Ru-N23 176.05(18), N22-Ru-N24 97.17(17), 
N23-Ru-N24 78.92(17). 
 
 
 
 
 
 
 
 
 
H8H8
*
 
 
Figure 7.2. Aromatic region (ppm) of the 1H NMR spectrum of (33) in D2O. The star indicates free 
9-MeG. 
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7.2 Conclusion 
In this brief chapter we have presented the first structurally characterized cis-bis purine complex 
of ruthenium. The two guanine bases are in a HT orientation which is the most common solid-state 
conformation of cis-bis(ligand) complexes of purines with PtII, CoIII, CuII and ZnII.16 The complex is 
stable in water for hours showing a slow off rate of base dissociation. Our results, in agreement with 
the experimental evidence mentioned above, confirm that DNA is a possible target of ruthenium-
based metal drugs. 
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Conclusions and Outlook 
 
This study subject of this thesis is focused on the interaction of the metal ions technetium (Tc) 
and rhenium (Re) with amino acids and DNA bases, in particular with guanine. The purpose and 
general aims underlying the study reside in the need to understand whether the above mentioned 
metal ions are capable of interacting with DNA bases in a fashion similar to cisplatin. It was 
mentioned in the introduction that while Tc is routinely used in hospitals for diagnosis, as β-particle 
emitters 186Re and 188Re are two promising FDA approved radionuclides that are extensively used 
for radiopharmaceutical applications as cytotoxic therapeutic agents in human medicine. A careful 
search of the recent publications that have appeared on PUBMED reveals a growing consensus in 
the medical community that by combining radiotherapy and chemotherapy, important therapeutic 
advantages can be obtained to cure cancer. The consensus might not yet be general given the fact 
that not all types of cancer respond better to a combined regime of radiotherapy and chemotherapy 
when compared to radiotherapy or chemotherapy alone. However for tumours that do respond the 
advantages are undeniable. In cancer treatment it is therefore desirable to employ compounds that 
might function mechanistically as cisplatin derivatives, thus mimicking the best chemotoxic agent 
known, in combination with an inherent radioactivity of the metal center, thus fulfilling a 
radiotherapeutic action.  
 
In the preceding chapters it was clearly demonstrated that the fac-[M(CO)3]+ core meets the above 
mentioned requirements. The core not only accommodates two untethered guanines but it forms 
stable adducts with longer oligonucleotides such as d(GpG) and d(CpGpG). The adducts formed 
with DNA bases by Tc and Re are generally less stable than the corresponding cisplatin adducts 
however the [Re(CO)3]+ moiety displays a principally similar reactivity pattern with plasmid DNA 
as cisplatin. Furthermore, several complexes based on the tricarbonyl core are cytotoxic showing 
high antiproliferative activity toward B16 F1 mouse melanoma cells. As the Ru based anticancer 
agents [ImH][trans-RuCl4(Im)2], ICR, and [ImH][trans-RuCl4(DMSO)(Im)], NAMI-A, Re 
compounds bearing at least one Im or HPz ligand generally best inhibit cell proliferation. This 
observation opens interesting possibilities for further studying the role of such five membered 
aromatic ligands in terms of cytotoxicity of octahedral complexes. In fact, while not yet 
demonstrated in the case of Re complexes, it has been shown that by replacing Im for thiazole Ru 
compounds become virtually noncytotoxic. Although some of the complexes investigated in this 
study are clearly cytotoxic, no structure-activity relationship could be elucidated from the results as 
both compounds with two exchangeable cis-coordinated ligands and compounds with one or no 
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exchangeable ligands show comparable activity. Hence it is important to clarify if in the cell Re 
compounds act at the DNA level or interfere with (bind to) other cellular components. 
 
In practical terms, the challenge facing further research on this subject is the design of a proper 
set of ligands for the tricarbonyl core. This study has demonstrated the fundamental potential of 
using the fac-[M(CO)3]+ moiety as a “chemo-radiotherapeutic agents”, however the solvated moiety 
(i.e. [M(H2O)3(CO)3]+) cannot be used as such for any feasible and realistic applications due to its 
reaction with blood proteins. In the preceding chapters it was shown that the core can be derivatized 
with coligands such as N,N-dimethylglycine that can be replaced by coordination to N7 of guanine 
yielding, therefore, Re complexes in the form of pro-drugs. Complexes with other amino acids are 
too stable in this respect but both complexes do not cross react with human serum. It was also 
demonstrated that a single imidazole ligand can also be replaced by coordination to N7 of guanine 
suggesting that a combination of such ligands (i.e. N,N-dimethylglycine and imidazole type 
ligands) may be a promising start. Solubility issues must of course be addressed and in this respect a 
combination of the monodentate imidazole (or pyrazole) ligand with a sterically hindered bidentate 
ligand derivatized so as to confer good water solubility to the complex appears, at the present stage, 
as the first step to undertake toward the development of useful Re-based “chemo-radiotherapeutic 
agents”. 
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Experimental Section 
Materials and Methods 
Unless otherwise specified, materials were purchased from commercial suppliers and used 
without further purification.  
 
IR , UV/Vis and NMR Spectroscopy 
IR spectra were recorded as pellets (KBr) using a Perkin Elmer FT-IR spectrometer. The peaks 
are reported using the following abbreviations: s (sharp) or b (broad). UV/Vis spectra were taken on 
a Perkin Elmer Cary 50 spectrometer with a Peltier thermostat. NMR spectra were recorded on a 
Bruker DRX 500 MHz spectrometer. The reported chemical shifts (δ/ppm) are relative to the 
residual solvent peak. The coupling constants (J) are given in Hz. Multiplicities are reported using 
the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad) 
or a suitable combination of them.  
 
Mass Spectrometry  
Mass spectra were recorded on a Merck M8000 HPLC/MS spectrometer with electrospray 
ionization (ESI).  
 
X-ray Data Collection and Processing  
Suitable crystals were covered with Paratone N oil, mounted on top of a glass fiber, and 
immediately transferred to a Stoe IPDS diffractometer. Data were collected at 183(2) K using 
graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). A total of 8000 reflections distributed 
over the whole limiting sphere were selected by the program SELECT and used for unit cell 
parameter refinement with the program CELL. Data were corrected for Lorenz and polarization 
effects as well as for absorption (numerical). Structures were solved with direct method using 
SHELXS-97 or SIR-97 and were refined by full-matrix least-squares methods on F2 with SHELXL-
97. 
 
Analytical High Performance Liquid Chromatography (HPLC) 
High performance liquid chromatography (HPLC) was performed on a Merck L7000 system, 
using a Macherey-Nagel EC 250/3 Nucleosil 100-5 C18HD column for non-radioactive compounds 
and a Macherey-Nagel EC 250/3 Nucleosil 100-5 C18 column for radioactive compounds. HPLC 
solvents were 0.1% Trifluoroacetic acid (solvent A) and Methanol HPLC grade (solvent B). The 
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HPLC gradient used is as follows: Gradient 1: 0-3 minutes: 100% A; 3.1-9 minutes: 75% A, 25% 
B; 9.1-20 minutes: linear gradient from 66% A (34% B) to 0% A (100% B); 20-28 minutes: 100% 
B; 28.1-30: 100% A. The flow rate was 0.5 ml/min. Gradient 2: 0-5 minutes: 75% A, 25% B; 5.1-30 
minutes:: linear gradient from 75% A (25% B) to 0% A (100% B); 30-35 minutes: 100% B; 35.1-
40: 75% A, 25% B. The flow rate was 0.5 ml/min. Detection was performed at 250 nm. The 
detection of radioactive 
99m
Tc complexes was performed with a Berthold LB506 radiodetector 
equipped with a NaI(Tl) scintillation detector.  
 
Gel Mobility Shift Assay 
ΦX174 plasmids were purchased from Promega and used without further purification. ΦX174 RF 
plasmid DNA (0.1 µg) was mixed with the rhenium complexes in H2O at [complex]/[bp] 0.018-
1.8/1. The mixtures were incubated in water at 37 oC for 22 h in the dark before analyzing by gel 
electrophoresis. The pH of the mixtures remained constant at ≈ 7 in all cases. Experiments 
performed in 1 mM or 10 mM NaClO4 showed no significant difference in the binding of 1 to 
ΦX174 RF plasmid DNA. DNA binding was examined by gel electrophoretic mobility shift assays 
through 9 cm 0.75% agarose slab gels with TAE running buffer. The gels were run at RT, with 
voltages varying between 50 and 75 V. Running time depended upon the voltage and were usually 
between 1.5-2 h. The resultant gels were stained with ethidium bromide in the buffer at a 
concentration of ≈ 0.3 µg/mL. Bands were visualized by software UV transillumination equipped 
with a digital camera.  
 
XTT Assay for Cell Proliferation 
An average of 1000-1500 cells were grown in microtiter plates (tissue culture grade, 96 wells, flat 
bottom) in a final volume of 100 µL culture medium per well in a humidified atmosphere (37 oC, 
>6.5% CO2). After 24 h the rhenium complexes were added to the wells (final concentrations 100 
and 200 µM) and the cells were grown for further 24 h under a humidified atmosphere. After the 
incubation period 50 µL of the XTT labeling mixture were added to each well. The plates were 
incubated again for 4 h. After the this final incubation period the spectrophotometrical absorbance 
(optical density OD) of each well was measured at 450 nm. Control experiments were performed as 
described above without the addition of the rhenium compounds. Blanks were obtained by adding 
the reagents to wells lacking cells. Experiments were done in double and the results represent the 
average. The % of cell survival was calculated base on the relative OD of the samples. Maximum 
control OD was set to 100% cell survival. 
 
Synthesis of Compounds 
 
Complexes [Re(His)(CO)3] (18), [Re(Im)3(CO)3](TFA) (19), [Et4N][ReBr2(Im)(CO)3] (28), 
[ReBr(HPz)2(CO)3] (30) and [Re2(µ-OH)2(Im)2(CO)6] (31) were prepared according to the reported 
procedures (see references 31 and 32 of Chapter 2 and references 14 and 15 of Chapter 6).  
 
[ReBr(G)2(CO)3] (3): (Et4N)2[ReBr3(CO)3] (101 mg, 0.13 mmol) was dissolved in hot (~40 0C) 
methanol (7 mL). Guanosine (75 mg, 0.26 mmol) suspended in hot methanol (8 mL) was slowly 
added. The mixture was heated to 50 0C under a slight N2 pressure. The colorless solution turned 
light yellow within minutes. The reaction was monitored by HPLC and it was stopped after 3.5 hr 
when no further change could be observed. The solution mixture was allowed to equilibrate to room 
temperature and then the solvent was dried under vacuum leaving a gelatinous yellow residue. This 
residue was washed with Et2O and CH2Cl2, dried under vacuum and finally washed with CH3OH. 
This final wash left a white microcrystalline solid  which was dissolved in H2O and purified on a 
short C18 column. Yield : 46 mg, 29%. 
Elemental analysis calculated for 3, C23H26BrN10O13Re (916.62): C, 30.14; H, 2.86; N, 15.28, 
found: C, 30.59; H, 2.81; N, 14.89. 
3: 1H NMR (200 MHz, DMSO-d6, δ/ppm): 10.63 (HA, s, 1H), 10.58 (HA, s, 1H), 8.33 (HB, s, 1H), 
7.92 (HB, s, 1H), 6.59 (HC, s, 1H), 6.55 (HC, s, 1H), 5.76 (HD, d, 3J = 5, 1H), 5.67 (HD, d, 3J = 5, 
1H), 5.54 (HE, d, 3J = 5, 1H), 5.43 (HE, d, 3J = 5, 1H), 5.16 (HF, d, 3J = 5, 1H), 5.07 (HF, d, 3J = 5, 
1H), 4.93 (HG, s, 1H), 4.48 (HG, s, 1H), 4.35 (HJ, dd, 3J = 6, 1H), 4.10 (HJ, dd, 3J = 6, 1H), 4.08-
3.50 (HK, HL, HM, m, 8H). FT-IR for 3 (KBr, ν/cm-1): (C≡O) 2025 (s), (C≡O) 1907 (b). ESI-MS for 
3 (ESI+, 60V, m/z): 836.5 ([M-Br]+). HPLC Rt for 3 (HPLC, Gradient 1, min): 17.9. 
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[ReBr(2dG)2(CO)3] (4): (Et4N)2[ReBr3(CO)3] (101 mg, 0.13 mmol) was dissolved in hot (~40 
0C) methanol (7 mL). 2-deoxyguanosine (70 mg, 0.26 mmol) suspended in hot methanol (8 mL) 
was slowly added. The mixture was heated to 50 0C under a slight N2 pressure. The colorless 
solution turned light yellow within minutes. The reaction was monitored by HPLC and it was 
stopped after 3.5 hr. The solution mixture was allowed to equilibrate to room temperature and then 
the solvent was dried under vacuum leaving a gelatinous yellow residue. This residue was washed 
with Et2O and CH2Cl2, dried under vacuum and finally washed with CH3OH. This final wash left a 
white microcrystalline solid  which was dissolved in H2O and purified on a short C18 column. 
Yield : 49 mg, 43%. 
Elemental analysis calculated for 4, C23H26BrN10O11Re (884.62): C, 31.23; H, 2.96; N, 15.83, 
found: C, 32.59; H, 2.21; N, 13.89. 
4: 1H NMR (200 MHz, DMSO-d6, δ/ppm): 10.64 (HA, s, 1H), 10.57 (HA, s, 1H), 8.18 (HB, s, 1H), 
7.92 (HB, s, 1H), 6.57 (HC, s, 2H), 6.12 (HD, m, 2H), 5.26 (HE, d, 3J = 4, 1H), 5.20 (HE, d, 3J = 4, 
1H), 4.80 (HF, s, 1H), 4.66 (HF, s, 1H), 4.31-4.22 (HG, m, 2H), 3.83-3.73 (HJ, m, 2H), 3.44-3.14 
(HK, HL, HM, m, 8H). FT-IR for 4 (KBr, ν/cm-1): (C≡O) 2024 (s), (C≡O) 1904 (b). ESI-MS for 4 
(ESI+, 60V, m/z): 804.9 ([M-Br]+). HPLC Rt for 4 (HPLC, Gradient 1, min): 18.1. 
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[ReBr(BzIm)2(CO)3] (6): (Et4N)2[ReBr3(CO)3] (300 mg, 0.39 mmol) of was dissolved in 
methanol (11 mL). Benzimidazole (93.1 mg, 0.79 mmol) in methanol (4 mL) was added. The 
reaction was allowed to proceed at 50 0C under a slight N2 pressure and it was monitored by HPLC. 
Complexation was judged complete after 1.5 hr when a single peak was visible in the 
chromatogram. At this point the reaction was stopped and the solution mixture was allowed to 
equilibrate to room temperature. The solvent was then dried under vacuum leaving a white residue. 
The complex was extracted with THF (4.5 mL)  and purified on a short C18 column. A white 
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crystalline solid was obtained. Yield : 131 mg, 22%. Crystals suitable for x-ray diffraction were 
obtained by slow diffusion of pentane into a dichloromethane solution of the complex. 
Elemental analysis calculated for 6, C17H12BrN4O3Re (586.41): C, 34.82; H, 2.06; N, 9.55, found: 
C, 34.59; H, 2.21; N, 9.89. 
6: 1H NMR (200 MHz, DMSO-d6, δ/ppm): 8.47 (HA, s, 1H), 7.63 (HB, d, 3J = 7, 1H), 7.47 (HB', d, 
3J = 7, 1H), 7.39-7.11 (HC, m, 2H) FT-IR for 6 (KBr, ν/cm-1): (C≡O) 2017 (s), (C≡O) 1899 (b), 
(C≡O) 1880 (b). ESI-MS for 6 (ESI+, 40V, m/z): 506.0 ([M-Br]+). HPLC Rt for 2 (HPLC, Gradient 
1, min): 22.6. 
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[Re(9-MeG)2(CH3OH)(CO)3](ClO4) • (Et4N)(ClO4) (7): (Et4N)2[ReBr3(CO)3] (30 mg, 0.04 
mmol) was dissolved in hot (~40 0C) methanol (3 mL). AgClO4 (28 mg, 0.14 mmol) was added and 
the mixture was stirred for 3 h after which time AgBr was filtered off. 9-methylguanine (16.5 mg, 
0.1 mmol) was added and the mixture was heated to 50 0C under a slight N2 pressure. The colorless 
solution turned light yellow within minutes. The reaction was monitored by HPLC and it was 
stopped after 3.5 hr. The solution mixture was allowed to equilibrate to room temperature and then 
pentane was allowed to diffuse into it depositing x-ray quality crystals. Yield : quantitative.  
Elemental analysis calculated for 7, C16H18ClN10O10Re (732.04): C, 26.25; H, 2.48; N, 19.13, 
found: C, 25.86; H, 2.67; N, 18.98. 
7: 1H NMR (500 MHz, D2O, δ/ppm): 8.31 (s, 1H), 3.66 (s, 3H). FT-IR for 7 (KBr, ν/cm-1): (C≡O) 
2027 (s), (C≡O) 1918 (b), (C≡O) 1897 (b). ESI-MS for 7 (ESI+, 40V, m/z): 600.5 ([M-CH3OH]+). 
HPLC Rt for 7 (HPLC, Gradient 1, min): 17.1. 
 
[99Tc(9-MeG)2(CH3OH)(CO)3](ClO4) • (Et4N)(ClO4) (8): (Et4N)2[99TcCl3(CO)3] (30 mg, 0.04 
mmol) was dissolved in hot (~40 0C) methanol (3 mL). AgClO4 (28 mg, 0.14 mmol) was added and 
the mixture was stirred for 3 h after which time AgBr was filtered off. 9-methylguanine (16.5 mg, 
0.1 mmol) was added and the mixture was heated to 50 0C under a slight N2 pressure. The reaction 
was monitored by HPLC and it was stopped after 3.5 hr. The solution mixture was allowed to 
equilibrate to room temperature and then pentane was allowed to diffuse into it depositing x-ray 
quality crystals. Yield : quantitative.  
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[Re(9-MeG)2(H2O)(CO)3](ClO4) (10HT): (Et4N)2[ReBr3(CO)3] (30 mg, 0.04 mmol) was 
dissolved in hot (~40 0C) methanol (3 mL). AgClO4 (28 mg, 0.14 mmol) was added and the mixture 
was stirred for 3 h after which time AgBr was filtered off. 9-methylguanine (16.5 mg, 0.1 mmol) 
was added and the mixture was heated to 50 0C under a slight N2 pressure. The colourless solution 
turned light yellow within minutes. The reaction was monitored by HPLC and it was stopped after 
3.5 hr when no further change could be observed. The solution mixture was allowed to equilibrate 
to room temperature, concentrated  and then purified on a short C18 column. To the methanol 
fraction containing the purified complex 3% H2O (v/v) was added. Pentane was allowed to diffuse 
into the solution depositing x-ray quality crystals. Yield : quantitative. 
Elemental analysis calculated for 10HT, C15H16ClN10O10Re (718.01): C, 25.09; H, 2.25; N, 
19.51, found: C, 25.34; H, 2.70; N, 19.45. 
10HT: 1H NMR (500 MHz, D2O, δ/ppm): 8.31 (s, 1H), 3.66 (s, 3H). FT-IR for 10HT (KBr, 
ν/cm-1): (C≡O) 2027 (s), (C≡O) 1918 (b), (C≡O) 1897 (b). ESI-MS for 10HT (ESI+, 40V, m/z): 
600.5 ([M-H2O]+). HPLC Rt for 5 (HPLC, Gradient 1, min): 17.1. 
 
[Re(9-MeG)2(H2O)(CO)3]Br (10HH): (Et4N)2[ReBr3(CO)3] (30 mg (0.04 mmol) was dissolved 
in  a water/methanol mixture (5 mL, 3:2). 9-methylguanine (16.5 mg, 0.1 mmol) was added and the 
mixture was heated to 50 0C under a slight N2 pressure. The colourless solution turned light yellow 
within minutes. The reaction was monitored by HPLC and it was stopped after 3.5 hr. The solution 
mixture was allowed to equilibrate to room temperature and left open to air to allow all the 
methanol to evaporate. After 1 week white crystals of the title compound were collected. Yield : 
quantitative. 
Elemental analysis calculated for 10HH, C15H16BrN10O6Re (698.46): C, 25.79; H, 2.31; N, 20.05, 
found: C, 25.39; H, 2.54; N, 19.78. 
10HH: 1H NMR (500 MHz, D2O, δ/ppm): 8.31 (s, 1H), 3.66 (s, 3H). FT-IR for 10HH (KBr, 
ν/cm-1): (C≡O) 2027 (s), (C≡O) 1915 (b), (C≡O) 1895 (b). ESI-MS for 10HH (ESI+, 40V, m/z): 
600.5 ([M-H2O]+). HPLC Rt for 10HH (HPLC, Gradient 1, min): 17.1. 
 
[ReBr(7-MeG)2(CO)3] (12HH): (Et4N)2[ReBr3(CO)3] (30 mg (0.04 mmol) was dissolved in  a 
water/methanol mixture (3 mL, 2:1). 7-methylguanine (16.5 mg, 0.1 mmol) was added and the 
mixture was heated to 50 0C under a slight N2 pressure. The colorless solution turned light yellow 
within minutes. The reaction was monitored by HPLC and it was stopped after 3.5 hr. The solution 
was allowed to equilibrate to room temperature concentrated and purified on a short C18 column. A 
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white crystalline solid was obtained. Yield : 18 mg, 68%. Crystals suitable for x-ray diffraction 
were obtained by slow diffusion of pentane into a methanolic solution of the complex. 
Elemental analysis calculated for 12HH, C15H14BrN10O5Re (680.45): C, 26.48; H, 2.07; N, 20.58, 
found: C, 26.21; H, 2.19; N, 19.97. 
12HH: 1H NMR (500 MHz, D2O, δ/ppm): 8.18 (s, 1H), 3.97 (s, 3H). FT-IR for 12HH (KBr, 
ν/cm-1): (C≡O) 2027 (s), (C≡O) 1897 (b). ESI-MS for 12HH (ESI+, 40V, m/z): 600.5 ([M-Br]+). 
HPLC Rt for 12HH (HPLC, Gradient 1, min): 17.8. 
 
[Re(7-MeG)2(H2O)(CO)3](ClO4) (12HT): (Et4N)2[ReBr3(CO)3] (50 mg, 0.065 mmol) was 
dissolved in methanol/water mixture (2:4, 6 mL). AgClO4 (44.5 mg, 0.22 mmol) was added, the 
mixture was stirred for 1h and then filtered from AgBr ppt. To the filtrate 7-methylguanine (23.6 
mg, 0.143 mmol) was added and the solution was heated to 50 0C under a slight N2 pressure. The 
reaction was monitored by HPLC and it was stopped after 3.5 hr. The solution was cooled to room 
temperature and then methanol was allowed to evaporate slowly. After 3-4 days x-ray quality 
crystals of the title compound were obtained. Yield : 23 mg, 49%. 
Elemental analysis calculated for 12HT, C15H16ClN10O10Re (718.01): C, 25.09; H, 2.25; N, 
19.51, found: C, 25.12; H, 2.20; N, 19.23. 
12HT: 1H NMR (500 MHz, D2O, δ/ppm): 8.18 (s, 1H), 3.97 (s, 3H). FT-IR for 12HT (KBr, 
ν/cm-1): (C≡O) 2030 (s), (C≡O) 1908 (b), (C≡O) 1876 (b). ESI-MS for 12HT (ESI+, 40V, m/z): 
600.5 ([M-H2O]+). HPLC Rt for 12HT (HPLC, Gradient 1, min): 17.8. 
 
[Re(Pro)(CO)3]3 (13): (Et4N)2[ReBr3(CO)3] (100 mg, 0.13 mmol) was dissolved in a 
methanol/water mixture (9:1, 5 mL). L-proline (52 mg, 0.46 mmol) was added and the mixture was 
stirred for 5 h at 50 0C under a slight N2 pressure. The reaction was monitored by HPLC and it was 
stopped when no further change could be observed (4h). The solution was allowed to equilibrate to 
room temperature concentrated and purified on a short C18 column. A white crystalline solid was 
obtained. Yield : 40.1 mg, 60%. Crystals suitable for x-ray diffraction were obtained by slow 
diffusion of THF into a methanolic solution of the complex. 
Elemental analysis calculated for 13, C24H24N3O15Re3 (1153.08): C, 25.00; H, 2.10; N, 3.64, 
found: C, 25.39; H, 2.42; N, 4.00. 
FT-IR for 13 (KBr, ν/cm-1): (C≡O) 2027 (s), (C≡O) 1908 (b), (C≡O) 1888 (b). ESI-MS for 13 
(ESI-, 40V, m/z): 1266.9 ([M+Pro-]-). HPLC Rt for 13 (HPLC, Gradient 1, min): 16.4 
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[Re(DMGly)(CO)3]3 (14): (Et4N)2[ReBr3(CO)3] (100 mg, 0.13 mmol) was dissolved in a 
methanol/water mixture (4:1, 10 mL). N,N-dimethylglycine (70 mg, 0.7 mmol) was added and the 
mixture was stirred for 12 h at 50 0C under a slight N2 pressure. The solution was allowed to 
equilibrate to room temperature concentrated and purified on a short C18 filter. A white crystalline 
solid was obtained. Yield : 20 mg, 40%. Crystals suitable for x-ray diffraction were obtained by 
slow diffusion of ether in a CH3CN solution of the complex. 
Elemental analysis calculated for 14, C21H24N3O15Re3 (1117.05): C, 22.58; H, 2.17; N, 3.76, 
found: C, 23.19; H, 2.78; N, 3.84. 
14: 1H NMR (500 MHz, DMSO-d6, δ/ppm): 4.18 (s, 2H), 3.46 (s, 3H), 3.15 (s, 3H). FT-IR for 14 
(KBr, ν/cm-1): (C≡O) 2022 (s), (C≡O) 1911 (b), (C≡O) 1890 (s), (C≡O) 1866 (s). ESI-MS for 14 
(ESI+, 40V, m/z): 1117.0 ([M]+). HPLC Rt for 14 (HPLC, Gradient 1, min): 15.7. 
 
[Re(Pro)(9-MeG)(CO)3] (15): (Et4N)2[ReBr3(CO)3] (18 mg, 0.02 mmol) was dissolved in 
methanol (3 mL). L-proline (8 mg, 0.06 mmol) was added. The solution was stirred and heated to 
50 0C under a slight N2 pressure until 13 had formed (4h, as revealed by HPLC). 9-methylguanine 
(5 mg, 0.03 mmol) was added and allowed to react until no further change could be observed in the 
HPLC (4h). The solution mixture was cooled to room temperature. Then pentane was allowed to 
diffuse into it depositing x-ray quality crystals. Yield : 10 mg, 78%. 
Elemental analysis calculated for 15, C14H15N6O6Re (549.51): C, 30.60; H, 2.75; N, 15.29, found: 
C, 30.96; H, 2.47; N, 15.70. 
15: 1H NMR (500 MHz, D2O, δ/ppm): 8.01(s, 1H), 5.92 (s, 1H; NH), 3.39 (m, 1H), 3.20 (m, 1H), 
2.66 (s, 3H; CH3), 2.19 (m, 1H), 1.98 (m, 2H), 1.81 (m, 1H), 1.70 (m, 1H). FT-IR for 15 (KBr, 
ν/cm-1): (C≡O) 2021 (s), (C≡O) 1894 (b). ESI-MS for 15 (ESI-, 40V, m/z): 548.5 ([M-1]-). HPLC 
Rt for 15 (HPLC, Gradient 1, min): 19.1.  
 
[ReBr(NH3)2(CO)3] (16): [ReBr(CO)5] (75 mg, 0.19 mmol) was dissolved in a NH3 saturated 
benzene solution (15 mL) and the mixture was heated to 60 0C under N2 pressure. After 2.5 hr a 
white precipitate appeared, this was filtered, washed with benzene and dried in vacuo. Yield : 35 
mg, 49%. Crystals suitable for x-ray diffraction were obtained by slow diffusion of hexane into a 
THF solution of the complex. 
Elemental analysis calculated for 16, C3H6BrN2O3Re (384.21): C, 9.38; H, 1.57; N, 7.29, found: 
C, 10.01; H, 1.79; N, 7.67. 
FT-IR for 16 (KBr, ν/cm-1): (C≡O) 2017 (s), (C≡O) 1884 (b). ESI-MS for 16 (ESI+, 40V, m/z): 
600.5 ([M-H2O]+). HPLC Rt for 16 (HPLC, Gradient 1, min): 9.6 
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B12-[Re(DMG)(CO)3] (22): Vitamin B12 (50 mg, 0.04 mmol) was dissolved in methanol (10 
mL). [Re(DMG)(CO)3]3 (45 mg, 0.04 mmol) was added and the mixture was stirred for at RT for 
12h. Two adducts (clearly distinguishable by HPLC) formed (yield 25% and 36%). These were 
isolated and purified by preparative HPLC. Yield: 10 mg, 14% (adduct 1), 12 mg, 17% (adduct 2). 
Crystals of adduct 1 suitable for x-ray analysis were obtained by vapour diffusion of acetone in a 
H2O solution of the complex. 
Elemental analysis calculated for 22a, C70H96CoN15O19PRe (1727,71): C, 48.66; H, 5.60; N, 
12.16, found: C, 48.42; H, 5.01; N, 12.04 (adduct 1). 
FT-IR for 22 (KBr, ν/cm-1): (C≡O) 2033 (s), (C≡O) 1928 (b), (C≡O) 1904 (b).ESI-MS for 22 
(ESI+, 30V, m/z): 1728.7 ([M]+ + 1). HPLC Rt for 22 (HPLC, Gradient 2, min): 19.2 (adduct 1, 
22a), 21.2 (adduct 2, 22b). 
 
[Re(L-Ser)2(CO)3] (23): (Et4N)2[ReBr3(CO)3] (100 mg, 0.13 mmol) was dissolved in a 
methanol/water mixture (9:1, 5 mL). L-serine (48 mg, 0.46 mmol) was added and the mixture was 
stirred for 3 h at 50 0C under a slight N2 pressure. The reaction was monitored by HPLC and it was 
stopped when no further change could be observed (3h). The solution was allowed to equilibrate to 
room temperature and purified by HPLC. A white solid was obtained. Yield : 23 mg, 37%. Crystals 
suitable for x-ray analysis were obtained by slow evaporation of H2O. 
Elemental analysis calculated for 23, C9H13N2O9Re (479,41): C, 22.55; H, 2.73; N, 5.84, found: 
C, 23.17; H, 3.20; N, 5.47. 
23: 1H NMR (500 MHz, D2O : MeOH-d4 2:1, δ/ppm): 3.98-3.89 (m, 2H), 3.80 (dd, 3J = 3.7, 5.8, 
1H). FT-IR for 23 (KBr, ν/cm-1): (C≡O) 2012 (s), (C≡O) 1889 (b), (C≡O) 1874 (b). ESI-MS for 23 
(ESI-, 30V, m/z): 479.5 ([M]+). HPLC Rt for 23 (HPLC, Gradient 1, min): 7.1. 
 
[Re(L-Ser)(7-MeG)(CO)3] (24): (Et4N)2[ReBr3(CO)3] (100 mg, 0.13 mmol) was dissolved in 
methanol/water mixture (9:1, 5 mL). L-serine (48 mg, 0.46 mmol) was added and the mixture was 
stirred for 3 h at 50 0C under a slight N2 pressure. 7-methylguanine (37 mg, 0.20 mmol) was added 
and the mixture was stirred for 3 h at 50 0C under a slight N2 pressure. The solution was allowed to 
equilibrate to room temperature concentrated and purified on a short C18 filter. A white crystalline 
solid was obtained. Yield : 45 mg, 58%. Crystals suitable for x-ray diffraction were obtained by 
slow diffusion of pentane into a methanolic solution of the complex. 
Elemental analysis calculated for 24, C12H13N6O7Re (539,47): C, 26.72; H, 2.43; N, 15.58, found: 
C, 26.66; H, 2.42; N, 15.19. 
 134
24: 1H NMR (500 MHz, D2O : MeOH-d4 1:1, δ/ppm): Species 1: 8.14 (s, 1H), 5.59 (m, 1H, NH), 
4.79 (m, 1H, NH), 3.97 (s, 3H, CH3), 3.83-3.79 (m, 2H, CH2), 3.19-3.16 (m, 1H, CH). Species 2: 
8.09 (s, 1H), 5.41 (m, 1H, NH), 4.76 (m, 1H, NH), 3.95 (s, 3H, CH3), 3.72-3.57 (m, 2H, CH2), 3.44-
3.42 (m, 1H, CH). FT-IR for 24 (KBr, ν/cm-1): (C≡O) 2023 (s), (C≡O) 1918 (b), (C≡O) 1890 (b) 
and (C≡O) 1893 (b), (C≡O) 1873 (b). ESI-MS for 24 (ESI-, 30V, m/z): 539.3 ([M]-). HPLC Rt for 
24 (HPLC, Gradient 1, min): 17.5. 
 
[Re(D-Ser)(7-MeG)(CO)3] (25): (Et4N)2[ReBr3(CO)3] (100 mg, 0.13 mmol) was dissolved in 
methanol/water mixture (9:1, 5 mL). D-serine (48 mg, 0.46 mmol) was added and the mixture was 
stirred for 3 h at 50 0C under a slight N2 pressure. 7-methylguanine (37 mg, 0.20 mmol) was added 
and the mixture was stirred for 3 h at 50 0C under a slight N2 pressure. The solution was allowed to 
equilibrate to room temperature concentrated and purified on a short C18 filter. A white crystalline 
solid was obtained. Yield : 40 mg, 52%. Crystals suitable for x-ray diffraction were obtained by 
slow evaporation of a water/methanol solution (1:1) of the complex. 
Elemental analysis calculated for 25, C12H13N6O7Re (539,47): C, 26.72; H, 2.43; N, 15.58, found: 
C, 25.92; H, 3.00; N, 14.99. 
25: 1H NMR (500 MHz, D2O : MeOH-d4 1:1, δ/ppm): Species 1: 8.14 (s, 1H), 5.59 (m, 1H, NH), 
4.79 (m, 1H, NH), 3.97 (s, 3H, CH3), 3.83-3.79 (m, 2H, CH2), 3.19-3.16 (m, 1H, CH). Species 2: 
8.09 (s, 1H), 5.41 (m, 1H, NH), 4.76 (m, 1H, NH), 3.95 (s, 3H, CH3), 3.72-3.57 (m, 2H, CH2), 3.44-
3.42 (m, 1H, CH). FT-IR for 25 (KBr, ν/cm-1): (C≡O) 2023 (s), (C≡O) 1918 (b), (C≡O) 1897 (b) 
and (C≡O) 1885 (b), (C≡O) 1874 (b). ESI-MS for 25 (ESI+, 30V, m/z): 539.3 ([M]+). HPLC Rt for 
25 (HPLC, Gradient 1, min): 17.5. 
 
[Re(L-Ser)(3-pic)(CO)3] (26): (Et4N)2[ReBr3(CO)3] (100 mg, 0.13 mmol) was dissolved in 
methanol/water mixture (9:1, 5 mL). L-serine (48 mg, 0.46 mmol) was added and the mixture was 
stirred for 3 h at 50 0C under a slight N2 pressure. 3-picoline (50 µL, 0.52 mmol) was added and the 
mixture was stirred for 1 day at 50 0C under a slight N2 pressure. The solution was allowed to 
equilibrate to room temperature concentrated and purified on a short C18 filter. A white crystalline 
solid was obtained. Yield : 43 mg, 72%. Crystals suitable for x-ray diffraction were obtained by 
slow diffusion of pentane into a methanolic solution of the complex. 
Elemental analysis calculated for 26, C12H13N2O6Re (467,45): C, 30.83; H, 2.80; N, 5.99, found: 
C, 31.48; H, 3.19; N, 6.39. 
26: 1H NMR (500 MHz, MeOH-d4, δ/ppm): Species 1: 8.56 (s, 1H), 8.55 (d, 3J = 5.7, 1H), 7.86 
(d, 3J = 7.8, 1H), 7.44 (dd, 3J = 5.7, 7.8, 1H), 3.64-3.50 (m, 2H), 3.35 (m, 1H), 2.40 (s, 3H). Species 
 135
2: 8.56 (s, 1H), 8.53 (d, 3J = 5.7, 1H), 7.89 (d, 3J = 7.8, 1H), 7.47 (dd, 3J = 5.7, 7.8, 1H), 3.79-3.71 
(m, 2H), 2.76 (m, 1H), 2.42 (s, 3H). FT-IR for 26 (KBr, ν/cm-1): (C≡O) 2023 (s), (C≡O) 1907 (b), 
(C≡O) 1881 (b). ESI-MS for 26 (ESI+, 40V, m/z): 468.0 ([M]+). HPLC Rt for 26 (HPLC, Gradient 
1, min): 18.2. 
 
[Re(L-Tryp)2(CO)3] (27): This compound was synthesized according to the procedure described 
for the synthesis of [Re(L-Ser)2(CO)3] (23) but using L-Tryptophan instead of L-Serine. Crystals 
suitable for x-ray diffraction were obtained by slow diffusion of pentane into a methanolic solution 
of the complex. 
FT-IR for 27 (KBr, ν/cm-1): (C≡O) 2016 (s), (C≡O) 1891 (s), (C≡O) 1869 (s). ESI-MS for 27 
(ESI+, 40V, m/z): 678.1 ([M]+). HPLC Rt for 27 (HPLC, Gradient 1, min): 17.7. 
 
[Ru(bpy)2(9-MeG)2](SO3CF3)2 (33): Ru(bpy)2Cl2 (50 mg, 0.1 mmol, prepared by standard 
methods) was dissolved in aqueous ethanol (10 mL). AgSO3CF3 (55 mg, 0.22 mmol) was added. 
After filtration of AgCl,  9-methylguanine (40 mg, 0.24 mmol) was added and the solution refluxed 
for 3 days. The reaction mixture was cooled to room temperature and filtered again. CH2Cl2 was 
then allowed to slowly diffuse into the solution depositing x-ray quality crystals after 2 days. Yield: 
quantitative. 
Elemental analysis calculated for 33, C34H30F6N14O8RuS2 (1041,88): C, 39.19; H, 2.90; N, 18.82, 
found: C, 40.04; H, 3.15; N, 19.01. 
33: 1H NMR (500 MHz, D2O, δ/ppm): 9.30, 8.79 (HA, d, 3J = 5.7, 2H), 7.81, 7.74 (HA', d, 3J = 5.7, 
2H), 8.60, 8.50 (HB, d, 3J = 8, 2H), 8.45, 8.39 (HB', d, 3J = 8, 2H), 8.19, 8.15 (HC, t, 3J = 8, 8, 2H), 
7.92, 7.84 (HC', t, 3J = 8, 8, 2H), 7.73, 7.67 (HD, t, 3J = 6, 8, 2H), 7.22, 7.18 (HD', t, 3J = 6, 8, 2H), 
8.02 (HE, s, 1H), 6.80 (HE', s, 1H), 3.67 (HF, s, 3H), 3.38 (HF', s, 3H). UV/VIS for 33 (H2O, nm, (ε, 
x10-4 M-1 cm-1)): 290 (6.37), 331 (1.04), 475 (1.01). ESI-MS for 33 (ESI+, 40V, m/2z): 289.2 
([Ru(bpy)2(9-MeG)]2+). 
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Summary  
 
It was shown in this thesis that two guanine bases can coordinate to a ReI or a TcI centre yielding 
reasonably stable complexes with slow on and off rates, the on rates being comparable to an active 
form of cisplatin. For the first time x-ray structures of a Tc- and Re-complexes with two purine 
bases bound cis to the metal center were presented. Guanine ligands can assume both a HH and a 
HT conformation in an octahedral complex around the ReI tricarbonyl core and these two forms are 
present in solution in equilibrium. Theoretical and 1H NMR studies indicate that the two guanines 
can freely rotate about the Re-N7(9) bond. This implies that the O6 carbonyl oxygen imposes no 
steric hindrance. The presence of HH and HT conformers in complexes with either 9-MeG or 7-
MeG in the solid state and in solution delineates the fact that intramolecular hydrogen bonding and 
steric hindrance imposed by the carbonyl oxygen of coordinated guanines are not driving forces for 
the preference of one or the other conformation.  
 
Rhenium forms stable adducts with d(GpG) and d(CpGpG) via coordination of the N7 atom of 
guanine residues as corroborated by the pH-dependence studies of the H8 resonances at pH values 
near 2. Reaction of 1 with d(GpG) yields two major adducts. NMR data and ring current shift 
calculations based Abraham’s model, tentatively suggest that these may be HH and HT conformers. 
Kinetic investigations have revealed that macrochelate closure is not the rate determining step but 
rather a fast step in the reaction. Interaction of 1 with d(CpGpG) yields a single major product. 
NMR investigation has proven that the olygonucleotide binds to the fac-[ReI(CO)3] core via the N7 
atom of guanine bases. 
 
The [Re(CO)3]+ moiety displays a principally similar reactivity pattern with plasmid DNA as e.g. 
cisplatin. It binds selectively to two free guanines, implying a possible interaction with adjacent 
guanines in DNA as well. To protect the Re center in plasma from unwanted coordination 
(trapping) to serum proteins coligands such as proline or N,N-dimethylglycine were used yielding 
the Re-complexes in the form of pro-drugs. DMGly in particular can be replaced by coordination to 
N7 of guanine. The complexes with other amino acids are too stable in this respect but both 
complexes do not cross react with human serum. If the coligands are labile enough the 
corresponding complexes such as [Re(DMGly)(CO)3]3 influence the tertiary structure of ΦX174 
DNA by altering the electrophoretic mobility of the open circular and the supercoiled form of 
plasmid DNA. The induced changes involve most likely covalent binding to two bases as found for 
cisplatin. Although less potent, the presented model complexes depict the in vitro reactivity 
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characteristics as required for therapeutic agents. They might therefore serve as future inorganic 
medicinal drugs provided that they are able to accumulate to a sufficient extent in the cell and in the 
nucleus in particular.  
 
The fac-[Re(CO)3]+ core can be derivatized with the amino acid serine and the appropriate 
nitrogenous base to yield nucleoside mimicking complexes. These compounds show an interesting 
solution behavior displaying an intramolecular rearrangement which, to our knowledge, has never 
been described for octahedral organometallic complexes in which the α-aminocarboxylate ligand is 
bound as a N,O-chelate. Nucleoside mimicking compounds where the nitrogenous base is 7-MeG 
are remarkably stable in Human Serum (HS) showing only about 50% decomposition (i.e. reaction 
with serum proteins) after 12h and being still visible in the HPLC chromatogram after a 24h 
incubation period. When the same compounds were subjected to in vitro phosphorylation tests and 
affinity measurements with HSV1 TK neither evidence of phosphorylation of pendent serine arm 
nor inhibition of HSV1 TK activity could be detected. However, the remarkable HS stability of the 
guanosine mimicking makes the compounds potentially useful inorganic medicinal drugs. In our 
vision, they may actively participate in the biochemistry at the desired target tumor site provided 
that they are able to accumulate to a sufficient extent in the cell and in the nucleus in particular and 
provided that they are substrates for enzymes involved in DNA synthesis. The amino acid 
complexes of Re can be bridged by CN- in B12 to yield robust complexes comprising the central 
structural feature [Co-CN-Re]. This concept allows direct labeling of B12 with complexes 
[99mTc(OH2)(N∩O)(CO)3] for radiodiagnosis or with Re as a mediator between B12 and additional 
biologically active molecules.  
 
Certain Re complexes show high antiproliferative activity toward B16 F1 mouse melanoma cells. 
Compounds bearing at least one Im or HPz ligand generally best inhibit cell proliferation. However, 
no structure-activity relationship can be extrapolated from our results as both compounds with two 
exchangeable cis-coordinated ligands and compounds with one or no exchangeable ligands show 
comparable activity. The results suggest that Im or HPz might be ligands for a model Re pro-drug 
protecting the [Re(CO)3]+ core from reacting with coordinating sites in blood proteins. 
 
Finally the first structurally characterized cis-bis purine complex of ruthenium was presented. The 
two guanine bases are in a HT orientation which is the most common solid-state conformation of 
cis-bis(ligand) complexes of purines with PtII, CoIII, CuII and ZnII. The complex is stable in water 
for hours showing a slow off rate of base dissociation. Our results, in agreement with the 
 138
experimental evidence mentioned above, confirm that DNA is a possible target of ruthenium-based 
metal drugs. 
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Crystallography Section. 
 
X-Ray Table 1.  [ReBr(BzIm)2(CO)3] (6) 
Empirical formula  C17 H10 Br N4 O3 Re 
Chemical name  Rhenium(I) Dibenzimidazoletricarbonylbromo 
Formula weight  584.40 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 8.3811(6) Å α= 90°. 
 b = 21.4230(14) Å β= 97.022(8)°. 
 c = 10.6260(7) Å γ = 90°. 
Volume 1893.6(2) Å3 
Z 4 
Density (calculated) 2.050 Mg/m3 
Absorption coefficient 8.551 mm-1 
F(000) 1096 
Crystal size 0.15 x 0.28 x 0.36 mm3 
Crystal description colorless plate 
Theta range for data collection 2.63 to 27.98°. 
Index ranges -11<=h<=11, -28<=k<=28, -13<=l<=13 
Reflections collected 26030 
Independent reflections 4527 [R(int) = 0.1144] 
Reflections observed 3612 
Criterion for observation >2sigma(I) 
Completeness to theta = 27.98° 99.5 %  
Absorption correction Numercial 
Max. and min. transmission 0.2911 and 0.0900 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4527 / 0 / 243 
Goodness-of-fit on F2 0.929 
Final R indices [I>2sigma(I)] R1 = 0.0361, wR2 = 0.0880 
R indices (all data) R1 = 0.0459, wR2 = 0.0905 
Largest diff. peak and hole 2.661 and -1.465 e.Å-3 
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X-Ray Table 2.  [Re(9-MeG)2(CH3OH)(CO)3](ClO4) • (Et4N)(ClO4) (7HT) 
Empirical formula  C24 H38 Cl2 N11 O14 Re 
Formula weight  961.75 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  I2/a 
Unit cell dimensions a = 28.8620(17) Å α= 90°. 
 b = 8.0097(3) Å β= 90.923(7)°. 
 c = 32.3708(19) Å γ = 90°. 
Volume 7482.4(7) Å3 
Z 8 
Density (calculated) 1.708 Mg/m3 
Absorption coefficient 3.467 mm-1 
F(000) 3840 
Crystal size 0.33 x 0.17 x 0.11 mm3 
Theta range for data collection 2.82 to 30.41°. 
Index ranges -40<=h<=40, -11<=k<=10, -42<=l<=45 
Reflections collected 43462 
Independent reflections 11248 [R(int) = 0.0587] 
Completeness to theta = 30.41° 99.2 %  
Absorption correction Numerical 
Max. and min. transmission 0.7301 and 0.4539 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11248 / 2 / 472 
Goodness-of-fit on F2 0.929 
Final R indices [I>2sigma(I)] R1 = 0.0510, wR2 = 0.1293 
R indices (all data) R1 = 0.0763, wR2 = 0.1373 
Largest diff. peak and hole 1.800 and -1.430 e.Å-3 
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X-Ray Table 3.  [99Tc(9-MeG)2(CH3OH)(CO)3](ClO4) • (Et4N)(ClO4) (8HT) 
Empirical formula  C24 H38 Cl2 N11 O14 Tc 
Formula weight  873.55 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  I2/a 
Unit cell dimensions a = 28.7533(14) Å α= 90°. 
 b = 8.0631(4) Å β= 91.543(6)°. 
 c = 32.3600(15) Å γ = 90°. 
Volume 7499.6(6) Å3 
Z 8 
Density (calculated) 1.547 Mg/m3 
Absorption coefficient 0.602 mm-1 
F(000) 3584 
Crystal size 0.70 x 0.58 x 0.50 mm3 
Crystal description colorless block 
Theta range for data collection 2.83 to 30.42°. 
Index ranges -40<=h<=40, -11<=k<=11, -45<=l<=46 
Reflections collected 41617 
Independent reflections 11284 [R(int) = 0.1011] 
Reflections observed 7224 
Criterion for observation >2sigma(I) 
Completeness to theta = 30.42° 99.2 %  
Absorption correction Numerical 
Max. and min. transmission 0.7869 and 0.6777 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11284 / 2 / 494 
Goodness-of-fit on F2 1.130 
Final R indices [I>2sigma(I)] R1 = 0.0692, wR2 = 0.1857 
R indices (all data) R1 = 0.0938, wR2 = 0.1954 
Largest diff. peak and hole 1.414 and -1.254 e.Å-3 
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X-Ray Table 4.  [Re(9-MeG)2(H2O)(CO)3](ClO4) • 3H2O (10HT) 
Empirical formula  C15 H22 Cl N10 O13 Re 
Formula weight  772.08 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.3307(10) Å α= 90°. 
 b = 16.2620(14) Å β= 105.525(9)°. 
 c = 13.7171(11) Å γ = 90°. 
Volume 2650.2(4) Å3 
Z 4 
Density (calculated) 1.935 Mg/m3 
Absorption coefficient 4.767 mm-1 
F(000) 1512 
Crystal size 0.39 x 0.26 x 0.13 mm3 
Crystal description colorless block 
Theta range for data collection 2.88 to 30.43°. 
Index ranges -17<=h<=17, -23<=k<=23, -19<=l<=19 
Reflections collected 29286 
Independent reflections 7942 [R(int) = 0.1153] 
Reflections observed 4393 
Criterion for observation >2sigma(I) 
Completeness to theta = 30.43° 98.7 %  
Absorption correction Numerical 
Max. and min. transmission 0.4671 and 0.3147 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7942 / 1 / 369 
Goodness-of-fit on F2 0.798 
Final R indices [I>2sigma(I)] R1 = 0.0435, wR2 = 0.0999 
R indices (all data) R1 = 0.0858, wR2 = 0.1105 
Largest diff. peak and hole 1.928 and -2.175 e.Å-3 
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X-Ray Table 5.  [Re(9-MeG)2(H2O)(CO)3]Br • H2O (10HH) 
Empirical formula  C15 H18 Br N10 O7 Re 
Formula weight  716.50 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 15.6260(13) Å α= 90°. 
 b = 9.5269(5) Å β= 76.951(10)°. 
 c = 15.4078(13) Å γ = 90°. 
Volume 2234.5(3) Å3 
Z 4 
Density (calculated) 2.130 Mg/m3 
Absorption coefficient 7.287 mm-1 
F(000) 1376 
Crystal size 0.171 x 0.030 x 0.025 mm3 
Crystal description colorless plate 
Theta range for data collection 2.52 to 28.21°. 
Index ranges -20<=h<=20, -12<=k<=11, -20<=l<=20 
Reflections collected 17788 
Independent reflections 5430 [R(int) = 0.1347] 
Reflections observed 2746 
Criterion for observation >2sigma(I) 
Completeness to theta = 28.21° 98.5 %  
Absorption correction Numerical 
Max. and min. transmission 0.8490 and 0.4576 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5430 / 2 / 317 
Goodness-of-fit on F2 0.868 
Final R indices [I>2sigma(I)] R1 = 0.0714, wR2 = 0.1577 
R indices (all data) R1 = 0.1408, wR2 = 0.1829 
Largest diff. peak and hole   1.830 and -1.128 e.Å-3
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X-Ray Table 6.  [ReBr(7-MeG)2(CO)3] • 2.5H2O (12HH) 
Empirical formula  C15 H19 Br N10 O7.50 Re 
Formula weight  725.51 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2/c 
Unit cell dimensions a = 17.5117(9) Å α= 90°. 
 b = 9.8842(5) Å β= 100.824(7)°. 
 c = 15.3539(10) Å γ = 90°. 
Volume 2610.3(3) Å3 
Z 4 
Density (calculated) 1.846 Mg/m3 
Absorption coefficient 6.240 mm-1 
F(000) 1396 
Crystal size 0.062 x 0.059 x 0.028 mm3 
Crystal description colorless plate 
Theta range for data collection 2.70 to 27.00°. 
Index ranges -22<=h<=22, -12<=k<=12, -19<=l<=19 
Reflections collected 21500 
Independent reflections 5427 [R(int) = 0.1211] 
Reflections observed 3026 
Criterion for observation >2sigma(I) 
Completeness to theta = 27.00° 95.1 %  
Absorption correction Numerical 
Max. and min. transmission 0.7673 and 0.6424 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5427 / 12 / 333 
Goodness-of-fit on F2 0.902 
Final R indices [I>2sigma(I)] R1 = 0.0641, wR2 = 0.1422 
R indices (all data) R1 = 0.1161, wR2 = 0.1658 
Largest diff. peak and hole 1.181 and -2.283 e.Å-3 
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X-Ray Table 7.  [Re(7-MeG)2(H2O)(CO)3](ClO4) • H2O • CH3OH (12HT) 
Empirical formula  C16 H22 Cl N10 O12 Re 
Formula weight  768.09 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 13.0708(9) Å α= 90°. 
 b = 15.4082(7) Å β= 117.236(7)°. 
 c = 14.3160(9) Å γ = 90°. 
Volume 2563.5(3) Å3 
Z 4 
Density (calculated) 1.990 Mg/m3 
Absorption coefficient 4.925 mm-1 
F(000) 1504 
Crystal size 0.38 x 0.32 x 0.09 mm3 
Crystal description colorless block 
Theta range for data collection 3.09 to 30.38°. 
Index ranges -18<=h<=18, -21<=k<=21, -20<=l<=20 
Reflections collected 43858 
Independent reflections 7625 [R(int) = 0.1059] 
Reflections observed 5946 
Criterion for observation >2sigma(I) 
Completeness to theta = 30.38° 98.6 %  
Absorption correction Numerical 
Max. and min. transmission 0.6573 and 0.2472 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7625 / 0 / 379 
Goodness-of-fit on F2 0.937 
Final R indices [I>2sigma(I)] R1 = 0.0416, wR2 = 0.1018 
R indices (all data) R1 = 0.0516, wR2 = 0.1050 
Largest diff. peak and hole 2.966 and -2.212 e.Å-3 
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X-Ray Table 8.  [Re(Pro)(CO)3]3 • 3THF (13) 
Empirical formula  C12 H16 N O6 Re 
Formula weight  456.46 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Trigonal 
Space group  R3 
Unit cell dimensions a = 21.6864(11) Å α= 90°. 
 b = 21.6864(11) Å β= 90°. 
 c = 8.1989(3) Å γ = 120°. 
Volume 3339.3(3) Å3 
Z 9 
Density (calculated) 2.043 Mg/m3 
Absorption coefficient 8.210 mm-1 
F(000) 1962 
Crystal size 0.25 x 0.07 x 0.06 mm3 
Crystal description colorless needle 
Theta range for data collection 3.25 to 30.16°. 
Index ranges -30<=h<=23, -30<=k<=30, -11<=l<=9 
Reflections collected 8254 
Independent reflections 4025 [R(int) = 0.0373] 
Reflections observed 3312 
Criterion for observation >2sigma(I) 
Completeness to theta = 30.16° 99.9 %  
Absorption correction Numerical 
Max. and min. transmission 0.6923 and 0.2355 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4025 / 2 / 184 
Goodness-of-fit on F2 0.874 
Final R indices [I>2sigma(I)] R1 = 0.0302, wR2 = 0.0596 
R indices (all data) R1 = 0.0402, wR2 = 0.0615 
Absolute structure parameter -0.028(12) 
Largest diff. peak and hole 1.417 and -0.587 e.Å-3 
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X-Ray Table 9.  [Re(DMGly)(CO)3]3 • (CH3CH2)2O (14) 
Empirical formula  C25 H34 N3 O16 Re3 
Formula weight  1191.15 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 22.0917(10) Å α= 90°. 
 b = 7.8752(4) Å β= 92.768(6)°. 
 c = 20.2707(12) Å γ = 90°. 
Volume 3522.5(3) Å3 
Z 4 
Density (calculated) 2.246 Mg/m3 
Absorption coefficient 10.355 mm-1 
F(000) 2232 
Crystal size 0.26 x 0.04 x 0.02 mm3 
Crystal description colorless plate 
Theta range for data collection 2.75 to 28.28°. 
Index ranges -29<=h<=29, -10<=k<=10, -26<=l<=26 
Reflections collected 34342 
Independent reflections 8613 [R(int) = 0.1416] 
Reflections observed 5543 
Criterion for observation >2sigma(I) 
Completeness to theta = 28.28° 98.6 %  
Absorption correction Numerical 
Max. and min. transmission 0.8359 and 0.2312 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8613 / 19 / 430 
Goodness-of-fit on F2 0.966 
Final R indices [I>2sigma(I)] R1 = 0.0708, wR2 = 0.1259 
R indices (all data) R1 = 0.1051, wR2 = 0.1381 
Largest diff. peak and hole 2.492 and -1.744 e.Å-3 
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X-Ray Table 10.  [Re(Pro)(9-MeG)(CO)3] • CH3OH • 1/3pentane (15) 
Empirical formula  C105 H150 N36 O42 Re6 
Formula weight  3705.81 
Temperature  183(2) K 
Wavelength      0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 15.1130(5) Å α= 90°. 
 b = 15.4589(7) Å β= 90.629(4)°. 
 c = 15.4093(5) Å γ = 90°. 
Volume 3599.9(2) Å3 
Z 1 
Density (calculated) 1.709 Mg/m3 
Absorption coefficient 5.111 mm-1 
F(000) 1818 
Crystal size 0.57 x 0.17 x 0.08 mm3 
Crystal description colorless needle 
Theta range for data collection 2.95 to 30.42°. 
Index ranges -21<=h<=21, -22<=k<=22, -21<=l<=21 
Reflections collected 78907 
Independent reflections 20395 [R(int) = 0.0402] 
Reflections observed 18665 
Criterion for observation >2sigma(I) 
Completeness to theta = 30.42° 93.1 %  
Absorption correction Numerical 
Max. and min. transmission 0.7018 and 0.3285 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 20395 / 69 / 889 
Goodness-of-fit on F2 0.996 
Final R indices [I>2sigma(I)] R1 = 0.0328, wR2 = 0.0821 
R indices (all data) R1 = 0.0356, wR2 = 0.0831 
Absolute structure parameter -0.015(6) 
Largest diff. peak and hole 1.857 and -0.550 e.Å-3 
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X-Ray Table 11.  [ReBr(NH3)2(CO)3] (16) 
Empirical formula  C3 H6 Br N2 O3 Re 
Formula weight  384.21 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorombic 
Space group  Pnma 
Unit cell dimensions a = 10.8300(6) Å α= 90°. 
 b = 9.8501(7) Å β= 90°. 
 c = 7.2163(8) Å γ = 90°. 
Volume 769.81(11) Å3 
Z 4 
Density (calculated) 3.315 Mg/m3 
Absorption coefficient 20.927 mm-1 
F(000) 688 
Crystal size 0.15 x 0.12 x 0.08 mm3 
Crystal description colorless block 
Theta range for data collection 3.39 to 30.47°. 
Index ranges -15<=h<=15, -13<=k<=13, -10<=l<=10 
Reflections collected 15621 
Independent reflections 1228 [R(int) = 0.0670] 
Reflections observed 876 
Criterion for observation >2sigma(I) 
Completeness to theta = 30.47° 99.5 %  
Absorption correction Numerical 
Max. and min. transmission 0.2764 and 0.1368 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1228 / 0 / 53 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0407, wR2 = 0.0975 
R indices (all data) R1 = 0.0540, wR2 = 0.1028 
Largest diff. peak and hole 1.687 and -2.438 e.Å-3 
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X-Ray Table 12.  [B12- Re(DMGly)(CO)3] • nH3O (22a) 
Empirical formula  C73 H112.60 Co N15 O27.30 P Re 
Formula weight  1913.28 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 15.8758(7) Å α= 90°. 
 b = 21.8451(10) Å β= 90°. 
 c = 26.3673(14) Å γ = 90°. 
Volume 9144.4(8) Å3 
Z 4 
Density (calculated) 1.390 Mg/m3 
Absorption coefficient 1.601 mm-1 
F(000) 3964 
Crystal size 0.46 x 0.08 x 0.07 mm3 
Theta range for data collection 1.86 to 26.00°. 
Index ranges -19<=h<=19, -26<=k<=26, -32<=l<=32 
Reflections collected 68628 
Independent reflections 17853 [R(int) = 0.1048] 
Completeness to theta = 26.00° 99.5 %  
Absorption correction Numerical 
Max. and min. transmission 0.9257 and 0.7060 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 17853 / 2 / 1071 
Goodness-of-fit on F2 0.900 
Final R indices [I>2sigma(I)] R1 = 0.0662, wR2 = 0.1588 
R indices (all data) R1 = 0.1159, wR2 = 0.1742 
Absolute structure parameter -0.014(8) 
Largest diff. peak and hole 2.044 and -1.063 e.Å-3 
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X-Ray Table 13.  [Re(L-Ser)2(CO)3] (23) 
Empirical formula  C9 H13 N2 O9 Re 
Formula weight  479.41 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.6071(5) Å α= 90°. 
 b = 13.0977(17) Å β= 90°. 
 c = 18.4664(19) Å γ = 90°. 
Volume 1356.2(3) Å3 
Z 4 
Density (calculated) 2.348 Mg/m3 
Absorption coefficient 9.009 mm-1 
F(000) 912 
Crystal size 0.18 x 0.03 x 0.02 mm3 
Theta range for data collection 1.91 to 26.07°. 
Index ranges -6<=h<=6, -16<=k<=15, -22<=l<=22 
Reflections collected 8330 
Independent reflections 2639 [R(int) = 0.0547] 
Completeness to theta = 26.07° 99.0 %  
Absorption correction Numerical 
Max. and min. transmission 0.8393 and 0.6899 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2639 / 18 / 191 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0400, wR2 = 0.0963 
R indices (all data) R1 = 0.0456, wR2 = 0.0978 
Absolute structure parameter 0.01(2) 
Largest diff. peak and hole 1.387 and -0.915 e.Å-3 
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X-Ray Table 14.  [Re(L-Ser)(7-MeG)(CO)3] (24) • 1/2 CH3OH 
Empirical formula  C25 H30 N12 O15 Re2 
Formula weight  1111.01 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorombic 
Space group  P212121 
Unit cell dimensions a = 10.0312(5) Å α= 90°. 
 b = 14.1639(5) Å β= 90°. 
 c = 24.9026(8) Å γ = 90°. 
Volume 3538.2(2) Å3 
Z 4 
Density (calculated) 2.086 Mg/m3 
Absorption coefficient 6.922 mm-1 
F(000) 2136 
Crystal size 0.16 x 0.082 x 0.022 mm3 
Theta range for data collection 2.84 to 30.46°. 
Index ranges -14<=h<=12, -20<=k<=19, -30<=l<=35 
Reflections collected 25535 
Independent reflections 10699 [R(int) = 0.0840] 
Completeness to theta = 30.46° 99.5 %  
Absorption correction Numerical 
Max. and min. transmission 0.8101 and 0.3713 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10699 / 4 / 516 
Goodness-of-fit on F2 0.895 
Final R indices [I>2sigma(I)] R1 = 0.0493, wR2 = 0.1064 
R indices (all data) R1 = 0.0812, wR2 = 0.1178 
Absolute structure parameter -0.007(15) 
Largest diff. peak and hole 1.773 and -2.120 e.Å-3 
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X-Ray Table 15.  [Re(D-Ser)(7-MeG)(CO)3] (25) • 1/2 H2O 
Empirical formula  C24 H26 N12 O14 Re2 
Formula weight  1078.97 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorombic 
Space group  P212121 
Unit cell dimensions a = 10.0219(4) Å α= 90°. 
 b = 12.7847(4) Å β= 90°. 
 c = 26.4572(10) Å γ = 90°. 
Volume 3389.9(2) Å3 
Z 4 
Density (calculated) 2.114 Mg/m3 
Absorption coefficient 7.219 mm-1 
F(000) 2064 
Crystal size 0.202 x 0.101 x 0.0012 mm3 
Theta range for data collection 2.81 to 30.47°. 
Index ranges -14<=h<=14, -17<=k<=18, -37<=l<=37 
Reflections collected 34305 
Independent reflections 10251 [R(int) = 0.1058] 
Completeness to theta = 30.47° 99.5 %  
Absorption correction Numerical 
Max. and min. transmission 0.9078 and 0.2391 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10251 / 6 / 504 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0467, wR2 = 0.1115 
R indices (all data) R1 = 0.0548, wR2 = 0.1155 
Absolute structure parameter -0.012(12) 
Largest diff. peak and hole                                          2.221 and -2.039 e.Å-3 
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X-Ray Table 16.  [Re(L-Ser)(3-pic)(CO)3] (26) 
Empirical formula  C12 H13 N2 O6 Re 
Formula weight  467.44 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 6.2005(3) Å α= 90°. 
 b = 26.1517(17) Å β= 92.112(7)°. 
 c = 8.7539(5) Å γ = 90°. 
Volume 1418.51(14) Å3 
Z 4 
Density (calculated) 2.189 Mg/m3 
Absorption coefficient 8.595 mm-1 
F(000) 888 
Crystal size 0.225 x 0.060 x 0.058 mm3 
Theta range for data collection 3.29 to 30.47°. 
Index ranges -8<=h<=8, -36<=k<=36, -12<=l<=12 
Reflections collected 13689 
Independent reflections 7224 [R(int) = 0.0922] 
Completeness to theta = 30.47° 87.9 %  
Absorption correction Numerical 
Max. and min. transmission 0.7042 and 0.3170 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7224 / 159 / 385 
Goodness-of-fit on F2 1.114 
Final R indices [I>2sigma(I)] R1 = 0.0867, wR2 = 0.2670 
R indices (all data) R1 = 0.1218, wR2 = 0.3031 
Absolute structure parameter -0.03(5) 
Largest diff. peak and hole 4.095 and -4.259 e.Å-3 
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X-Ray Table 17.  [Ru(bpy)2(9-MeG)2](SO3CF3)2 • CH2Cl2 (33) 
Empirical formula  C35 H32 Cl2 F6 N14 O8 Ru S2 
Formula weight  1126.84 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.5159(6) Å α= 90°. 
 b = 20.0904(13) Å β= 98.981(6)°. 
 c = 17.1202(9) Å γ = 90°. 
Volume 4252.1(4) Å3 
Z 4 
Density (calculated) 1.760 Mg/m3 
Absorption coefficient 0.689 mm-1 
F(000) 2272 
Crystal size 0.11 x 0.07 x 0.05 mm3 
Crystal description red block 
Theta range for data collection 2.36 to 28.10°. 
Index ranges -16<=h<=16, -25<=k<=26, -20<=l<=22 
Reflections collected 23723 
Independent reflections 10149 [R(int) = 0.1119] 
Reflections observed 3786 
Criterion for observation >2sigma(I) 
Completeness to theta = 28.10° 97.8 %  
Absorption correction Numerical 
Max. and min. transmission 0.9766 and 0.9256 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10149 / 0 / 639 
Goodness-of-fit on F2 0.692 
Final R indices [I>2sigma(I)] R1 = 0.0502, wR2 = 0.0846 
R indices (all data) R1 = 0.1535, wR2 = 0.1044 
Largest diff. peak and hole 0.761 and -0.482 e.Å-3 
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